"brandDrugName","originalDrugName","drugName","drugId","sponsor","properties","therapeuticArea","indication","diseaseName","diseaseIds","diseaseClass","reviewType","yearApproval","targetIds","interactorIds","datatypeId","datasourceId","score","evidenceCount","phenotype","comment"
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000160014","literature","europepmc",0.0303965398805811,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000160014","literature","europepmc",0.0303965398805811,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000160014","literature","europepmc",0.0303965398805811,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000136573","known_drug","chembl",0.18101206819213,11,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000136573","known_drug","chembl",0.18101206819213,11,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000136573","known_drug","chembl",0.18101206819213,11,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000136573","known_drug","chembl",0.18101206819213,11,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000136573","known_drug","chembl",0.18101206819213,11,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000100591","literature","europepmc",0.0364758478566973,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000100591","literature","europepmc",0.0364758478566973,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000100591","literature","europepmc",0.0364758478566973,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000124942","literature","europepmc",0.0425551558328135,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000124942","literature","europepmc",0.0425551558328135,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000124942","literature","europepmc",0.0425551558328135,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000124942","rna_expression","expression_atlas",0.0822024124443281,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000124942","rna_expression","expression_atlas",0.0822024124443281,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000124942","rna_expression","expression_atlas",0.0822024124443281,3,NA,NA
"Parsabiv","Etelcalcetide","VELCALCETIDE","CHEMBL3545184","Amgen/Kai Pharmaceuticals","Calcium-sensing receptor agonist","Other indication","Secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis","hyperparathyroidism","EFO_0008506","Not serious","S",2017,"ENSG00000036828","ENSG00000036828","genetic_association","gene_burden",0.265993746466458,3,NA,NA
"Parsabiv","Etelcalcetide","VELCALCETIDE","CHEMBL3545184","Amgen/Kai Pharmaceuticals","Calcium-sensing receptor agonist","Other indication","Secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis","hyperparathyroidism","EFO_0008506","Not serious","S",2017,"ENSG00000036828","ENSG00000036828","animal_model","impc",0.636560577705911,26,NA,NA
"Parsabiv","Etelcalcetide","VELCALCETIDE","CHEMBL3545184","Amgen/Kai Pharmaceuticals","Calcium-sensing receptor agonist","Other indication","Secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis","hyperparathyroidism","EFO_0008506","Not serious","S",2017,"ENSG00000036828","ENSG00000036828","genetic_association","uniprot_literature",0.607930797611621,1,NA,NA
"Parsabiv","Etelcalcetide","VELCALCETIDE","CHEMBL3545184","Amgen/Kai Pharmaceuticals","Calcium-sensing receptor agonist","Other indication","Secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis","hyperparathyroidism","EFO_0008506","Not serious","S",2017,"ENSG00000036828","ENSG00000036828","genetic_association","uniprot_variants",0.865457038266544,4,NA,NA
"Parsabiv","Etelcalcetide","VELCALCETIDE","CHEMBL3545184","Amgen/Kai Pharmaceuticals","Calcium-sensing receptor agonist","Other indication","Secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis","hyperparathyroidism","EFO_0008506","Not serious","S",2017,"ENSG00000036828","ENSG00000036828","genetic_association","orphanet",0.607930797611621,1,NA,NA
"Parsabiv","Etelcalcetide","VELCALCETIDE","CHEMBL3545184","Amgen/Kai Pharmaceuticals","Calcium-sensing receptor agonist","Other indication","Secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis","hyperparathyroidism","EFO_0008506","Not serious","S",2017,"ENSG00000036828","ENSG00000036828","literature","europepmc",0.51962419769697,306,NA,NA
"Parsabiv","Etelcalcetide","VELCALCETIDE","CHEMBL3545184","Amgen/Kai Pharmaceuticals","Calcium-sensing receptor agonist","Other indication","Secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis","hyperparathyroidism","EFO_0008506","Not serious","S",2017,"ENSG00000036828","ENSG00000036828","known_drug","chembl",0.978253223865683,60,NA,NA
"Parsabiv","Etelcalcetide","VELCALCETIDE","CHEMBL3545184","Amgen/Kai Pharmaceuticals","Calcium-sensing receptor agonist","Other indication","Secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis","hyperparathyroidism","EFO_0008506","Not serious","S",2017,"ENSG00000036828","ENSG00000036828","genetic_association","genomics_england",0.936072224944711,9,NA,NA
"Parsabiv","Etelcalcetide","VELCALCETIDE","CHEMBL3545184","Amgen/Kai Pharmaceuticals","Calcium-sensing receptor agonist","Other indication","Secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis","hyperparathyroidism","EFO_0008506","Not serious","S",2017,"ENSG00000036828","ENSG00000036828","genetic_association","eva",0.904364743813464,196,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000113070","affected_pathway","slapenrich",0.964559697608137,17,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000113070","affected_pathway","slapenrich",0.964559697608137,17,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000113070","affected_pathway","slapenrich",0.964559697608137,17,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000113070","literature","europepmc",0.195044464233728,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000113070","literature","europepmc",0.195044464233728,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000113070","literature","europepmc",0.195044464233728,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000182718","literature","europepmc",0.245684992392648,11,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000182718","literature","europepmc",0.245684992392648,11,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000182718","literature","europepmc",0.245684992392648,11,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000113070","rna_expression","expression_atlas",0.168842894170922,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000113070","rna_expression","expression_atlas",0.168842894170922,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000113070","rna_expression","expression_atlas",0.168842894170922,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000107317","literature","europepmc",0.0699120417253364,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000107317","literature","europepmc",0.0699120417253364,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000107317","literature","europepmc",0.0699120417253364,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000163235","literature","europepmc",0.390559041625819,45,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000163235","literature","europepmc",0.390559041625819,45,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000163235","literature","europepmc",0.390559041625819,45,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000182636","literature","europepmc",0.151982699402905,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000182636","literature","europepmc",0.151982699402905,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000182636","literature","europepmc",0.151982699402905,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000100170","literature","europepmc",0.629883854192041,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000100170","literature","europepmc",0.629883854192041,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000100170","literature","europepmc",0.629883854192041,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000104756","literature","europepmc",0.12766546749844,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000104756","literature","europepmc",0.12766546749844,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000104756","literature","europepmc",0.12766546749844,1,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000204410","animal_model","impc",0.364332927008645,2,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000204410","animal_model","impc",0.364332927008645,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000043462","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000043462","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000043462","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000043462","literature","europepmc",0.615529932581766,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000043462","literature","europepmc",0.615529932581766,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000043462","literature","europepmc",0.615529932581766,2,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000157764","affected_pathway","cancer_biomarkers",0.958096407436196,14,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000157764","affected_pathway","cancer_biomarkers",0.958096407436196,14,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000157764","somatic_mutation","cancer_gene_census",0.702054168708533,9,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000157764","somatic_mutation","cancer_gene_census",0.702054168708533,9,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000157764","affected_pathway","slapenrich",0.96301031118991,17,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000157764","affected_pathway","slapenrich",0.96301031118991,17,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000157764","literature","europepmc",0.977741729055153,422,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000157764","literature","europepmc",0.977741729055153,422,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000157764","known_drug","chembl",0.591462924221893,36,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000157764","known_drug","chembl",0.591462924221893,36,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000157764","somatic_mutation","intogen",0.826764369665677,3,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000157764","somatic_mutation","intogen",0.826764369665677,3,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000157764","genetic_association","uniprot_literature",0.759913497014526,2,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000157764","genetic_association","uniprot_literature",0.759913497014526,2,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000157764","somatic_mutation","eva_somatic",0.897992886967732,39,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000157764","somatic_mutation","eva_somatic",0.897992886967732,39,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000157764","genetic_association","genomics_england",0.759913497014526,2,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000157764","genetic_association","genomics_england",0.759913497014526,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000110651","literature","europepmc",0.229716784057511,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000110651","literature","europepmc",0.229716784057511,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000110651","literature","europepmc",0.229716784057511,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000198909","literature","europepmc",0.620322453702938,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000198909","literature","europepmc",0.620322453702938,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000198909","literature","europepmc",0.620322453702938,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000106211","literature","europepmc",0.791228523157374,11,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000106211","literature","europepmc",0.791228523157374,11,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000106211","literature","europepmc",0.791228523157374,11,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000106211","known_drug","chembl",0.121586159522324,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000106211","known_drug","chembl",0.121586159522324,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000106211","known_drug","chembl",0.121586159522324,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000126561","affected_pathway","slapenrich",0.865457038266544,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000126561","affected_pathway","slapenrich",0.865457038266544,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000126561","affected_pathway","slapenrich",0.865457038266544,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000012061","literature","europepmc",0.934323306610809,293,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000012061","literature","europepmc",0.934323306610809,293,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000012061","literature","europepmc",0.934323306610809,293,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000067606","literature","europepmc",0.0672945619022864,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000067606","literature","europepmc",0.0672945619022864,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000067606","literature","europepmc",0.0672945619022864,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000126561","literature","europepmc",0.507481950793329,7,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000126561","literature","europepmc",0.507481950793329,7,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000126561","literature","europepmc",0.507481950793329,7,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000067606","known_drug","chembl",0.0607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000067606","known_drug","chembl",0.0607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000067606","known_drug","chembl",0.0607930797611621,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000081237","somatic_mutation","cancer_gene_census",0.66125139465214,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000081237","somatic_mutation","cancer_gene_census",0.66125139465214,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000081237","somatic_mutation","cancer_gene_census",0.66125139465214,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000081237","somatic_mutation","cancer_gene_census",0.66125139465214,5,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000081237","somatic_mutation","cancer_gene_census",0.66125139465214,5,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000110395","somatic_mutation","cancer_gene_census",0.60370905596154,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000110395","somatic_mutation","cancer_gene_census",0.60370905596154,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000110395","somatic_mutation","cancer_gene_census",0.60370905596154,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000110395","somatic_mutation","cancer_gene_census",0.60370905596154,3,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000110395","somatic_mutation","cancer_gene_census",0.60370905596154,3,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000081237","affected_pathway","slapenrich",0.332516934361418,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000081237","affected_pathway","slapenrich",0.332516934361418,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000081237","affected_pathway","slapenrich",0.332516934361418,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000081237","affected_pathway","slapenrich",0.332516934361418,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000081237","affected_pathway","slapenrich",0.332516934361418,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000110395","affected_pathway","slapenrich",0.962686599080584,16,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000110395","affected_pathway","slapenrich",0.962686599080584,16,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000110395","affected_pathway","slapenrich",0.962686599080584,16,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000110395","affected_pathway","slapenrich",0.962686599080584,16,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000110395","affected_pathway","slapenrich",0.962686599080584,16,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000115415","affected_pathway","slapenrich",0.884792994627107,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000115415","affected_pathway","slapenrich",0.884792994627107,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000115415","affected_pathway","slapenrich",0.884792994627107,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000115415","affected_pathway","progeny",0.303965398805811,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000115415","affected_pathway","progeny",0.303965398805811,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000115415","affected_pathway","progeny",0.303965398805811,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000081237","literature","europepmc",0.764559524654506,29,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000081237","literature","europepmc",0.764559524654506,29,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000081237","literature","europepmc",0.764559524654506,29,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000081237","literature","europepmc",0.764559524654506,29,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000081237","literature","europepmc",0.764559524654506,29,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000110395","literature","europepmc",0.335335444485587,12,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000110395","literature","europepmc",0.335335444485587,12,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000110395","literature","europepmc",0.335335444485587,12,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000110395","literature","europepmc",0.335335444485587,12,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000110395","literature","europepmc",0.335335444485587,12,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000115415","literature","europepmc",0.827691258380803,36,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000115415","literature","europepmc",0.827691258380803,36,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000115415","literature","europepmc",0.827691258380803,36,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000143322","somatic_mutation","cancer_gene_census",0.669694877952302,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000143322","somatic_mutation","cancer_gene_census",0.669694877952302,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000143322","somatic_mutation","cancer_gene_census",0.669694877952302,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000143322","somatic_mutation","cancer_gene_census",0.669694877952302,6,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000143322","somatic_mutation","cancer_gene_census",0.669694877952302,6,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000143322","literature","europepmc",0.0273568858925229,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000143322","literature","europepmc",0.0273568858925229,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000143322","literature","europepmc",0.0273568858925229,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000143322","literature","europepmc",0.0273568858925229,2,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000143322","literature","europepmc",0.0273568858925229,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000131016","literature","europepmc",0.0653525607432493,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000131016","literature","europepmc",0.0653525607432493,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000131016","literature","europepmc",0.0653525607432493,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000131016","rna_expression","expression_atlas",0.148457106810175,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000131016","rna_expression","expression_atlas",0.148457106810175,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000131016","rna_expression","expression_atlas",0.148457106810175,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000130340","literature","europepmc",0.0243172319044648,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000130340","literature","europepmc",0.0243172319044648,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000130340","literature","europepmc",0.0243172319044648,1,NA,NA
"Beovu","Brolucizumab","BROLUCIZUMAB","CHEMBL3707357","Novartis","VEGF inhibitor","Other indication","Wet age-related macular degeneration","macular degeneration","EFO_0009606","Not concordant","S",2019,"ENSG00000112715","ENSG00000112715","literature","europepmc",0.987681787833251,2797,NA,NA
"Beovu","Brolucizumab","BROLUCIZUMAB","CHEMBL3707357","Novartis","VEGF inhibitor","Other indication","Wet age-related macular degeneration","macular degeneration","EFO_0009606","Not concordant","S",2019,"ENSG00000112715","ENSG00000112715","known_drug","chembl",0.996650253079664,423,NA,NA
"Beovu","Brolucizumab","BROLUCIZUMAB","CHEMBL3707357","Novartis","VEGF inhibitor","Other indication","Wet age-related macular degeneration","macular degeneration","EFO_0009606","Not concordant","S",2019,"ENSG00000112715","ENSG00000112715","genetic_association","ot_genetics_portal",0.457998843449737,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000134308","literature","europepmc",0.0607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000134308","literature","europepmc",0.0607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000134308","literature","europepmc",0.0607930797611621,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000127329","somatic_mutation","cancer_gene_census",0.675774185928418,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000127329","somatic_mutation","cancer_gene_census",0.675774185928418,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000127329","somatic_mutation","cancer_gene_census",0.675774185928418,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000127329","somatic_mutation","cancer_gene_census",0.675774185928418,6,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000127329","somatic_mutation","cancer_gene_census",0.675774185928418,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000138363","somatic_mutation","cancer_gene_census",0.772578721964768,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000138363","somatic_mutation","cancer_gene_census",0.772578721964768,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000138363","somatic_mutation","cancer_gene_census",0.772578721964768,3,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000104341","literature","europepmc",0.67484878015872,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000104341","literature","europepmc",0.67484878015872,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000104341","literature","europepmc",0.67484878015872,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000104341","literature","europepmc",0.67484878015872,5,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000104341","literature","europepmc",0.67484878015872,5,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000127329","literature","europepmc",0.206696471187951,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000127329","literature","europepmc",0.206696471187951,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000127329","literature","europepmc",0.206696471187951,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000127329","literature","europepmc",0.206696471187951,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000127329","literature","europepmc",0.206696471187951,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000138363","literature","europepmc",0.0455948098208716,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000138363","literature","europepmc",0.0455948098208716,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000138363","literature","europepmc",0.0455948098208716,2,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000104341","rna_expression","expression_atlas",0.092542265666429,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000104341","rna_expression","expression_atlas",0.092542265666429,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000104341","rna_expression","expression_atlas",0.092542265666429,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000104341","rna_expression","expression_atlas",0.092542265666429,2,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000104341","rna_expression","expression_atlas",0.092542265666429,2,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000127329","rna_expression","expression_atlas",0.271918978746819,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000127329","rna_expression","expression_atlas",0.271918978746819,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000127329","rna_expression","expression_atlas",0.271918978746819,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000127329","rna_expression","expression_atlas",0.271918978746819,5,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000127329","rna_expression","expression_atlas",0.271918978746819,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000061273","literature","europepmc",0.0759913497014526,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000061273","literature","europepmc",0.0759913497014526,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000061273","literature","europepmc",0.0759913497014526,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000151491","literature","europepmc",0.0501542908029587,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000151491","literature","europepmc",0.0501542908029587,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000151491","literature","europepmc",0.0501542908029587,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000061273","known_drug","chembl",0.18478706776072,14,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000061273","known_drug","chembl",0.18478706776072,14,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000061273","known_drug","chembl",0.18478706776072,14,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000079308","literature","europepmc",0.0121586159522324,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000079308","literature","europepmc",0.0121586159522324,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000079308","rna_expression","expression_atlas",0.153336076380827,4,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000079308","rna_expression","expression_atlas",0.153336076380827,4,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000158092","affected_pathway","slapenrich",0.395207928536576,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000158092","affected_pathway","slapenrich",0.395207928536576,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000158092","affected_pathway","slapenrich",0.395207928536576,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000158092","affected_pathway","slapenrich",0.395207928536576,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000158092","affected_pathway","slapenrich",0.395207928536576,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000058262","literature","europepmc",0.0607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000058262","literature","europepmc",0.0607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000058262","literature","europepmc",0.0607930797611621,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000158092","literature","europepmc",0.35834143125885,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000158092","literature","europepmc",0.35834143125885,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000158092","literature","europepmc",0.35834143125885,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000158092","literature","europepmc",0.35834143125885,3,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000158092","literature","europepmc",0.35834143125885,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000186868","literature","europepmc",0.341329501105685,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000186868","literature","europepmc",0.341329501105685,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000186868","literature","europepmc",0.341329501105685,6,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000185338","somatic_mutation","cancer_gene_census",0.531939447910168,2,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000185338","somatic_mutation","cancer_gene_census",0.531939447910168,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000115145","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000115145","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000115145","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000197943","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000197943","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000197943","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000197943","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000197943","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000154556","literature","europepmc",0.0607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000154556","literature","europepmc",0.0607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000154556","literature","europepmc",0.0607930797611621,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000185338","literature","europepmc",0.44800164505238,9,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000185338","literature","europepmc",0.44800164505238,9,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000197943","literature","europepmc",0.325242976722217,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000197943","literature","europepmc",0.325242976722217,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000197943","literature","europepmc",0.325242976722217,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000197943","literature","europepmc",0.325242976722217,2,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000197943","literature","europepmc",0.325242976722217,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000154556","rna_expression","expression_atlas",0.119977500257756,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000154556","rna_expression","expression_atlas",0.119977500257756,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000154556","rna_expression","expression_atlas",0.119977500257756,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000091831","somatic_mutation","cancer_gene_census",0.60370905596154,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000091831","somatic_mutation","cancer_gene_census",0.60370905596154,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000091831","somatic_mutation","cancer_gene_census",0.60370905596154,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000091831","affected_pathway","slapenrich",0.854180858059224,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000091831","affected_pathway","slapenrich",0.854180858059224,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000091831","affected_pathway","slapenrich",0.854180858059224,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000091831","affected_pathway","progeny",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000091831","affected_pathway","progeny",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000091831","affected_pathway","progeny",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000091831","literature","europepmc",0.868798284727335,113,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000091831","literature","europepmc",0.868798284727335,113,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000091831","literature","europepmc",0.868798284727335,113,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000091831","known_drug","chembl",0.147338783587816,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000091831","known_drug","chembl",0.147338783587816,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000091831","known_drug","chembl",0.147338783587816,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000196961","affected_pathway","slapenrich",0.80472070794997,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000196961","affected_pathway","slapenrich",0.80472070794997,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000196961","affected_pathway","slapenrich",0.80472070794997,3,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000079805","animal_model","impc",0.681468776193473,18,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000079805","animal_model","impc",0.681468776193473,18,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000168036","somatic_mutation","cancer_gene_census",0.859673252205933,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000168036","somatic_mutation","cancer_gene_census",0.859673252205933,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000168036","somatic_mutation","cancer_gene_census",0.859673252205933,6,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000115290","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000115290","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000140575","affected_pathway","slapenrich",0.919067987742997,7,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000140575","affected_pathway","slapenrich",0.919067987742997,7,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000140575","affected_pathway","slapenrich",0.919067987742997,7,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000168036","affected_pathway","slapenrich",0.545701046583835,9,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000168036","affected_pathway","slapenrich",0.545701046583835,9,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000168036","affected_pathway","slapenrich",0.545701046583835,9,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000140575","literature","europepmc",0.368147692763657,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000140575","literature","europepmc",0.368147692763657,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000140575","literature","europepmc",0.368147692763657,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000168036","literature","europepmc",0.747968162047402,62,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000168036","literature","europepmc",0.747968162047402,62,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000168036","literature","europepmc",0.747968162047402,62,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000168036","somatic_mutation","intogen",0.438836647998701,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000168036","somatic_mutation","intogen",0.438836647998701,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000168036","somatic_mutation","intogen",0.438836647998701,2,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000115290","rna_expression","expression_atlas",0.0482950704333688,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000115290","rna_expression","expression_atlas",0.0482950704333688,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000168036","somatic_mutation","eva_somatic",0.681093964070172,22,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000168036","somatic_mutation","eva_somatic",0.681093964070172,22,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000168036","somatic_mutation","eva_somatic",0.681093964070172,22,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000124207","literature","europepmc",0.174780104313341,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000124207","literature","europepmc",0.174780104313341,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000124207","literature","europepmc",0.174780104313341,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000006125","affected_pathway","slapenrich",0.80472070794997,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000006125","affected_pathway","slapenrich",0.80472070794997,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000006125","affected_pathway","slapenrich",0.80472070794997,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000006125","literature","europepmc",0.0303965398805811,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000006125","literature","europepmc",0.0303965398805811,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000006125","literature","europepmc",0.0303965398805811,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000204388","literature","europepmc",0.0212775779164067,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000204388","literature","europepmc",0.0212775779164067,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000204388","literature","europepmc",0.0212775779164067,2,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000117461","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000117461","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000117461","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000117461","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000117461","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000171132","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000171132","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000171132","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000117152","literature","europepmc",0.185418893271544,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000117152","literature","europepmc",0.185418893271544,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000117152","literature","europepmc",0.185418893271544,2,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000117461","literature","europepmc",0.155245261350088,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000117461","literature","europepmc",0.155245261350088,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000117461","literature","europepmc",0.155245261350088,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000117461","literature","europepmc",0.155245261350088,6,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000117461","literature","europepmc",0.155245261350088,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000171132","literature","europepmc",0.794969973858464,15,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000171132","literature","europepmc",0.794969973858464,15,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000171132","literature","europepmc",0.794969973858464,15,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000117461","known_drug","chembl",0.172054822661783,16,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000117461","known_drug","chembl",0.172054822661783,16,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000117461","known_drug","chembl",0.172054822661783,16,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000117461","known_drug","chembl",0.172054822661783,16,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000117461","known_drug","chembl",0.172054822661783,16,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000171132","known_drug","chembl",0.0607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000171132","known_drug","chembl",0.0607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000171132","known_drug","chembl",0.0607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000171132","rna_expression","expression_atlas",0.149430174518435,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000171132","rna_expression","expression_atlas",0.149430174518435,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000171132","rna_expression","expression_atlas",0.149430174518435,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000096384","somatic_mutation","cancer_gene_census",0.303965398805811,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000096384","somatic_mutation","cancer_gene_census",0.303965398805811,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000096384","somatic_mutation","cancer_gene_census",0.303965398805811,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000096384","affected_pathway","slapenrich",0.817491411921584,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000096384","affected_pathway","slapenrich",0.817491411921584,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000096384","affected_pathway","slapenrich",0.817491411921584,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000096384","literature","europepmc",0.651942482075732,10,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000096384","literature","europepmc",0.651942482075732,10,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000096384","literature","europepmc",0.651942482075732,10,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000096384","known_drug","chembl",0.281932434788242,17,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000096384","known_drug","chembl",0.281932434788242,17,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000096384","known_drug","chembl",0.281932434788242,17,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000146648","affected_pathway","cancer_biomarkers",0.968836966996368,19,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000146648","affected_pathway","cancer_biomarkers",0.968836966996368,19,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000146648","affected_pathway","cancer_biomarkers",0.968836966996368,19,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000146648","affected_pathway","cancer_biomarkers",0.968836966996368,19,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000146648","affected_pathway","cancer_biomarkers",0.968836966996368,19,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000146648","somatic_mutation","cancer_gene_census",0.932610299336596,13,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000146648","somatic_mutation","cancer_gene_census",0.932610299336596,13,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000146648","somatic_mutation","cancer_gene_census",0.932610299336596,13,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000146648","somatic_mutation","cancer_gene_census",0.932610299336596,13,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000146648","somatic_mutation","cancer_gene_census",0.932610299336596,13,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000146648","affected_pathway","slapenrich",0.977654451498777,27,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000146648","affected_pathway","slapenrich",0.977654451498777,27,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000146648","affected_pathway","slapenrich",0.977654451498777,27,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000146648","affected_pathway","slapenrich",0.977654451498777,27,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000146648","affected_pathway","slapenrich",0.977654451498777,27,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000146648","affected_pathway","progeny",0.593265567332442,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000146648","affected_pathway","progeny",0.593265567332442,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000146648","affected_pathway","progeny",0.593265567332442,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000146648","affected_pathway","progeny",0.593265567332442,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000146648","affected_pathway","progeny",0.593265567332442,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000111816","literature","europepmc",0.128447334052035,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000111816","literature","europepmc",0.128447334052035,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000111816","literature","europepmc",0.128447334052035,5,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000146648","literature","europepmc",0.999198925304483,9058,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000146648","literature","europepmc",0.999198925304483,9058,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000146648","literature","europepmc",0.999198925304483,9058,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000146648","literature","europepmc",0.999198925304483,9058,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000146648","literature","europepmc",0.999198925304483,9058,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000111816","known_drug","chembl",0.18101206819213,11,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000111816","known_drug","chembl",0.18101206819213,11,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000111816","known_drug","chembl",0.18101206819213,11,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000146648","known_drug","chembl",0.994709248502641,941,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000146648","known_drug","chembl",0.994709248502641,941,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000146648","known_drug","chembl",0.994709248502641,941,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000146648","known_drug","chembl",0.994709248502641,941,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000146648","known_drug","chembl",0.994709248502641,941,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000146648","somatic_mutation","intogen",0.850675779255117,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000146648","somatic_mutation","intogen",0.850675779255117,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000146648","somatic_mutation","intogen",0.850675779255117,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000146648","somatic_mutation","intogen",0.850675779255117,4,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000146648","somatic_mutation","intogen",0.850675779255117,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000111816","rna_expression","expression_atlas",0.0641974922277872,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000111816","rna_expression","expression_atlas",0.0641974922277872,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000111816","rna_expression","expression_atlas",0.0641974922277872,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000146648","genetic_association","clingen",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000146648","genetic_association","clingen",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000146648","genetic_association","clingen",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000146648","genetic_association","clingen",0.607930797611621,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000146648","genetic_association","clingen",0.607930797611621,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000146648","affected_pathway","crispr",0.378816878261741,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000146648","affected_pathway","crispr",0.378816878261741,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000146648","affected_pathway","crispr",0.378816878261741,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000146648","affected_pathway","crispr",0.378816878261741,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000146648","affected_pathway","crispr",0.378816878261741,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000146648","genetic_association","uniprot_literature",0.759913497014526,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000146648","genetic_association","uniprot_literature",0.759913497014526,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000146648","genetic_association","uniprot_literature",0.759913497014526,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000146648","genetic_association","uniprot_literature",0.759913497014526,2,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000146648","genetic_association","uniprot_literature",0.759913497014526,2,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000146648","genetic_association","eva",0.823172073899336,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000146648","genetic_association","eva",0.823172073899336,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000146648","genetic_association","eva",0.823172073899336,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000146648","genetic_association","eva",0.823172073899336,6,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000146648","genetic_association","eva",0.823172073899336,6,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000146648","somatic_mutation","eva_somatic",0.900195720739544,45,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000146648","somatic_mutation","eva_somatic",0.900195720739544,45,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000146648","somatic_mutation","eva_somatic",0.900195720739544,45,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000146648","somatic_mutation","eva_somatic",0.900195720739544,45,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000146648","somatic_mutation","eva_somatic",0.900195720739544,45,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000174791","literature","europepmc",0.2249343951163,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000174791","literature","europepmc",0.2249343951163,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000174791","literature","europepmc",0.2249343951163,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000213658","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000213658","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000213658","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000213658","literature","europepmc",0.170220623331254,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000213658","literature","europepmc",0.170220623331254,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000213658","literature","europepmc",0.170220623331254,1,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000064703","literature","europepmc",0.0182379239283486,1,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000064703","literature","europepmc",0.0182379239283486,1,NA,NA
"Imfinzi","Durvalumab","DURVALUMAB","CHEMBL3301587","AstraZeneca","PDL1-blocking antibody","Oncology","Urothelial carcinoma","urothelial carcinoma","EFO_0008528","Serious","P,B,A",2017,"ENSG00000120217","ENSG00000188389","literature","europepmc",0.298240786932488,26,NA,NA
"Tecentriq","Atezolizumab","ATEZOLIZUMAB","CHEMBL3707227","Genentech","PDL1 inhibitor","Oncology","Urothelial carcinoma","urothelial carcinoma","EFO_0008528","Serious","P,B,A",2016,"ENSG00000120217","ENSG00000188389","literature","europepmc",0.298240786932488,26,NA,NA
"Imfinzi","Durvalumab","DURVALUMAB","CHEMBL3301587","AstraZeneca","PDL1-blocking antibody","Oncology","Urothelial carcinoma","urothelial carcinoma","EFO_0008528","Serious","P,B,A",2017,"ENSG00000120217","ENSG00000188389","known_drug","chembl",0.673238543555348,55,NA,NA
"Tecentriq","Atezolizumab","ATEZOLIZUMAB","CHEMBL3707227","Genentech","PDL1 inhibitor","Oncology","Urothelial carcinoma","urothelial carcinoma","EFO_0008528","Serious","P,B,A",2016,"ENSG00000120217","ENSG00000188389","known_drug","chembl",0.673238543555348,55,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000160255","literature","europepmc",0.0273568858925229,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000160255","literature","europepmc",0.0273568858925229,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000160255","literature","europepmc",0.0273568858925229,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000133124","somatic_mutation","cancer_gene_census",0.757296017191476,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000133124","somatic_mutation","cancer_gene_census",0.757296017191476,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000133124","somatic_mutation","cancer_gene_census",0.757296017191476,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000107643","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000107643","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000107643","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000137267","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000137267","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000137267","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000107643","literature","europepmc",0.761659839465343,96,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000107643","literature","europepmc",0.761659839465343,96,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000107643","literature","europepmc",0.761659839465343,96,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000133124","literature","europepmc",0.133744775474557,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000133124","literature","europepmc",0.133744775474557,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000133124","literature","europepmc",0.133744775474557,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000137267","literature","europepmc",0.0121586159522324,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000137267","literature","europepmc",0.0121586159522324,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000137267","literature","europepmc",0.0121586159522324,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000137267","known_drug","chembl",0.995750329176035,1214,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000137267","known_drug","chembl",0.995750329176035,1214,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000137267","known_drug","chembl",0.995750329176035,1214,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000000938","affected_pathway","slapenrich",0.340232786294737,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000000938","affected_pathway","slapenrich",0.340232786294737,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000000938","affected_pathway","slapenrich",0.340232786294737,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000000938","affected_pathway","slapenrich",0.340232786294737,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000000938","affected_pathway","slapenrich",0.340232786294737,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000000938","literature","europepmc",0.0729516957133945,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000000938","literature","europepmc",0.0729516957133945,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000000938","literature","europepmc",0.0729516957133945,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000000938","literature","europepmc",0.0729516957133945,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000000938","literature","europepmc",0.0729516957133945,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000171150","literature","europepmc",0.0243172319044648,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000171150","literature","europepmc",0.0243172319044648,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000000938","known_drug","chembl",0.18101206819213,11,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000000938","known_drug","chembl",0.18101206819213,11,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000000938","known_drug","chembl",0.18101206819213,11,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000000938","known_drug","chembl",0.18101206819213,11,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000000938","known_drug","chembl",0.18101206819213,11,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000000938","rna_expression","expression_atlas",0.177014249994564,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000000938","rna_expression","expression_atlas",0.177014249994564,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000000938","rna_expression","expression_atlas",0.177014249994564,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000000938","rna_expression","expression_atlas",0.177014249994564,2,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000000938","rna_expression","expression_atlas",0.177014249994564,2,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000136205","affected_pathway","slapenrich",0.822682441882312,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000136205","affected_pathway","slapenrich",0.822682441882312,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000136205","affected_pathway","slapenrich",0.822682441882312,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000136205","affected_pathway","slapenrich",0.822682441882312,3,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000136205","affected_pathway","slapenrich",0.822682441882312,3,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000136205","genetic_association","ot_genetics_portal",0.472898738633536,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000136205","genetic_association","ot_genetics_portal",0.472898738633536,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000136205","genetic_association","ot_genetics_portal",0.472898738633536,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000136205","genetic_association","ot_genetics_portal",0.472898738633536,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000136205","genetic_association","ot_genetics_portal",0.472898738633536,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000074966","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000074966","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000166313","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000166313","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000166313","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000120833","literature","europepmc",0.685683492669593,11,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000120833","literature","europepmc",0.685683492669593,11,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000166313","literature","europepmc",0.0607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000166313","literature","europepmc",0.0607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000166313","literature","europepmc",0.0607930797611621,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000120833","rna_expression","expression_atlas",0.164219642470092,5,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000120833","rna_expression","expression_atlas",0.164219642470092,5,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000198574","rna_expression","expression_atlas",0.0884539310524909,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000198574","rna_expression","expression_atlas",0.0884539310524909,1,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000163517","literature","europepmc",0.0243172319044648,1,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000163517","literature","europepmc",0.0243172319044648,1,NA,NA
"Empliciti","Elotuzumab","ELOTUZUMAB","CHEMBL1743010","Bristol-Myers Squibb","SLAMF7-directed mAb","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,B",2015,"ENSG00000026751","ENSG00000026751","literature","europepmc",0.762565344337522,72,"MONDO_0004095","multiple myeloma -> B-cell neoplasm (parent)"
"Empliciti","Elotuzumab","ELOTUZUMAB","CHEMBL1743010","Bristol-Myers Squibb","SLAMF7-directed mAb","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,B",2015,"ENSG00000026751","ENSG00000026751","known_drug","chembl",0.84762634511975,52,"MONDO_0004095","multiple myeloma -> B-cell neoplasm (parent)"
"Beovu","Brolucizumab","BROLUCIZUMAB","CHEMBL3707357","Novartis","VEGF inhibitor","Other indication","Wet age-related macular degeneration","macular degeneration","EFO_0009606","Not concordant","S",2019,"ENSG00000112715","ENSG00000148346","literature","europepmc",0.697752572958738,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000064999","literature","europepmc",0.0486344638089297,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000064999","literature","europepmc",0.0486344638089297,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000064999","literature","europepmc",0.0486344638089297,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000147010","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000147010","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000147010","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000135046","literature","europepmc",0.526530863911078,11,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000135046","literature","europepmc",0.526530863911078,11,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000135046","literature","europepmc",0.526530863911078,11,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000184557","literature","europepmc",0.7073830977216,18,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000184557","literature","europepmc",0.7073830977216,18,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000184557","literature","europepmc",0.7073830977216,18,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000184557","literature","europepmc",0.7073830977216,18,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000184557","literature","europepmc",0.7073830977216,18,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000184557","rna_expression","expression_atlas",0.135016402289565,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000184557","rna_expression","expression_atlas",0.135016402289565,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000184557","rna_expression","expression_atlas",0.135016402289565,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000184557","rna_expression","expression_atlas",0.135016402289565,3,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000184557","rna_expression","expression_atlas",0.135016402289565,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000186834","literature","europepmc",0.121586159522324,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000186834","literature","europepmc",0.121586159522324,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000186834","literature","europepmc",0.121586159522324,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000148053","literature","europepmc",0.667487092741678,13,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000148053","literature","europepmc",0.667487092741678,13,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000148053","literature","europepmc",0.667487092741678,13,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000148053","known_drug","chembl",0.842034815591896,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000148053","known_drug","chembl",0.842034815591896,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000148053","known_drug","chembl",0.842034815591896,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000148053","rna_expression","expression_atlas",0.0469393414925954,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000148053","rna_expression","expression_atlas",0.0469393414925954,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000148053","rna_expression","expression_atlas",0.0469393414925954,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000114805","literature","europepmc",0.0911896196417432,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000114805","literature","europepmc",0.0911896196417432,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000114805","literature","europepmc",0.0911896196417432,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000096968","somatic_mutation","cancer_gene_census",0.669694877952302,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000096968","somatic_mutation","cancer_gene_census",0.669694877952302,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000096968","somatic_mutation","cancer_gene_census",0.669694877952302,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000096968","affected_pathway","slapenrich",0.94224934834845,11,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000096968","affected_pathway","slapenrich",0.94224934834845,11,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000096968","affected_pathway","slapenrich",0.94224934834845,11,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000096968","affected_pathway","progeny",0.303965398805811,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000096968","affected_pathway","progeny",0.303965398805811,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000096968","affected_pathway","progeny",0.303965398805811,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000096968","literature","europepmc",0.756449654184459,61,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000096968","literature","europepmc",0.756449654184459,61,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000096968","literature","europepmc",0.756449654184459,61,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000096968","known_drug","chembl",0.0919067987742997,7,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000096968","known_drug","chembl",0.0919067987742997,7,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000096968","known_drug","chembl",0.0919067987742997,7,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000159352","affected_pathway","slapenrich",0.936072224944711,9,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000159352","affected_pathway","slapenrich",0.936072224944711,9,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000159352","affected_pathway","slapenrich",0.936072224944711,9,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000159352","literature","europepmc",0.0121586159522324,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000159352","literature","europepmc",0.0121586159522324,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000159352","literature","europepmc",0.0121586159522324,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000044574","animal_model","impc",0.288888715025042,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000044574","animal_model","impc",0.288888715025042,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000044574","animal_model","impc",0.288888715025042,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000044574","literature","europepmc",0.421606562976305,31,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000044574","literature","europepmc",0.421606562976305,31,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000044574","literature","europepmc",0.421606562976305,31,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000145016","literature","europepmc",0.185418893271544,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000145016","literature","europepmc",0.185418893271544,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000145016","literature","europepmc",0.185418893271544,2,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000197122","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000197122","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000197122","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000197122","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000197122","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000102606","affected_pathway","slapenrich",0.718713997019573,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000102606","affected_pathway","slapenrich",0.718713997019573,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000102606","affected_pathway","slapenrich",0.718713997019573,2,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000197122","affected_pathway","slapenrich",0.97255335649672,22,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000197122","affected_pathway","slapenrich",0.97255335649672,22,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000197122","affected_pathway","slapenrich",0.97255335649672,22,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000197122","affected_pathway","slapenrich",0.97255335649672,22,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000197122","affected_pathway","slapenrich",0.97255335649672,22,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000197122","literature","europepmc",0.934770044644843,116,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000197122","literature","europepmc",0.934770044644843,116,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000197122","literature","europepmc",0.934770044644843,116,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000197122","literature","europepmc",0.934770044644843,116,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000197122","literature","europepmc",0.934770044644843,116,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000197122","known_drug","chembl",0.627770327331351,33,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000197122","known_drug","chembl",0.627770327331351,33,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000197122","known_drug","chembl",0.627770327331351,33,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000197122","known_drug","chembl",0.627770327331351,33,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000197122","known_drug","chembl",0.627770327331351,33,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000080031","literature","europepmc",0.314435318098011,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000080031","literature","europepmc",0.314435318098011,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000080031","literature","europepmc",0.314435318098011,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000145335","literature","europepmc",0.616036541579776,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000145335","literature","europepmc",0.616036541579776,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000145335","literature","europepmc",0.616036541579776,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000080031","rna_expression","expression_atlas",0.320491523432369,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000080031","rna_expression","expression_atlas",0.320491523432369,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000080031","rna_expression","expression_atlas",0.320491523432369,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000145335","rna_expression","expression_atlas",0.0641974922277872,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000145335","rna_expression","expression_atlas",0.0641974922277872,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000145335","rna_expression","expression_atlas",0.0641974922277872,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000071537","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000071537","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000071537","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000071537","literature","europepmc",0.0911896196417432,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000071537","literature","europepmc",0.0911896196417432,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000071537","literature","europepmc",0.0911896196417432,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000100324","affected_pathway","slapenrich",0.559536468037777,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000100324","affected_pathway","slapenrich",0.559536468037777,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000100324","affected_pathway","slapenrich",0.559536468037777,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000100324","literature","europepmc",0.145903391426789,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000100324","literature","europepmc",0.145903391426789,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000100324","literature","europepmc",0.145903391426789,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000185483","literature","europepmc",0.472159586145026,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000185483","literature","europepmc",0.472159586145026,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000185483","literature","europepmc",0.472159586145026,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000185483","known_drug","chembl",0.121586159522324,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000185483","known_drug","chembl",0.121586159522324,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000185483","known_drug","chembl",0.121586159522324,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000185483","rna_expression","expression_atlas",0.0707631448419927,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000185483","rna_expression","expression_atlas",0.0707631448419927,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000185483","rna_expression","expression_atlas",0.0707631448419927,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000182511","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000182511","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000182511","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000182511","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000182511","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000182511","affected_pathway","slapenrich",0.31872146740219,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000182511","affected_pathway","slapenrich",0.31872146740219,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000182511","affected_pathway","slapenrich",0.31872146740219,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000182511","affected_pathway","slapenrich",0.31872146740219,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000182511","affected_pathway","slapenrich",0.31872146740219,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000105245","literature","europepmc",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000105245","literature","europepmc",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000105245","literature","europepmc",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000142208","somatic_mutation","cancer_gene_census",0.649092778699908,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000142208","somatic_mutation","cancer_gene_census",0.649092778699908,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000142208","somatic_mutation","cancer_gene_census",0.649092778699908,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000142208","affected_pathway","slapenrich",0.963173051770418,16,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000142208","affected_pathway","slapenrich",0.963173051770418,16,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000142208","affected_pathway","slapenrich",0.963173051770418,16,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000142208","literature","europepmc",0.990897813318602,1066,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000142208","literature","europepmc",0.990897813318602,1066,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000142208","literature","europepmc",0.990897813318602,1066,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000142208","known_drug","chembl",0.183522814322701,8,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000142208","known_drug","chembl",0.183522814322701,8,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000142208","known_drug","chembl",0.183522814322701,8,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000142208","somatic_mutation","eva_somatic",0.653525607432493,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000142208","somatic_mutation","eva_somatic",0.653525607432493,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000142208","somatic_mutation","eva_somatic",0.653525607432493,2,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000105976","animal_model","impc",0.346581347718385,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000105976","animal_model","impc",0.346581347718385,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000105976","animal_model","impc",0.346581347718385,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000105976","animal_model","impc",0.346581347718385,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000105976","animal_model","impc",0.346581347718385,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000105976","affected_pathway","cancer_biomarkers",0.919067987742997,7,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000105976","affected_pathway","cancer_biomarkers",0.919067987742997,7,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000105976","affected_pathway","cancer_biomarkers",0.919067987742997,7,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000105976","affected_pathway","cancer_biomarkers",0.919067987742997,7,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000105976","affected_pathway","cancer_biomarkers",0.919067987742997,7,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000105976","somatic_mutation","cancer_gene_census",0.90704317994023,9,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000105976","somatic_mutation","cancer_gene_census",0.90704317994023,9,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000105976","somatic_mutation","cancer_gene_census",0.90704317994023,9,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000105976","somatic_mutation","cancer_gene_census",0.90704317994023,9,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000105976","somatic_mutation","cancer_gene_census",0.90704317994023,9,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000105976","affected_pathway","slapenrich",0.957622468381807,14,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000105976","affected_pathway","slapenrich",0.957622468381807,14,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000105976","affected_pathway","slapenrich",0.957622468381807,14,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000105976","affected_pathway","slapenrich",0.957622468381807,14,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000105976","affected_pathway","slapenrich",0.957622468381807,14,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000105976","literature","europepmc",0.976581725537189,270,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000105976","literature","europepmc",0.976581725537189,270,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000105976","literature","europepmc",0.976581725537189,270,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000105976","literature","europepmc",0.976581725537189,270,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000105976","literature","europepmc",0.976581725537189,270,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000105976","known_drug","chembl",0.976687856397572,125,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000105976","known_drug","chembl",0.976687856397572,125,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000105976","known_drug","chembl",0.976687856397572,125,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000105976","known_drug","chembl",0.976687856397572,125,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000105976","known_drug","chembl",0.976687856397572,125,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000004478","literature","europepmc",0.174611234647338,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000004478","literature","europepmc",0.174611234647338,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000004478","literature","europepmc",0.174611234647338,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000044115","somatic_mutation","cancer_gene_census",0.379956748507263,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000044115","somatic_mutation","cancer_gene_census",0.379956748507263,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000044115","somatic_mutation","cancer_gene_census",0.379956748507263,2,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000148082","literature","europepmc",0.0151982699402905,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000148082","literature","europepmc",0.0151982699402905,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000148082","literature","europepmc",0.0151982699402905,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000148082","literature","europepmc",0.0151982699402905,2,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000148082","literature","europepmc",0.0151982699402905,2,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000187191","animal_model","impc",0.379622386568577,2,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000187191","animal_model","impc",0.379622386568577,2,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000135605","somatic_mutation","cancer_gene_census",0.35884804025686,3,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000135605","somatic_mutation","cancer_gene_census",0.35884804025686,3,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000135605","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000135605","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000135605","literature","europepmc",0.0486344638089297,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000135605","literature","europepmc",0.0486344638089297,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000170312","affected_pathway","slapenrich",0.936072224944711,9,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000170312","affected_pathway","slapenrich",0.936072224944711,9,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000170312","affected_pathway","slapenrich",0.936072224944711,9,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000133961","literature","europepmc",0.661168727972614,10,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000133961","literature","europepmc",0.661168727972614,10,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000133961","literature","europepmc",0.661168727972614,10,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000170312","literature","europepmc",0.89823858479019,59,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000170312","literature","europepmc",0.89823858479019,59,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000170312","literature","europepmc",0.89823858479019,59,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000170312","known_drug","chembl",0.136784429462615,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000170312","known_drug","chembl",0.136784429462615,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000170312","known_drug","chembl",0.136784429462615,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000170312","rna_expression","expression_atlas",0.19896769224624,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000170312","rna_expression","expression_atlas",0.19896769224624,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000170312","rna_expression","expression_atlas",0.19896769224624,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000126581","animal_model","impc",0.341353142858925,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000126581","animal_model","impc",0.341353142858925,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000126581","animal_model","impc",0.341353142858925,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000198561","somatic_mutation","cancer_gene_census",0.406342633820268,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000198561","somatic_mutation","cancer_gene_census",0.406342633820268,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000198561","somatic_mutation","cancer_gene_census",0.406342633820268,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000161203","affected_pathway","slapenrich",0.80472070794997,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000161203","affected_pathway","slapenrich",0.80472070794997,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000161203","affected_pathway","slapenrich",0.80472070794997,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000113013","literature","europepmc",0.7199663914911,9,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000113013","literature","europepmc",0.7199663914911,9,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000113013","literature","europepmc",0.7199663914911,9,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000126581","literature","europepmc",0.879860950379892,50,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000126581","literature","europepmc",0.879860950379892,50,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000126581","literature","europepmc",0.879860950379892,50,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000113580","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000113580","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000113580","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000113580","literature","europepmc",0.482929464489364,8,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000113580","literature","europepmc",0.482929464489364,8,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000113580","literature","europepmc",0.482929464489364,8,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000154277","literature","europepmc",0.859299295339394,26,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000154277","literature","europepmc",0.859299295339394,26,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000154277","literature","europepmc",0.859299295339394,26,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000113580","known_drug","chembl",0.828317351732793,17,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000113580","known_drug","chembl",0.828317351732793,17,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000113580","known_drug","chembl",0.828317351732793,17,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000154277","rna_expression","expression_atlas",0.279453064700792,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000154277","rna_expression","expression_atlas",0.279453064700792,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000154277","rna_expression","expression_atlas",0.279453064700792,5,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000149177","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000149177","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000149177","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000149177","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000149177","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000149177","literature","europepmc",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000149177","literature","europepmc",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000149177","literature","europepmc",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000149177","literature","europepmc",0.607930797611621,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000149177","literature","europepmc",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000169375","literature","europepmc",0.175175104247401,8,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000169375","literature","europepmc",0.175175104247401,8,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000169375","literature","europepmc",0.175175104247401,8,NA,NA
"Imfinzi","Durvalumab","DURVALUMAB","CHEMBL3301587","AstraZeneca","PDL1-blocking antibody","Oncology","Urothelial carcinoma","urothelial carcinoma","EFO_0008528","Serious","P,B,A",2017,"ENSG00000120217","ENSG00000197646","literature","europepmc",0.0121586159522324,1,NA,NA
"Tecentriq","Atezolizumab","ATEZOLIZUMAB","CHEMBL3707227","Genentech","PDL1 inhibitor","Oncology","Urothelial carcinoma","urothelial carcinoma","EFO_0008528","Serious","P,B,A",2016,"ENSG00000120217","ENSG00000197646","literature","europepmc",0.0121586159522324,1,NA,NA
"Imfinzi","Durvalumab","DURVALUMAB","CHEMBL3301587","AstraZeneca","PDL1-blocking antibody","Oncology","Urothelial carcinoma","urothelial carcinoma","EFO_0008528","Serious","P,B,A",2017,"ENSG00000120217","ENSG00000197646","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Tecentriq","Atezolizumab","ATEZOLIZUMAB","CHEMBL3707227","Genentech","PDL1 inhibitor","Oncology","Urothelial carcinoma","urothelial carcinoma","EFO_0008528","Serious","P,B,A",2016,"ENSG00000120217","ENSG00000197646","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000111252","somatic_mutation","cancer_gene_census",0.60370905596154,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000111252","somatic_mutation","cancer_gene_census",0.60370905596154,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000111252","somatic_mutation","cancer_gene_census",0.60370905596154,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000111252","somatic_mutation","cancer_gene_census",0.60370905596154,3,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000111252","somatic_mutation","cancer_gene_census",0.60370905596154,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000109971","affected_pathway","slapenrich",0.332865881097454,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000109971","affected_pathway","slapenrich",0.332865881097454,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000109971","affected_pathway","slapenrich",0.332865881097454,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000109971","literature","europepmc",0.0392621973457505,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000109971","literature","europepmc",0.0392621973457505,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000109971","literature","europepmc",0.0392621973457505,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000111679","animal_model","impc",0.269799687980037,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000111679","animal_model","impc",0.269799687980037,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000111679","animal_model","impc",0.269799687980037,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000111679","somatic_mutation","cancer_gene_census",0.35884804025686,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000111679","somatic_mutation","cancer_gene_census",0.35884804025686,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000111679","somatic_mutation","cancer_gene_census",0.35884804025686,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000111679","affected_pathway","slapenrich",0.692988994185305,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000111679","affected_pathway","slapenrich",0.692988994185305,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000111679","affected_pathway","slapenrich",0.692988994185305,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000103653","literature","europepmc",0.0182379239283486,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000103653","literature","europepmc",0.0182379239283486,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000103653","literature","europepmc",0.0182379239283486,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000111679","literature","europepmc",0.0790310036895107,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000111679","literature","europepmc",0.0790310036895107,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000111679","literature","europepmc",0.0790310036895107,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000141655","literature","europepmc",0.604766180070721,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000141655","literature","europepmc",0.604766180070721,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000141655","literature","europepmc",0.604766180070721,6,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000113263","somatic_mutation","cancer_gene_census",0.406342633820268,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000113263","somatic_mutation","cancer_gene_census",0.406342633820268,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000113263","somatic_mutation","cancer_gene_census",0.406342633820268,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000113263","somatic_mutation","cancer_gene_census",0.406342633820268,4,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000113263","somatic_mutation","cancer_gene_census",0.406342633820268,4,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000113263","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000113263","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000113263","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000113263","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000113263","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000169047","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000169047","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000169047","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000113263","literature","europepmc",0.182379239283486,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000113263","literature","europepmc",0.182379239283486,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000113263","literature","europepmc",0.182379239283486,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000113263","literature","europepmc",0.182379239283486,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000113263","literature","europepmc",0.182379239283486,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000169047","literature","europepmc",0.738993132977068,16,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000169047","literature","europepmc",0.738993132977068,16,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000169047","literature","europepmc",0.738993132977068,16,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000113263","known_drug","chembl",0.186624374213169,11,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000113263","known_drug","chembl",0.186624374213169,11,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000113263","known_drug","chembl",0.186624374213169,11,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000113263","known_drug","chembl",0.186624374213169,11,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000113263","known_drug","chembl",0.186624374213169,11,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000111077","rna_expression","expression_atlas",0.120649302841295,2,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000111077","rna_expression","expression_atlas",0.120649302841295,2,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000092208","literature","europepmc",0.0121586159522324,1,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000092208","literature","europepmc",0.0121586159522324,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000115325","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000115325","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000115325","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000168003","literature","europepmc",0.689703617915207,12,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000168003","literature","europepmc",0.689703617915207,12,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000168003","literature","europepmc",0.689703617915207,12,NA,NA
"Praluent","Alirocumab","ALIROCUMAB","CHEMBL2109540","Sanofi","PCSK9 inhibitor","Other indication","LDL lowering","low density lipoprotein cholesterol measurement","EFO_0004611","Not serious","P",2015,"ENSG00000169174","ENSG00000130164","genetic_association","ot_genetics_portal",0.671224263348315,89,NA,NA
"Praluent","Alirocumab","ALIROCUMAB","CHEMBL2109540","Sanofi","PCSK9 inhibitor","Other indication","LDL lowering","low density lipoprotein cholesterol measurement","EFO_0004611","Not serious","P",2015,"ENSG00000169174","ENSG00000130164","genetic_association","gene_burden",0.960188179680329,17,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000183020","affected_pathway","slapenrich",0.80472070794997,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000183020","affected_pathway","slapenrich",0.80472070794997,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000183020","affected_pathway","slapenrich",0.80472070794997,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000172757","literature","europepmc",0.195117697507054,12,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000172757","literature","europepmc",0.195117697507054,12,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000172757","literature","europepmc",0.195117697507054,12,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000172757","affected_pathway","crispr",0.275848599416273,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000172757","affected_pathway","crispr",0.275848599416273,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000172757","affected_pathway","crispr",0.275848599416273,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000142949","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000142949","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000142949","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000142949","literature","europepmc",0.19723976989177,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000142949","literature","europepmc",0.19723976989177,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000142949","literature","europepmc",0.19723976989177,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000178568","affected_pathway","cancer_biomarkers",0.759913497014526,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000178568","affected_pathway","cancer_biomarkers",0.759913497014526,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000178568","affected_pathway","cancer_biomarkers",0.759913497014526,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000178568","somatic_mutation","cancer_gene_census",0.812178658642525,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000178568","somatic_mutation","cancer_gene_census",0.812178658642525,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000178568","somatic_mutation","cancer_gene_census",0.812178658642525,6,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000141738","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000141738","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000178568","affected_pathway","slapenrich",0.961203999188419,16,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000178568","affected_pathway","slapenrich",0.961203999188419,16,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000178568","affected_pathway","slapenrich",0.961203999188419,16,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000109321","literature","europepmc",0.28448041903902,31,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000109321","literature","europepmc",0.28448041903902,31,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000109321","literature","europepmc",0.28448041903902,31,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000141738","literature","europepmc",0.0607930797611621,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000141738","literature","europepmc",0.0607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000178568","literature","europepmc",0.344239895693024,33,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000178568","literature","europepmc",0.344239895693024,33,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000178568","literature","europepmc",0.344239895693024,33,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000178568","known_drug","chembl",0.970956194362574,111,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000178568","known_drug","chembl",0.970956194362574,111,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000178568","known_drug","chembl",0.970956194362574,111,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000109321","rna_expression","expression_atlas",0.107438360692095,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000109321","rna_expression","expression_atlas",0.107438360692095,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000109321","rna_expression","expression_atlas",0.107438360692095,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000127191","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000127191","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000127191","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000014641","literature","europepmc",0.0121586159522324,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000014641","literature","europepmc",0.0121586159522324,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000014641","literature","europepmc",0.0121586159522324,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000103423","literature","europepmc",0.760528182598778,6,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000103423","literature","europepmc",0.760528182598778,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000170248","literature","europepmc",0.115506851546208,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000170248","literature","europepmc",0.115506851546208,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000170248","literature","europepmc",0.115506851546208,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000071051","affected_pathway","slapenrich",0.541934779765952,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000071051","affected_pathway","slapenrich",0.541934779765952,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000071051","affected_pathway","slapenrich",0.541934779765952,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000071051","affected_pathway","slapenrich",0.541934779765952,2,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000071051","affected_pathway","slapenrich",0.541934779765952,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000141480","affected_pathway","slapenrich",0.928566906455679,8,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000141480","affected_pathway","slapenrich",0.928566906455679,8,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000141480","affected_pathway","slapenrich",0.928566906455679,8,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000198668","affected_pathway","slapenrich",0.795395301045547,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000198668","affected_pathway","slapenrich",0.795395301045547,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000198668","affected_pathway","slapenrich",0.795395301045547,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000141480","literature","europepmc",0.0697431720593332,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000141480","literature","europepmc",0.0697431720593332,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000141480","literature","europepmc",0.0697431720593332,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000198668","literature","europepmc",0.0364758478566973,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000198668","literature","europepmc",0.0364758478566973,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000198668","literature","europepmc",0.0364758478566973,1,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000167037","literature","europepmc",0.0151982699402905,2,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000167037","literature","europepmc",0.0151982699402905,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000101182","affected_pathway","slapenrich",0.936072224944711,9,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000101182","affected_pathway","slapenrich",0.936072224944711,9,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000101182","affected_pathway","slapenrich",0.936072224944711,9,NA,NA
"Empliciti","Elotuzumab","ELOTUZUMAB","CHEMBL1743010","Bristol-Myers Squibb","SLAMF7-directed mAb","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,B",2015,"ENSG00000026751","ENSG00000183918","animal_model","impc",0.51897832548173,8,"MONDO_0004095","multiple myeloma -> B-cell neoplasm (parent)"
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000144749","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000144749","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000144749","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000144749","literature","europepmc",0.685475468025079,12,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000144749","literature","europepmc",0.685475468025079,12,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000144749","literature","europepmc",0.685475468025079,12,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000196154","animal_model","impc",0.301108124057036,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000196154","animal_model","impc",0.301108124057036,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000196154","animal_model","impc",0.301108124057036,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000007264","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000007264","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000196154","literature","europepmc",0.816317348095827,22,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000196154","literature","europepmc",0.816317348095827,22,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000196154","literature","europepmc",0.816317348095827,22,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000196154","rna_expression","expression_atlas",0.149825502301314,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000196154","rna_expression","expression_atlas",0.149825502301314,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000196154","rna_expression","expression_atlas",0.149825502301314,4,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000010017","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000010017","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000149428","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000149428","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000149428","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000149428","literature","europepmc",0.623129067551912,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000149428","literature","europepmc",0.623129067551912,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000149428","literature","europepmc",0.623129067551912,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000143294","somatic_mutation","cancer_gene_census",0.303965398805811,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000143294","somatic_mutation","cancer_gene_census",0.303965398805811,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000143294","somatic_mutation","cancer_gene_census",0.303965398805811,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000057294","literature","europepmc",0.218601782641179,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000057294","literature","europepmc",0.218601782641179,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000057294","literature","europepmc",0.218601782641179,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000114737","literature","europepmc",0.209736125176009,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000114737","literature","europepmc",0.209736125176009,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000114737","literature","europepmc",0.209736125176009,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000143294","literature","europepmc",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000143294","literature","europepmc",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000143294","literature","europepmc",0.607930797611621,1,NA,NA
"Xpovio","Selinexor","SELINEXOR","CHEMBL3545185","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019,"ENSG00000082898","ENSG00000135829","rna_expression","expression_atlas",0.0246814623944667,1,"MONDO_0004095","multiple myeloma -> B-cell neoplasm (parent)"
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000101336","animal_model","impc",0.295211195320203,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000101336","animal_model","impc",0.295211195320203,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000101336","animal_model","impc",0.295211195320203,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000101336","animal_model","impc",0.295211195320203,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000101336","animal_model","impc",0.295211195320203,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000101336","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000101336","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000101336","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000101336","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000101336","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000103266","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000103266","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000103266","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000101336","literature","europepmc",0.0303965398805811,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000101336","literature","europepmc",0.0303965398805811,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000101336","literature","europepmc",0.0303965398805811,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000101336","literature","europepmc",0.0303965398805811,2,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000101336","literature","europepmc",0.0303965398805811,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000103266","literature","europepmc",0.406607500721914,8,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000103266","literature","europepmc",0.406607500721914,8,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000103266","literature","europepmc",0.406607500721914,8,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000134242","literature","europepmc",0.121586159522324,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000134242","literature","europepmc",0.121586159522324,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000134242","literature","europepmc",0.121586159522324,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000101336","known_drug","chembl",0.181474366348028,12,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000101336","known_drug","chembl",0.181474366348028,12,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000101336","known_drug","chembl",0.181474366348028,12,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000101336","known_drug","chembl",0.181474366348028,12,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000101336","known_drug","chembl",0.181474366348028,12,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000137076","affected_pathway","slapenrich",0.919067987742997,7,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000137076","affected_pathway","slapenrich",0.919067987742997,7,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000137076","affected_pathway","slapenrich",0.919067987742997,7,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000163563","literature","europepmc",0.103348235593976,2,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000163563","literature","europepmc",0.103348235593976,2,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000163563","rna_expression","expression_atlas",0.17085255832375,3,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000163563","rna_expression","expression_atlas",0.17085255832375,3,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000152894","somatic_mutation","cancer_gene_census",0.584711218536177,4,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000152894","somatic_mutation","cancer_gene_census",0.584711218536177,4,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000152894","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000152894","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000152894","literature","europepmc",0.192849158575687,3,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000152894","literature","europepmc",0.192849158575687,3,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000152894","somatic_mutation","intogen",0.161569819042579,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000152894","somatic_mutation","intogen",0.161569819042579,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000135052","literature","europepmc",0.807130093198176,8,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000135052","literature","europepmc",0.807130093198176,8,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000135052","literature","europepmc",0.807130093198176,8,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000135052","rna_expression","expression_atlas",0.158683447749913,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000135052","rna_expression","expression_atlas",0.158683447749913,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000135052","rna_expression","expression_atlas",0.158683447749913,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000105974","literature","europepmc",0.898378281236576,50,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000105974","literature","europepmc",0.898378281236576,50,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000105974","literature","europepmc",0.898378281236576,50,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000105974","rna_expression","expression_atlas",0.272413311624789,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000105974","rna_expression","expression_atlas",0.272413311624789,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000105974","rna_expression","expression_atlas",0.272413311624789,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000124882","affected_pathway","slapenrich",0.959877476978866,15,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000124882","affected_pathway","slapenrich",0.959877476978866,15,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000124882","affected_pathway","slapenrich",0.959877476978866,15,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000124882","literature","europepmc",0.738720822056216,10,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000124882","literature","europepmc",0.738720822056216,10,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000124882","literature","europepmc",0.738720822056216,10,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000124882","rna_expression","expression_atlas",0.0101259522740381,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000124882","rna_expression","expression_atlas",0.0101259522740381,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000124882","rna_expression","expression_atlas",0.0101259522740381,1,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000197442","literature","europepmc",0.0121586159522324,1,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000197442","literature","europepmc",0.0121586159522324,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000165025","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000165025","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000165025","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000165025","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000165025","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000127824","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000127824","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000127824","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000142627","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000142627","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000142627","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000165025","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000165025","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000165025","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000165025","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000165025","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000142627","literature","europepmc",0.893725627691073,25,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000142627","literature","europepmc",0.893725627691073,25,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000142627","literature","europepmc",0.893725627691073,25,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000165025","literature","europepmc",0.17157158065928,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000165025","literature","europepmc",0.17157158065928,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000165025","literature","europepmc",0.17157158065928,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000165025","literature","europepmc",0.17157158065928,3,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000165025","literature","europepmc",0.17157158065928,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000127824","known_drug","chembl",0.603445306969319,13,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000127824","known_drug","chembl",0.603445306969319,13,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000127824","known_drug","chembl",0.603445306969319,13,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000142627","known_drug","chembl",0.627417610703034,30,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000142627","known_drug","chembl",0.627417610703034,30,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000142627","known_drug","chembl",0.627417610703034,30,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000169045","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000169045","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000169045","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000067560","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000067560","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000134853","somatic_mutation","cancer_gene_census",0.639593859987226,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000134853","somatic_mutation","cancer_gene_census",0.639593859987226,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000134853","somatic_mutation","cancer_gene_census",0.639593859987226,4,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000067560","affected_pathway","slapenrich",0.906661236771331,6,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000067560","affected_pathway","slapenrich",0.906661236771331,6,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000134215","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000134215","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000134853","affected_pathway","slapenrich",0.865457038266544,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000134853","affected_pathway","slapenrich",0.865457038266544,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000134853","affected_pathway","slapenrich",0.865457038266544,4,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000067560","literature","europepmc",0.249935068335889,28,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000067560","literature","europepmc",0.249935068335889,28,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000111640","literature","europepmc",0.666795726593032,27,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000111640","literature","europepmc",0.666795726593032,27,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000111640","literature","europepmc",0.666795726593032,27,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000134215","literature","europepmc",0.0682233450653041,3,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000134215","literature","europepmc",0.0682233450653041,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000134853","literature","europepmc",0.315612937843516,34,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000134853","literature","europepmc",0.315612937843516,34,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000134853","literature","europepmc",0.315612937843516,34,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000134853","known_drug","chembl",0.666650008369588,71,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000134853","known_drug","chembl",0.666650008369588,71,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000134853","known_drug","chembl",0.666650008369588,71,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000067560","affected_pathway","crispr",0.302445571811781,1,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000067560","affected_pathway","crispr",0.302445571811781,1,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000067560","somatic_mutation","eva_somatic",0.531939447910168,2,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000067560","somatic_mutation","eva_somatic",0.531939447910168,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000137486","affected_pathway","slapenrich",0.928566906455679,8,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000137486","affected_pathway","slapenrich",0.928566906455679,8,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000137486","affected_pathway","slapenrich",0.928566906455679,8,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000137486","literature","europepmc",0.349249488441236,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000137486","literature","europepmc",0.349249488441236,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000137486","literature","europepmc",0.349249488441236,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000137486","rna_expression","expression_atlas",0.180303524256945,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000137486","rna_expression","expression_atlas",0.180303524256945,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000137486","rna_expression","expression_atlas",0.180303524256945,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000107295","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000107295","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000107295","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000107295","rna_expression","expression_atlas",0.0758697635419303,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000107295","rna_expression","expression_atlas",0.0758697635419303,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000107295","rna_expression","expression_atlas",0.0758697635419303,1,NA,NA
"Xpovio","Selinexor","SELINEXOR","CHEMBL3545185","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019,"ENSG00000082898","ENSG00000123908","literature","europepmc",0.486984550733858,7,"MONDO_0004095","multiple myeloma -> B-cell neoplasm (parent)"
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000165731","affected_pathway","cancer_biomarkers",0.906661236771331,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000165731","affected_pathway","cancer_biomarkers",0.906661236771331,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000165731","affected_pathway","cancer_biomarkers",0.906661236771331,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000165731","somatic_mutation","cancer_gene_census",0.910414709730225,8,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000165731","somatic_mutation","cancer_gene_census",0.910414709730225,8,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000165731","somatic_mutation","cancer_gene_census",0.910414709730225,8,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000169398","affected_pathway","slapenrich",0.862768894903947,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000169398","affected_pathway","slapenrich",0.862768894903947,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000169398","affected_pathway","slapenrich",0.862768894903947,4,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000198753","affected_pathway","slapenrich",0.332516934361418,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000198753","affected_pathway","slapenrich",0.332516934361418,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000149925","literature","europepmc",0.0965934489538465,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000149925","literature","europepmc",0.0965934489538465,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000149925","literature","europepmc",0.0965934489538465,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000165731","literature","europepmc",0.972309629803176,247,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000165731","literature","europepmc",0.972309629803176,247,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000165731","literature","europepmc",0.972309629803176,247,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000169398","literature","europepmc",0.800980361019288,76,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000169398","literature","europepmc",0.800980361019288,76,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000169398","literature","europepmc",0.800980361019288,76,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000198753","literature","europepmc",0.0303965398805811,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000198753","literature","europepmc",0.0303965398805811,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000165731","known_drug","chembl",0.94445999328347,92,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000165731","known_drug","chembl",0.94445999328347,92,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000165731","known_drug","chembl",0.94445999328347,92,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000169398","known_drug","chembl",0.162537053528107,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000169398","known_drug","chembl",0.162537053528107,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000169398","known_drug","chembl",0.162537053528107,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000165731","somatic_mutation","intogen",0.151982699402905,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000165731","somatic_mutation","intogen",0.151982699402905,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000165731","somatic_mutation","intogen",0.151982699402905,1,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000197386","animal_model","impc",0.327431527593619,2,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000197386","animal_model","impc",0.327431527593619,2,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000197386","literature","europepmc",0.22810239005052,6,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000197386","literature","europepmc",0.22810239005052,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000110711","animal_model","impc",0.293691368326174,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000110711","animal_model","impc",0.293691368326174,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000110711","animal_model","impc",0.293691368326174,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000141736","affected_pathway","cancer_biomarkers",0.951397496038773,12,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000141736","affected_pathway","cancer_biomarkers",0.951397496038773,12,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000141736","affected_pathway","cancer_biomarkers",0.951397496038773,12,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000141736","somatic_mutation","cancer_gene_census",0.669694877952302,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000141736","somatic_mutation","cancer_gene_census",0.669694877952302,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000141736","somatic_mutation","cancer_gene_census",0.669694877952302,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000141736","affected_pathway","slapenrich",0.959996460388616,15,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000141736","affected_pathway","slapenrich",0.959996460388616,15,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000141736","affected_pathway","slapenrich",0.959996460388616,15,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000141736","literature","europepmc",0.982466620532768,590,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000141736","literature","europepmc",0.982466620532768,590,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000141736","literature","europepmc",0.982466620532768,590,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000141736","known_drug","chembl",0.972514955141993,147,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000141736","known_drug","chembl",0.972514955141993,147,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000141736","known_drug","chembl",0.972514955141993,147,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000141736","somatic_mutation","intogen",0.280179292109923,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000141736","somatic_mutation","intogen",0.280179292109923,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000141736","somatic_mutation","intogen",0.280179292109923,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000141736","genetic_association","uniprot_variants",0.759913497014526,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000141736","genetic_association","uniprot_variants",0.759913497014526,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000141736","genetic_association","uniprot_variants",0.759913497014526,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000141736","somatic_mutation","eva_somatic",0.86717354571265,17,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000141736","somatic_mutation","eva_somatic",0.86717354571265,17,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000141736","somatic_mutation","eva_somatic",0.86717354571265,17,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000089280","literature","europepmc",0.335474634700966,8,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000089280","literature","europepmc",0.335474634700966,8,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000092820","somatic_mutation","cancer_gene_census",0.759913497014526,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000092820","somatic_mutation","cancer_gene_census",0.759913497014526,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000092820","somatic_mutation","cancer_gene_census",0.759913497014526,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000092820","literature","europepmc",0.75323398777802,14,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000092820","literature","europepmc",0.75323398777802,14,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000092820","literature","europepmc",0.75323398777802,14,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000010671","somatic_mutation","cancer_gene_census",0.622706893386904,4,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000010671","somatic_mutation","cancer_gene_census",0.622706893386904,4,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000010671","affected_pathway","slapenrich",0.808937366025272,5,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000010671","affected_pathway","slapenrich",0.808937366025272,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000140600","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000140600","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000140600","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000010671","literature","europepmc",0.154243464028705,13,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000010671","literature","europepmc",0.154243464028705,13,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000010671","known_drug","chembl",0.602397013097096,14,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000010671","known_drug","chembl",0.602397013097096,14,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000010671","somatic_mutation","intogen",0.220323757346611,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000010671","somatic_mutation","intogen",0.220323757346611,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000140600","rna_expression","expression_atlas",0.105947277481124,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000140600","rna_expression","expression_atlas",0.105947277481124,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000140600","rna_expression","expression_atlas",0.105947277481124,2,NA,NA
"Xpovio","Selinexor","SELINEXOR","CHEMBL3545185","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019,"ENSG00000082898","ENSG00000141736","literature","europepmc",0.163366819936436,17,"MONDO_0004095","multiple myeloma -> B-cell neoplasm (parent)"
"Xpovio","Selinexor","SELINEXOR","CHEMBL3545185","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019,"ENSG00000082898","ENSG00000141736","somatic_mutation","cancer_gene_census",0.455948098208716,1,"MONDO_0004095","multiple myeloma -> B-cell neoplasm (parent)"
"Xpovio","Selinexor","SELINEXOR","CHEMBL3545185","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019,"ENSG00000082898","ENSG00000141736","known_drug","chembl",0.173091407653309,4,"MONDO_0004095","multiple myeloma -> B-cell neoplasm (parent)"
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000097007","somatic_mutation","cancer_gene_census",0.649092778699908,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000097007","somatic_mutation","cancer_gene_census",0.649092778699908,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000097007","somatic_mutation","cancer_gene_census",0.649092778699908,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000097007","affected_pathway","slapenrich",0.815792993463765,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000097007","affected_pathway","slapenrich",0.815792993463765,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000097007","affected_pathway","slapenrich",0.815792993463765,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000174808","affected_pathway","slapenrich",0.959877476978866,15,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000174808","affected_pathway","slapenrich",0.959877476978866,15,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000174808","affected_pathway","slapenrich",0.959877476978866,15,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000097007","literature","europepmc",0.325329458622341,31,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000097007","literature","europepmc",0.325329458622341,31,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000097007","literature","europepmc",0.325329458622341,31,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000167601","literature","europepmc",0.924587750911534,94,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000167601","literature","europepmc",0.924587750911534,94,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000167601","literature","europepmc",0.924587750911534,94,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000174808","literature","europepmc",0.425551558328135,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000174808","literature","europepmc",0.425551558328135,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000174808","literature","europepmc",0.425551558328135,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000097007","known_drug","chembl",0.191677263488207,20,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000097007","known_drug","chembl",0.191677263488207,20,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000097007","known_drug","chembl",0.191677263488207,20,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000167601","known_drug","chembl",0.150614855108279,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000167601","known_drug","chembl",0.150614855108279,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000167601","known_drug","chembl",0.150614855108279,6,NA,NA
"Beovu","Brolucizumab","BROLUCIZUMAB","CHEMBL3707357","Novartis","VEGF inhibitor","Other indication","Wet age-related macular degeneration","macular degeneration","EFO_0009606","Not concordant","S",2019,"ENSG00000112715","ENSG00000102755","literature","europepmc",0.308615997916721,22,NA,NA
"Beovu","Brolucizumab","BROLUCIZUMAB","CHEMBL3707357","Novartis","VEGF inhibitor","Other indication","Wet age-related macular degeneration","macular degeneration","EFO_0009606","Not concordant","S",2019,"ENSG00000112715","ENSG00000102755","known_drug","chembl",0.187986630983524,15,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000164050","literature","europepmc",0.0182379239283486,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000164050","literature","europepmc",0.0182379239283486,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000204389","literature","europepmc",0.11246719755815,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000204389","literature","europepmc",0.11246719755815,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000204389","literature","europepmc",0.11246719755815,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000046653","rna_expression","expression_atlas",0.170420055787954,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000046653","rna_expression","expression_atlas",0.170420055787954,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000046653","rna_expression","expression_atlas",0.170420055787954,4,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000143398","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000143398","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000143398","literature","europepmc",0.0395155018447554,2,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000143398","literature","europepmc",0.0395155018447554,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000198799","literature","europepmc",0.0683922147313074,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000198799","literature","europepmc",0.0683922147313074,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000198799","literature","europepmc",0.0683922147313074,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000105971","rna_expression","expression_atlas",0.143157570657577,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000105971","rna_expression","expression_atlas",0.143157570657577,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000105971","rna_expression","expression_atlas",0.143157570657577,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000120694","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000120694","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000120694","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000120694","literature","europepmc",0.0729516957133945,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000120694","literature","europepmc",0.0729516957133945,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000120694","literature","europepmc",0.0729516957133945,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000254087","somatic_mutation","cancer_gene_census",0.396843715107586,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000254087","somatic_mutation","cancer_gene_census",0.396843715107586,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000254087","somatic_mutation","cancer_gene_census",0.396843715107586,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000254087","somatic_mutation","cancer_gene_census",0.396843715107586,3,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000254087","somatic_mutation","cancer_gene_census",0.396843715107586,3,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000254087","affected_pathway","slapenrich",0.796603064405007,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000254087","affected_pathway","slapenrich",0.796603064405007,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000254087","affected_pathway","slapenrich",0.796603064405007,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000254087","affected_pathway","slapenrich",0.796603064405007,3,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000254087","affected_pathway","slapenrich",0.796603064405007,3,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000254087","literature","europepmc",0.242454622964135,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000254087","literature","europepmc",0.242454622964135,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000254087","literature","europepmc",0.242454622964135,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000254087","literature","europepmc",0.242454622964135,4,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000254087","literature","europepmc",0.242454622964135,4,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000254087","known_drug","chembl",0.181474366348028,12,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000254087","known_drug","chembl",0.181474366348028,12,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000254087","known_drug","chembl",0.181474366348028,12,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000254087","known_drug","chembl",0.181474366348028,12,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000254087","known_drug","chembl",0.181474366348028,12,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000121058","literature","europepmc",0.0838860065871035,4,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000121058","literature","europepmc",0.0838860065871035,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000087586","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000087586","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000087586","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000087586","literature","europepmc",0.870872514256317,32,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000087586","literature","europepmc",0.870872514256317,32,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000087586","literature","europepmc",0.870872514256317,32,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000101265","literature","europepmc",0.106050150250027,3,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000101265","literature","europepmc",0.106050150250027,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000087586","known_drug","chembl",0.143539216102744,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000087586","known_drug","chembl",0.143539216102744,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000087586","known_drug","chembl",0.143539216102744,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000087586","rna_expression","expression_atlas",0.211361311107265,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000087586","rna_expression","expression_atlas",0.211361311107265,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000087586","rna_expression","expression_atlas",0.211361311107265,5,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000101265","rna_expression","expression_atlas",0.135528039147551,3,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000101265","rna_expression","expression_atlas",0.135528039147551,3,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000179295","somatic_mutation","cancer_gene_census",0.651752475939459,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000179295","somatic_mutation","cancer_gene_census",0.651752475939459,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000179295","somatic_mutation","cancer_gene_census",0.651752475939459,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000179295","somatic_mutation","cancer_gene_census",0.651752475939459,5,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000179295","somatic_mutation","cancer_gene_census",0.651752475939459,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000167552","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000167552","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000167552","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000179295","affected_pathway","slapenrich",0.977932070180821,28,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000179295","affected_pathway","slapenrich",0.977932070180821,28,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000179295","affected_pathway","slapenrich",0.977932070180821,28,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000179295","affected_pathway","slapenrich",0.977932070180821,28,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000179295","affected_pathway","slapenrich",0.977932070180821,28,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000179295","literature","europepmc",0.840615639416052,40,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000179295","literature","europepmc",0.840615639416052,40,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000179295","literature","europepmc",0.840615639416052,40,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000179295","literature","europepmc",0.840615639416052,40,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000179295","literature","europepmc",0.840615639416052,40,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000167552","known_drug","chembl",0.603445306969319,13,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000167552","known_drug","chembl",0.603445306969319,13,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000167552","known_drug","chembl",0.603445306969319,13,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000179295","affected_pathway","crispr",0.329249848609275,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000179295","affected_pathway","crispr",0.329249848609275,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000179295","affected_pathway","crispr",0.329249848609275,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000179295","affected_pathway","crispr",0.329249848609275,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000179295","affected_pathway","crispr",0.329249848609275,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000179295","somatic_mutation","eva_somatic",0.425551558328135,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000179295","somatic_mutation","eva_somatic",0.425551558328135,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000179295","somatic_mutation","eva_somatic",0.425551558328135,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000179295","somatic_mutation","eva_somatic",0.425551558328135,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000179295","somatic_mutation","eva_somatic",0.425551558328135,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000131746","affected_pathway","slapenrich",0.822682441882312,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000131746","affected_pathway","slapenrich",0.822682441882312,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000131746","affected_pathway","slapenrich",0.822682441882312,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000131746","affected_pathway","slapenrich",0.822682441882312,3,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000131746","affected_pathway","slapenrich",0.822682441882312,3,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000131746","literature","europepmc",0.179001845963422,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000131746","literature","europepmc",0.179001845963422,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000131746","literature","europepmc",0.179001845963422,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000131746","literature","europepmc",0.179001845963422,3,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000131746","literature","europepmc",0.179001845963422,3,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000131746","rna_expression","expression_atlas",0.334546850970665,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000131746","rna_expression","expression_atlas",0.334546850970665,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000131746","rna_expression","expression_atlas",0.334546850970665,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000131746","rna_expression","expression_atlas",0.334546850970665,4,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000131746","rna_expression","expression_atlas",0.334546850970665,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000159176","rna_expression","expression_atlas",0.0125811957485049,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000159176","rna_expression","expression_atlas",0.0125811957485049,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000159176","rna_expression","expression_atlas",0.0125811957485049,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000165527","literature","europepmc",0.135940081132599,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000165527","literature","europepmc",0.135940081132599,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000165527","literature","europepmc",0.135940081132599,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000109458","affected_pathway","slapenrich",0.981778740939984,33,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000109458","affected_pathway","slapenrich",0.981778740939984,33,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000109458","affected_pathway","slapenrich",0.981778740939984,33,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000109458","literature","europepmc",0.0942292736298013,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000109458","literature","europepmc",0.0942292736298013,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000109458","literature","europepmc",0.0942292736298013,2,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000019991","affected_pathway","slapenrich",0.96038772495641,15,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000019991","affected_pathway","slapenrich",0.96038772495641,15,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000019991","literature","europepmc",0.925742919858872,84,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000019991","literature","europepmc",0.925742919858872,84,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000019991","known_drug","chembl",0.121586159522324,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000019991","known_drug","chembl",0.121586159522324,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000019991","rna_expression","expression_atlas",0.105050441827288,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000019991","rna_expression","expression_atlas",0.105050441827288,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000065361","somatic_mutation","cancer_gene_census",0.651752475939459,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000065361","somatic_mutation","cancer_gene_census",0.651752475939459,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000065361","somatic_mutation","cancer_gene_census",0.651752475939459,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000065361","affected_pathway","slapenrich",0.951397496038773,12,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000065361","affected_pathway","slapenrich",0.951397496038773,12,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000065361","affected_pathway","slapenrich",0.951397496038773,12,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000065361","literature","europepmc",0.913717609677202,96,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000065361","literature","europepmc",0.913717609677202,96,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000065361","literature","europepmc",0.913717609677202,96,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000156973","literature","europepmc",0.0182379239283486,1,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000156973","literature","europepmc",0.0182379239283486,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000065361","known_drug","chembl",0.655859973145328,41,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000065361","known_drug","chembl",0.655859973145328,41,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000065361","known_drug","chembl",0.655859973145328,41,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000156973","known_drug","chembl",0.121586159522324,1,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000156973","known_drug","chembl",0.121586159522324,1,NA,NA
"Beovu","Brolucizumab","BROLUCIZUMAB","CHEMBL3707357","Novartis","VEGF inhibitor","Other indication","Wet age-related macular degeneration","macular degeneration","EFO_0009606","Not concordant","S",2019,"ENSG00000112715","ENSG00000128052","literature","europepmc",0.725553301027683,52,NA,NA
"Beovu","Brolucizumab","BROLUCIZUMAB","CHEMBL3707357","Novartis","VEGF inhibitor","Other indication","Wet age-related macular degeneration","macular degeneration","EFO_0009606","Not concordant","S",2019,"ENSG00000112715","ENSG00000128052","known_drug","chembl",0.189740387345205,19,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000033327","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000033327","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000033327","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000151834","affected_pathway","slapenrich",0.604479163804229,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000151834","affected_pathway","slapenrich",0.604479163804229,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000151834","affected_pathway","slapenrich",0.604479163804229,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000033327","literature","europepmc",0.124625813510382,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000033327","literature","europepmc",0.124625813510382,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000033327","literature","europepmc",0.124625813510382,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000106070","literature","europepmc",0.0303965398805811,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000106070","literature","europepmc",0.0303965398805811,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000106070","literature","europepmc",0.0303965398805811,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000170606","literature","europepmc",0.0303965398805811,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000170606","literature","europepmc",0.0303965398805811,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000170606","literature","europepmc",0.0303965398805811,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000151834","known_drug","chembl",0.0827461363415817,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000151834","known_drug","chembl",0.0827461363415817,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000151834","known_drug","chembl",0.0827461363415817,3,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000182004","animal_model","impc",0.249859557818376,1,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000182004","animal_model","impc",0.249859557818376,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000117450","animal_model","impc",0.303539847247482,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000117450","animal_model","impc",0.303539847247482,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000117450","animal_model","impc",0.303539847247482,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000185499","somatic_mutation","cancer_gene_census",0.341961073656537,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000185499","somatic_mutation","cancer_gene_census",0.341961073656537,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000185499","somatic_mutation","cancer_gene_census",0.341961073656537,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000117450","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000117450","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000117450","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000185499","affected_pathway","slapenrich",0.865457038266544,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000185499","affected_pathway","slapenrich",0.865457038266544,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000185499","affected_pathway","slapenrich",0.865457038266544,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000117450","literature","europepmc",0.438572477936095,8,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000117450","literature","europepmc",0.438572477936095,8,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000117450","literature","europepmc",0.438572477936095,8,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000185499","literature","europepmc",0.909031739227639,104,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000185499","literature","europepmc",0.909031739227639,104,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000185499","literature","europepmc",0.909031739227639,104,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000185499","known_drug","chembl",0.593374232402143,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000185499","known_drug","chembl",0.593374232402143,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000185499","known_drug","chembl",0.593374232402143,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000185499","rna_expression","expression_atlas",0.066525320294239,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000185499","rna_expression","expression_atlas",0.066525320294239,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000185499","rna_expression","expression_atlas",0.066525320294239,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000189043","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000189043","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000189043","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000163697","literature","europepmc",0.0243172319044648,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000163697","literature","europepmc",0.0243172319044648,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000163697","literature","europepmc",0.0243172319044648,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000189043","literature","europepmc",0.0911896196417432,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000189043","literature","europepmc",0.0911896196417432,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000189043","literature","europepmc",0.0911896196417432,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000189043","known_drug","chembl",0.573387338140547,18,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000189043","known_drug","chembl",0.573387338140547,18,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000189043","known_drug","chembl",0.573387338140547,18,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000082516","literature","europepmc",0.0121586159522324,1,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000082516","literature","europepmc",0.0121586159522324,1,NA,NA
"Imfinzi","Durvalumab","DURVALUMAB","CHEMBL3301587","AstraZeneca","PDL1-blocking antibody","Oncology","Urothelial carcinoma","urothelial carcinoma","EFO_0008528","Serious","P,B,A",2017,"ENSG00000120217","ENSG00000121594","literature","europepmc",0.126145640504411,2,NA,NA
"Tecentriq","Atezolizumab","ATEZOLIZUMAB","CHEMBL3707227","Genentech","PDL1 inhibitor","Oncology","Urothelial carcinoma","urothelial carcinoma","EFO_0008528","Serious","P,B,A",2016,"ENSG00000120217","ENSG00000121594","literature","europepmc",0.126145640504411,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000153707","somatic_mutation","cancer_gene_census",0.446131256502385,7,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000153707","somatic_mutation","cancer_gene_census",0.446131256502385,7,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000153707","somatic_mutation","cancer_gene_census",0.446131256502385,7,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000153707","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000153707","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000153707","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000067182","affected_pathway","progeny",0.303965398805811,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000067182","affected_pathway","progeny",0.303965398805811,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000067182","affected_pathway","progeny",0.303965398805811,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000067182","literature","europepmc",0.123607564164488,11,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000067182","literature","europepmc",0.123607564164488,11,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000067182","literature","europepmc",0.123607564164488,11,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000153707","literature","europepmc",0.358986447328521,10,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000153707","literature","europepmc",0.358986447328521,10,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000153707","literature","europepmc",0.358986447328521,10,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000153707","somatic_mutation","intogen",0.209901008450455,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000153707","somatic_mutation","intogen",0.209901008450455,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000153707","somatic_mutation","intogen",0.209901008450455,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000153707","rna_expression","expression_atlas",0.0766600735788254,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000153707","rna_expression","expression_atlas",0.0766600735788254,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000153707","rna_expression","expression_atlas",0.0766600735788254,1,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000132155","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000132155","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000132155","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000132155","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000132155","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000132155","affected_pathway","slapenrich",0.950985207217944,13,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000132155","affected_pathway","slapenrich",0.950985207217944,13,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000132155","affected_pathway","slapenrich",0.950985207217944,13,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000132155","affected_pathway","slapenrich",0.950985207217944,13,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000132155","affected_pathway","slapenrich",0.950985207217944,13,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000177885","affected_pathway","slapenrich",0.988290346081569,52,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000177885","affected_pathway","slapenrich",0.988290346081569,52,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000177885","affected_pathway","slapenrich",0.988290346081569,52,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000177885","affected_pathway","slapenrich",0.988290346081569,52,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000177885","affected_pathway","slapenrich",0.988290346081569,52,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000132155","affected_pathway","progeny",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000132155","affected_pathway","progeny",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000132155","affected_pathway","progeny",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000132155","affected_pathway","progeny",0.607930797611621,1,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000132155","affected_pathway","progeny",0.607930797611621,1,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000132155","literature","europepmc",0.440496220435041,28,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000132155","literature","europepmc",0.440496220435041,28,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000132155","literature","europepmc",0.440496220435041,28,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000132155","literature","europepmc",0.440496220435041,28,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000132155","literature","europepmc",0.440496220435041,28,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000177885","literature","europepmc",0.108747784088053,11,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000177885","literature","europepmc",0.108747784088053,11,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000177885","literature","europepmc",0.108747784088053,11,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000177885","literature","europepmc",0.108747784088053,11,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000177885","literature","europepmc",0.108747784088053,11,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000132155","known_drug","chembl",0.589055924775277,25,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000132155","known_drug","chembl",0.589055924775277,25,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000132155","known_drug","chembl",0.589055924775277,25,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000132155","known_drug","chembl",0.589055924775277,25,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000132155","known_drug","chembl",0.589055924775277,25,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000177885","affected_pathway","crispr",0.283102429693375,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000177885","affected_pathway","crispr",0.283102429693375,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000177885","affected_pathway","crispr",0.283102429693375,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000177885","affected_pathway","crispr",0.283102429693375,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000177885","affected_pathway","crispr",0.283102429693375,1,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000132155","somatic_mutation","eva_somatic",0.531939447910168,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000132155","somatic_mutation","eva_somatic",0.531939447910168,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000132155","somatic_mutation","eva_somatic",0.531939447910168,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000132155","somatic_mutation","eva_somatic",0.531939447910168,2,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000132155","somatic_mutation","eva_somatic",0.531939447910168,2,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000169057","animal_model","impc",0.398751097985092,4,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000169057","animal_model","impc",0.398751097985092,4,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000169057","literature","europepmc",0.434670520292309,2,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000169057","literature","europepmc",0.434670520292309,2,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000182866","somatic_mutation","cancer_gene_census",0.531939447910168,2,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000182866","somatic_mutation","cancer_gene_census",0.531939447910168,2,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000182866","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000182866","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000188191","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000188191","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000188191","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000144746","literature","europepmc",0.0243172319044648,1,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000144746","literature","europepmc",0.0243172319044648,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000182866","literature","europepmc",0.0615952106746774,4,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000182866","literature","europepmc",0.0615952106746774,4,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000182866","known_drug","chembl",0.191953910394831,22,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000182866","known_drug","chembl",0.191953910394831,22,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000101213","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000101213","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000101213","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000101213","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000101213","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000099942","affected_pathway","slapenrich",0.811929868431923,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000099942","affected_pathway","slapenrich",0.811929868431923,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000099942","affected_pathway","slapenrich",0.811929868431923,3,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000101213","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000101213","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000101213","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000101213","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000101213","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000099942","literature","europepmc",0.359759490346336,10,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000099942","literature","europepmc",0.359759490346336,10,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000099942","literature","europepmc",0.359759490346336,10,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000101213","literature","europepmc",0.290540260358554,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000101213","literature","europepmc",0.290540260358554,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000101213","literature","europepmc",0.290540260358554,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000101213","literature","europepmc",0.290540260358554,4,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000101213","literature","europepmc",0.290540260358554,4,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000101213","known_drug","chembl",0.625573839275931,20,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000101213","known_drug","chembl",0.625573839275931,20,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000101213","known_drug","chembl",0.625573839275931,20,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000101213","known_drug","chembl",0.625573839275931,20,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000101213","known_drug","chembl",0.625573839275931,20,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000133703","animal_model","impc",0.415414312277961,2,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000133703","animal_model","impc",0.415414312277961,2,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000133703","affected_pathway","cancer_biomarkers",0.942151532920827,10,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000133703","affected_pathway","cancer_biomarkers",0.942151532920827,10,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000133703","somatic_mutation","cancer_gene_census",0.890156213339907,9,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000133703","somatic_mutation","cancer_gene_census",0.890156213339907,9,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000133703","affected_pathway","slapenrich",0.989052667521338,55,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000133703","affected_pathway","slapenrich",0.989052667521338,55,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000133703","literature","europepmc",0.960602054785848,105,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000133703","literature","europepmc",0.960602054785848,105,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000164615","literature","europepmc",0.0121586159522324,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000164615","literature","europepmc",0.0121586159522324,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000164615","literature","europepmc",0.0121586159522324,1,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000133703","known_drug","chembl",0.753581225084035,17,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000133703","known_drug","chembl",0.753581225084035,17,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000133703","somatic_mutation","intogen",0.865457038266544,4,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000133703","somatic_mutation","intogen",0.865457038266544,4,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000133703","affected_pathway","crispr",0.272428988679708,1,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000133703","affected_pathway","crispr",0.272428988679708,1,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000133703","somatic_mutation","eva_somatic",0.893596278167008,23,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000133703","somatic_mutation","eva_somatic",0.893596278167008,23,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000105401","affected_pathway","slapenrich",0.919067987742997,7,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000105401","affected_pathway","slapenrich",0.919067987742997,7,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000105401","affected_pathway","slapenrich",0.919067987742997,7,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000166598","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000166598","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000166598","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000166598","literature","europepmc",0.243290527810851,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000166598","literature","europepmc",0.243290527810851,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000166598","literature","europepmc",0.243290527810851,6,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000137936","literature","europepmc",0.0243172319044648,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000137936","literature","europepmc",0.0243172319044648,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000173801","literature","europepmc",0.155804219944558,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000173801","literature","europepmc",0.155804219944558,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000173801","literature","europepmc",0.155804219944558,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000173801","rna_expression","expression_atlas",0.114366776011118,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000173801","rna_expression","expression_atlas",0.114366776011118,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000173801","rna_expression","expression_atlas",0.114366776011118,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000168610","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000168610","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000168610","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000168610","affected_pathway","slapenrich",0.948440334795705,12,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000168610","affected_pathway","slapenrich",0.948440334795705,12,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000168610","affected_pathway","slapenrich",0.948440334795705,12,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000168610","literature","europepmc",0.978824315998647,352,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000168610","literature","europepmc",0.978824315998647,352,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000168610","literature","europepmc",0.978824315998647,352,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000168610","known_drug","chembl",0.158737486043034,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000168610","known_drug","chembl",0.158737486043034,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000168610","known_drug","chembl",0.158737486043034,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000168610","affected_pathway","crispr",0.3034589924514,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000168610","affected_pathway","crispr",0.3034589924514,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000168610","affected_pathway","crispr",0.3034589924514,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000095370","rna_expression","expression_atlas",0.13601438378564,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000095370","rna_expression","expression_atlas",0.13601438378564,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000095370","rna_expression","expression_atlas",0.13601438378564,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000095370","rna_expression","expression_atlas",0.13601438378564,3,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000095370","rna_expression","expression_atlas",0.13601438378564,3,NA,NA
"Xpovio","Selinexor","SELINEXOR","CHEMBL3545185","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019,"ENSG00000082898","ENSG00000141510","literature","europepmc",0.756709182171599,209,"MONDO_0004095","multiple myeloma -> B-cell neoplasm (parent)"
"Xpovio","Selinexor","SELINEXOR","CHEMBL3545185","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019,"ENSG00000082898","ENSG00000141510","affected_pathway","slapenrich",0.607018496493418,11,"MONDO_0004095","multiple myeloma -> B-cell neoplasm (parent)"
"Xpovio","Selinexor","SELINEXOR","CHEMBL3545185","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019,"ENSG00000082898","ENSG00000141510","somatic_mutation","eva_somatic",0.815191264041805,66,"MONDO_0004095","multiple myeloma -> B-cell neoplasm (parent)"
"Xpovio","Selinexor","SELINEXOR","CHEMBL3545185","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019,"ENSG00000082898","ENSG00000141510","somatic_mutation","cancer_gene_census",0.455948098208716,1,"MONDO_0004095","multiple myeloma -> B-cell neoplasm (parent)"
"Xpovio","Selinexor","SELINEXOR","CHEMBL3545185","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019,"ENSG00000082898","ENSG00000141510","known_drug","chembl",0.0759913497014526,2,"MONDO_0004095","multiple myeloma -> B-cell neoplasm (parent)"
"Xpovio","Selinexor","SELINEXOR","CHEMBL3545185","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019,"ENSG00000082898","ENSG00000141510","somatic_mutation","intogen",0.80588177305074,3,"MONDO_0004095","multiple myeloma -> B-cell neoplasm (parent)"
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000011485","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000011485","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000011485","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000123384","affected_pathway","slapenrich",0.711077570552259,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000123384","affected_pathway","slapenrich",0.711077570552259,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000123384","affected_pathway","slapenrich",0.711077570552259,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000123384","literature","europepmc",0.0121586159522324,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000123384","literature","europepmc",0.0121586159522324,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000123384","literature","europepmc",0.0121586159522324,1,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000172062","animal_model","impc",0.470741080950599,3,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000172062","animal_model","impc",0.470741080950599,3,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000172062","genetic_association","uniprot_literature",0.919067987742997,7,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000172062","genetic_association","uniprot_literature",0.919067987742997,7,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000172062","genetic_association","uniprot_variants",0.981301991569547,32,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000172062","genetic_association","uniprot_variants",0.981301991569547,32,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000172062","genetic_association","orphanet",0.865457038266544,4,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000172062","genetic_association","orphanet",0.865457038266544,4,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000172062","literature","europepmc",0.191268346561338,23,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000172062","literature","europepmc",0.191268346561338,23,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000172062","known_drug","chembl",0.936151065679273,12,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000172062","known_drug","chembl",0.936151065679273,12,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000172062","genetic_association","genomics_england",0.967152948166419,18,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000172062","genetic_association","genomics_england",0.967152948166419,18,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000172062","genetic_association","eva",0.935145435728092,90,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000172062","genetic_association","eva",0.935145435728092,90,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000140538","somatic_mutation","cancer_gene_census",0.671148794081794,8,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000140538","somatic_mutation","cancer_gene_census",0.671148794081794,8,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000149269","affected_pathway","slapenrich",0.846599828758795,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000149269","affected_pathway","slapenrich",0.846599828758795,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000149269","affected_pathway","slapenrich",0.846599828758795,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000104814","literature","europepmc",0.0243172319044648,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000104814","literature","europepmc",0.0243172319044648,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000104814","literature","europepmc",0.0243172319044648,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000140009","literature","europepmc",0.893335765322115,65,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000140009","literature","europepmc",0.893335765322115,65,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000140009","literature","europepmc",0.893335765322115,65,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000140538","literature","europepmc",0.233411309632312,10,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000140538","literature","europepmc",0.233411309632312,10,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000144724","literature","europepmc",0.728503739137926,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000144724","literature","europepmc",0.728503739137926,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000144724","literature","europepmc",0.728503739137926,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000144724","literature","europepmc",0.728503739137926,3,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000144724","literature","europepmc",0.728503739137926,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000149269","literature","europepmc",0.622575175047421,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000149269","literature","europepmc",0.622575175047421,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000149269","literature","europepmc",0.622575175047421,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000140009","known_drug","chembl",0.147338783587816,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000140009","known_drug","chembl",0.147338783587816,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000140009","known_drug","chembl",0.147338783587816,4,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000140538","known_drug","chembl",0.842034815591896,6,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000140538","known_drug","chembl",0.842034815591896,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000101134","rna_expression","expression_atlas",0.0753615574298455,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000101134","rna_expression","expression_atlas",0.0753615574298455,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000101134","rna_expression","expression_atlas",0.0753615574298455,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000178078","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000178078","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000178078","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000132970","literature","europepmc",0.174780104313341,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000132970","literature","europepmc",0.174780104313341,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000132970","literature","europepmc",0.174780104313341,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000132970","rna_expression","expression_atlas",0.120595327167835,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000132970","rna_expression","expression_atlas",0.120595327167835,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000132970","rna_expression","expression_atlas",0.120595327167835,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000178078","rna_expression","expression_atlas",0.0098648712743464,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000178078","rna_expression","expression_atlas",0.0098648712743464,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000178078","rna_expression","expression_atlas",0.0098648712743464,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000141968","somatic_mutation","cancer_gene_census",0.396843715107586,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000141968","somatic_mutation","cancer_gene_census",0.396843715107586,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000141968","somatic_mutation","cancer_gene_census",0.396843715107586,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000141968","affected_pathway","slapenrich",0.878665282527117,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000141968","affected_pathway","slapenrich",0.878665282527117,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000141968","affected_pathway","slapenrich",0.878665282527117,5,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000145715","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000145715","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000145715","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000145715","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000145715","affected_pathway","slapenrich",0.889774270171009,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000170581","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000170581","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000170581","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000170581","affected_pathway","progeny",0.303965398805811,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000170581","affected_pathway","progeny",0.303965398805811,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000170581","affected_pathway","progeny",0.303965398805811,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000141968","literature","europepmc",0.0182379239283486,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000141968","literature","europepmc",0.0182379239283486,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000141968","literature","europepmc",0.0182379239283486,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000145715","literature","europepmc",0.0729516957133945,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000145715","literature","europepmc",0.0729516957133945,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000145715","literature","europepmc",0.0729516957133945,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000145715","literature","europepmc",0.0729516957133945,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000145715","literature","europepmc",0.0729516957133945,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000162591","literature","europepmc",0.0243172319044648,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000162591","literature","europepmc",0.0243172319044648,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000162591","literature","europepmc",0.0243172319044648,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000170581","literature","europepmc",0.125976770838408,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000170581","literature","europepmc",0.125976770838408,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000170581","literature","europepmc",0.125976770838408,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000105613","rna_expression","expression_atlas",0.248734885842795,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000105613","rna_expression","expression_atlas",0.248734885842795,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000105613","rna_expression","expression_atlas",0.248734885842795,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000253729","affected_pathway","slapenrich",0.791212836775118,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000253729","affected_pathway","slapenrich",0.791212836775118,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000253729","affected_pathway","slapenrich",0.791212836775118,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000253729","literature","europepmc",0.803259292566404,39,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000253729","literature","europepmc",0.803259292566404,39,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000253729","literature","europepmc",0.803259292566404,39,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000124181","somatic_mutation","cancer_gene_census",0.622706893386904,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000124181","somatic_mutation","cancer_gene_census",0.622706893386904,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000124181","somatic_mutation","cancer_gene_census",0.622706893386904,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000124181","somatic_mutation","cancer_gene_census",0.622706893386904,4,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000124181","somatic_mutation","cancer_gene_census",0.622706893386904,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000144554","somatic_mutation","cancer_gene_census",0.669694877952302,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000144554","somatic_mutation","cancer_gene_census",0.669694877952302,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000144554","somatic_mutation","cancer_gene_census",0.669694877952302,6,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000145675","somatic_mutation","cancer_gene_census",0.622706893386904,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000145675","somatic_mutation","cancer_gene_census",0.622706893386904,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000145675","somatic_mutation","cancer_gene_census",0.622706893386904,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000145675","somatic_mutation","cancer_gene_census",0.622706893386904,4,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000145675","somatic_mutation","cancer_gene_census",0.622706893386904,4,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000124181","affected_pathway","slapenrich",0.975724349982968,25,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000124181","affected_pathway","slapenrich",0.975724349982968,25,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000124181","affected_pathway","slapenrich",0.975724349982968,25,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000124181","affected_pathway","slapenrich",0.975724349982968,25,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000124181","affected_pathway","slapenrich",0.975724349982968,25,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000144554","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000144554","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000144554","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000145675","affected_pathway","slapenrich",0.98220689985874,34,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000145675","affected_pathway","slapenrich",0.98220689985874,34,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000145675","affected_pathway","slapenrich",0.98220689985874,34,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000145675","affected_pathway","slapenrich",0.98220689985874,34,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000145675","affected_pathway","slapenrich",0.98220689985874,34,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000124181","literature","europepmc",0.0801286565185317,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000124181","literature","europepmc",0.0801286565185317,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000124181","literature","europepmc",0.0801286565185317,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000124181","literature","europepmc",0.0801286565185317,4,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000124181","literature","europepmc",0.0801286565185317,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000144554","literature","europepmc",0.704937830963552,13,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000144554","literature","europepmc",0.704937830963552,13,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000144554","literature","europepmc",0.704937830963552,13,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000145675","literature","europepmc",0.0472632421209835,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000145675","literature","europepmc",0.0472632421209835,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000145675","literature","europepmc",0.0472632421209835,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000145675","literature","europepmc",0.0472632421209835,5,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000145675","literature","europepmc",0.0472632421209835,5,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000145675","known_drug","chembl",0.172054822661783,16,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000145675","known_drug","chembl",0.172054822661783,16,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000145675","known_drug","chembl",0.172054822661783,16,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000145675","known_drug","chembl",0.172054822661783,16,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000145675","known_drug","chembl",0.172054822661783,16,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000144554","rna_expression","expression_atlas",0.0207705220882869,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000144554","rna_expression","expression_atlas",0.0207705220882869,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000144554","rna_expression","expression_atlas",0.0207705220882869,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000145675","rna_expression","expression_atlas",0.0498770842537513,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000145675","rna_expression","expression_atlas",0.0498770842537513,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000145675","rna_expression","expression_atlas",0.0498770842537513,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000145675","rna_expression","expression_atlas",0.0498770842537513,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000145675","rna_expression","expression_atlas",0.0498770842537513,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000198399","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000198399","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000198399","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000159228","literature","europepmc",0.0243172319044648,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000159228","literature","europepmc",0.0243172319044648,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000159228","literature","europepmc",0.0243172319044648,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000127947","affected_pathway","slapenrich",0.865457038266544,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000127947","affected_pathway","slapenrich",0.865457038266544,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000127947","affected_pathway","slapenrich",0.865457038266544,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000127947","affected_pathway","slapenrich",0.865457038266544,4,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000127947","affected_pathway","slapenrich",0.865457038266544,4,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000127947","literature","europepmc",0.43264408430027,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000127947","literature","europepmc",0.43264408430027,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000127947","literature","europepmc",0.43264408430027,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000127947","literature","europepmc",0.43264408430027,3,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000127947","literature","europepmc",0.43264408430027,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000130402","literature","europepmc",0.657642649889651,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000130402","literature","europepmc",0.657642649889651,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000130402","literature","europepmc",0.657642649889651,5,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000178188","literature","europepmc",0.291806782853578,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000178188","literature","europepmc",0.291806782853578,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000178188","literature","europepmc",0.291806782853578,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000178188","literature","europepmc",0.291806782853578,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000178188","literature","europepmc",0.291806782853578,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000138798","affected_pathway","slapenrich",0.972991377243103,22,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000138798","affected_pathway","slapenrich",0.972991377243103,22,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000138798","affected_pathway","slapenrich",0.972991377243103,22,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000116285","literature","europepmc",0.261072503640991,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000116285","literature","europepmc",0.261072503640991,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000116285","literature","europepmc",0.261072503640991,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000125170","literature","europepmc",0.234053357080474,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000125170","literature","europepmc",0.234053357080474,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000125170","literature","europepmc",0.234053357080474,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000138798","literature","europepmc",0.933392859647397,246,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000138798","literature","europepmc",0.933392859647397,246,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000138798","literature","europepmc",0.933392859647397,246,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000197102","literature","europepmc",0.121586159522324,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000197102","literature","europepmc",0.121586159522324,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000197102","literature","europepmc",0.121586159522324,1,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000078061","affected_pathway","cancer_biomarkers",0.607930797611621,1,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000078061","affected_pathway","cancer_biomarkers",0.607930797611621,1,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000078061","somatic_mutation","cancer_gene_census",0.406342633820268,4,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000078061","somatic_mutation","cancer_gene_census",0.406342633820268,4,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000078061","affected_pathway","slapenrich",0.936072224944711,9,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000078061","affected_pathway","slapenrich",0.936072224944711,9,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000078061","literature","europepmc",0.0653525607432493,2,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000078061","literature","europepmc",0.0653525607432493,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000240972","literature","europepmc",0.840001194377615,22,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000240972","literature","europepmc",0.840001194377615,22,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000240972","literature","europepmc",0.840001194377615,22,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000078061","known_drug","chembl",0.0303965398805811,1,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000078061","known_drug","chembl",0.0303965398805811,1,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000078061","somatic_mutation","eva_somatic",0.579222954391072,3,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000078061","somatic_mutation","eva_somatic",0.579222954391072,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000204305","literature","europepmc",0.653160551461131,15,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000204305","literature","europepmc",0.653160551461131,15,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000204305","literature","europepmc",0.653160551461131,15,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000204305","rna_expression","expression_atlas",0.46866640068707,7,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000204305","rna_expression","expression_atlas",0.46866640068707,7,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000204305","rna_expression","expression_atlas",0.46866640068707,7,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000184144","affected_pathway","slapenrich",0.431546554652796,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000184144","affected_pathway","slapenrich",0.431546554652796,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000184144","affected_pathway","slapenrich",0.431546554652796,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000131558","literature","europepmc",0.0243172319044648,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000131558","literature","europepmc",0.0243172319044648,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000131558","literature","europepmc",0.0243172319044648,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000184144","literature","europepmc",0.0364758478566973,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000184144","literature","europepmc",0.0364758478566973,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000184144","literature","europepmc",0.0364758478566973,1,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000142192","affected_pathway","slapenrich",0.692660899799067,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000142192","affected_pathway","slapenrich",0.692660899799067,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000142192","affected_pathway","slapenrich",0.692660899799067,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000142192","affected_pathway","slapenrich",0.692660899799067,2,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000142192","affected_pathway","slapenrich",0.692660899799067,2,NA,NA
"Lumakras","Sotorasib","Sotorasib","CHEMBL4535757","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000133703","ENSG00000142192","literature","europepmc",0.253955388177693,8,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000142192","literature","europepmc",0.253955388177693,8,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000142192","literature","europepmc",0.253955388177693,8,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000142192","literature","europepmc",0.253955388177693,8,NA,NA
"Krazati","Adagrasib","Adagrasib","CHEMBL4594350","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022,"ENSG00000133703","ENSG00000142192","literature","europepmc",0.253955388177693,8,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000050748","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000050748","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000050748","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000174437","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000174437","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000174437","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000050748","literature","europepmc",0.554736852820604,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000050748","literature","europepmc",0.554736852820604,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000050748","literature","europepmc",0.554736852820604,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000094631","literature","europepmc",0.821838667277132,23,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000094631","literature","europepmc",0.821838667277132,23,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000094631","literature","europepmc",0.821838667277132,23,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000174437","literature","europepmc",0.0121586159522324,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000174437","literature","europepmc",0.0121586159522324,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000174437","literature","europepmc",0.0121586159522324,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000094631","known_drug","chembl",0.190830487398688,30,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000094631","known_drug","chembl",0.190830487398688,30,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000094631","known_drug","chembl",0.190830487398688,30,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000174437","rna_expression","expression_atlas",0.0981808238142768,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000174437","rna_expression","expression_atlas",0.0981808238142768,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000174437","rna_expression","expression_atlas",0.0981808238142768,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000160691","affected_pathway","slapenrich",0.977520973024455,27,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000160691","affected_pathway","slapenrich",0.977520973024455,27,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000160691","affected_pathway","slapenrich",0.977520973024455,27,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000160691","affected_pathway","slapenrich",0.977520973024455,27,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000160691","affected_pathway","slapenrich",0.977520973024455,27,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000160691","literature","europepmc",0.837161400731229,8,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000160691","literature","europepmc",0.837161400731229,8,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000160691","literature","europepmc",0.837161400731229,8,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000160691","literature","europepmc",0.837161400731229,8,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000160691","literature","europepmc",0.837161400731229,8,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000160691","affected_pathway","crispr",0.32017708938572,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000160691","affected_pathway","crispr",0.32017708938572,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000160691","affected_pathway","crispr",0.32017708938572,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000160691","affected_pathway","crispr",0.32017708938572,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000160691","affected_pathway","crispr",0.32017708938572,1,NA,NA
"Beovu","Brolucizumab","BROLUCIZUMAB","CHEMBL3707357","Novartis","VEGF inhibitor","Other indication","Wet age-related macular degeneration","macular degeneration","EFO_0009606","Not concordant","S",2019,"ENSG00000112715","ENSG00000099250","literature","europepmc",0.253557803503847,4,NA,NA
"Beovu","Brolucizumab","BROLUCIZUMAB","CHEMBL3707357","Novartis","VEGF inhibitor","Other indication","Wet age-related macular degeneration","macular degeneration","EFO_0009606","Not concordant","S",2019,"ENSG00000112715","ENSG00000099250","animal_model","impc",0.639177680695361,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000158402","affected_pathway","slapenrich",0.906661236771331,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000158402","affected_pathway","slapenrich",0.906661236771331,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000158402","affected_pathway","slapenrich",0.906661236771331,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000158402","literature","europepmc",0.649771904038549,11,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000158402","literature","europepmc",0.649771904038549,11,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000158402","literature","europepmc",0.649771904038549,11,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000170677","literature","europepmc",0.267489550949113,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000170677","literature","europepmc",0.267489550949113,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000170677","literature","europepmc",0.267489550949113,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000170677","literature","europepmc",0.267489550949113,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000170677","literature","europepmc",0.267489550949113,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000158402","rna_expression","expression_atlas",0.250899290339566,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000158402","rna_expression","expression_atlas",0.250899290339566,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000158402","rna_expression","expression_atlas",0.250899290339566,3,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000107290","animal_model","impc",0.371901665438909,2,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000107290","animal_model","impc",0.371901665438909,2,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000107290","literature","europepmc",0.089686576224723,7,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000107290","literature","europepmc",0.089686576224723,7,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000107290","genetic_association","eva",0.227974049104358,2,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000107290","genetic_association","eva",0.227974049104358,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000100485","affected_pathway","slapenrich",0.395207928536576,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000100485","affected_pathway","slapenrich",0.395207928536576,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000100485","affected_pathway","slapenrich",0.395207928536576,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000115904","affected_pathway","slapenrich",0.98505968729173,41,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000115904","affected_pathway","slapenrich",0.98505968729173,41,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000115904","affected_pathway","slapenrich",0.98505968729173,41,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000100485","literature","europepmc",0.0425551558328135,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000100485","literature","europepmc",0.0425551558328135,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000100485","literature","europepmc",0.0425551558328135,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000115904","literature","europepmc",0.080297526184535,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000115904","literature","europepmc",0.080297526184535,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000115904","literature","europepmc",0.080297526184535,4,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000167193","literature","europepmc",0.68883469987468,13,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000167193","literature","europepmc",0.68883469987468,13,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000167193","literature","europepmc",0.68883469987468,13,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000167193","literature","europepmc",0.68883469987468,13,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000167193","literature","europepmc",0.68883469987468,13,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000115904","somatic_mutation","eva_somatic",0.425551558328135,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000115904","somatic_mutation","eva_somatic",0.425551558328135,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000115904","somatic_mutation","eva_somatic",0.425551558328135,1,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000205571","animal_model","impc",0.470741080950599,3,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000205571","animal_model","impc",0.470741080950599,3,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000205571","genetic_association","uniprot_literature",0.919067987742997,7,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000205571","genetic_association","uniprot_literature",0.919067987742997,7,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000205571","genetic_association","uniprot_variants",0.981301991569547,32,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000205571","genetic_association","uniprot_variants",0.981301991569547,32,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000205571","genetic_association","orphanet",0.865457038266544,4,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000205571","genetic_association","orphanet",0.865457038266544,4,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000205571","literature","europepmc",0.59435281169358,217,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000205571","literature","europepmc",0.59435281169358,217,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000205571","known_drug","chembl",0.964271195034828,38,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000205571","known_drug","chembl",0.964271195034828,38,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000205571","genetic_association","eva",0.50481560215673,5,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000205571","genetic_association","eva",0.50481560215673,5,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000165458","literature","europepmc",0.100308581605917,2,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000165458","literature","europepmc",0.100308581605917,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000154127","rna_expression","expression_atlas",0.0135266025123176,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000154127","rna_expression","expression_atlas",0.0135266025123176,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000154127","rna_expression","expression_atlas",0.0135266025123176,1,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000141499","literature","europepmc",0.0486344638089297,1,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000141499","literature","europepmc",0.0486344638089297,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000177666","literature","europepmc",0.351988554423809,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000177666","literature","europepmc",0.351988554423809,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000177666","literature","europepmc",0.351988554423809,5,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000023734","literature","europepmc",0.0243172319044648,1,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000023734","literature","europepmc",0.0243172319044648,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000137193","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000137193","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000137193","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000176105","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000176105","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000176105","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000176105","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000176105","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000136810","literature","europepmc",0.289661190357416,8,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000136810","literature","europepmc",0.289661190357416,8,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000136810","literature","europepmc",0.289661190357416,8,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000137193","literature","europepmc",0.310510787060096,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000137193","literature","europepmc",0.310510787060096,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000137193","literature","europepmc",0.310510787060096,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000164924","literature","europepmc",0.674468823410213,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000164924","literature","europepmc",0.674468823410213,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000164924","literature","europepmc",0.674468823410213,6,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000176105","literature","europepmc",0.197398248903835,8,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000176105","literature","europepmc",0.197398248903835,8,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000176105","literature","europepmc",0.197398248903835,8,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000176105","literature","europepmc",0.197398248903835,8,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000176105","literature","europepmc",0.197398248903835,8,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000176105","known_drug","chembl",0.18101206819213,11,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000176105","known_drug","chembl",0.18101206819213,11,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000176105","known_drug","chembl",0.18101206819213,11,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000176105","known_drug","chembl",0.18101206819213,11,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000176105","known_drug","chembl",0.18101206819213,11,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000070159","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000070159","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000070159","literature","europepmc",0.0182379239283486,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000070159","literature","europepmc",0.0182379239283486,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000130558","rna_expression","expression_atlas",0.00992161179186163,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000130558","rna_expression","expression_atlas",0.00992161179186163,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000130558","rna_expression","expression_atlas",0.00992161179186163,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000069869","affected_pathway","slapenrich",0.692828219023013,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000069869","affected_pathway","slapenrich",0.692828219023013,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000069869","affected_pathway","slapenrich",0.692828219023013,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000154229","affected_pathway","slapenrich",0.878422427345274,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000154229","affected_pathway","slapenrich",0.878422427345274,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000154229","affected_pathway","slapenrich",0.878422427345274,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000069869","literature","europepmc",0.127507076558991,9,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000069869","literature","europepmc",0.127507076558991,9,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000069869","literature","europepmc",0.127507076558991,9,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000154229","literature","europepmc",0.756819529359234,36,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000154229","literature","europepmc",0.756819529359234,36,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000154229","literature","europepmc",0.756819529359234,36,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000154229","known_drug","chembl",0.462702884848845,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000154229","known_drug","chembl",0.462702884848845,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000154229","known_drug","chembl",0.462702884848845,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000088930","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000088930","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000088930","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000146674","affected_pathway","slapenrich",0.801007900134697,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000146674","affected_pathway","slapenrich",0.801007900134697,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000146674","affected_pathway","slapenrich",0.801007900134697,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000146674","literature","europepmc",0.738553389667202,49,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000146674","literature","europepmc",0.738553389667202,49,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000146674","literature","europepmc",0.738553389667202,49,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000146674","rna_expression","expression_atlas",0.232522419347963,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000146674","rna_expression","expression_atlas",0.232522419347963,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000146674","rna_expression","expression_atlas",0.232522419347963,4,NA,NA
"Xpovio","Selinexor","SELINEXOR","CHEMBL3545185","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019,"ENSG00000082898","ENSG00000089685","literature","europepmc",0.272418971817229,36,"MONDO_0004095","multiple myeloma -> B-cell neoplasm (parent)"
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000132639","literature","europepmc",0.085110311665627,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000132639","literature","europepmc",0.085110311665627,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000132639","literature","europepmc",0.085110311665627,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000102010","literature","europepmc",0.0820706576775689,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000102010","literature","europepmc",0.0820706576775689,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000102010","literature","europepmc",0.0820706576775689,2,NA,NA
"Evrysdi","Risdiplam","RISDIPLAM","CHEMBL4297528","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020,"ENSG00000205571","ENSG00000198513","literature","europepmc",0.126145640504411,2,NA,NA
"Spinraza","Nusinersen","NUSINERSEN","CHEMBL3301572","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016,"ENSG00000205571","ENSG00000198513","literature","europepmc",0.126145640504411,2,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000105647","affected_pathway","slapenrich",0.919067987742997,7,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000105647","affected_pathway","slapenrich",0.919067987742997,7,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000105647","affected_pathway","slapenrich",0.919067987742997,7,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000105647","affected_pathway","slapenrich",0.919067987742997,7,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000105647","affected_pathway","slapenrich",0.919067987742997,7,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000105647","literature","europepmc",0.132626858285615,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000105647","literature","europepmc",0.132626858285615,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000105647","literature","europepmc",0.132626858285615,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000105647","literature","europepmc",0.132626858285615,5,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000105647","literature","europepmc",0.132626858285615,5,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000105647","known_drug","chembl",0.172054822661783,16,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000105647","known_drug","chembl",0.172054822661783,16,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000105647","known_drug","chembl",0.172054822661783,16,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000105647","known_drug","chembl",0.172054822661783,16,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000105647","known_drug","chembl",0.172054822661783,16,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000138698","somatic_mutation","cancer_gene_census",0.565713381110814,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000138698","somatic_mutation","cancer_gene_census",0.565713381110814,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000138698","somatic_mutation","cancer_gene_census",0.565713381110814,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000092758","affected_pathway","slapenrich",0.71581743627482,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000092758","affected_pathway","slapenrich",0.71581743627482,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000092758","affected_pathway","slapenrich",0.71581743627482,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000169139","affected_pathway","slapenrich",0.900287248473754,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000169139","affected_pathway","slapenrich",0.900287248473754,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000169139","affected_pathway","slapenrich",0.900287248473754,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000138698","literature","europepmc",0.0243172319044648,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000138698","literature","europepmc",0.0243172319044648,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000138698","literature","europepmc",0.0243172319044648,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000148180","literature","europepmc",0.324101314390444,7,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000148180","literature","europepmc",0.324101314390444,7,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000148180","literature","europepmc",0.324101314390444,7,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000169139","literature","europepmc",0.261410242972997,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000169139","literature","europepmc",0.261410242972997,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000169139","literature","europepmc",0.261410242972997,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000169139","rna_expression","expression_atlas",0.0101378010403593,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000169139","rna_expression","expression_atlas",0.0101378010403593,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000169139","rna_expression","expression_atlas",0.0101378010403593,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000080824","somatic_mutation","cancer_gene_census",0.35884804025686,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000080824","somatic_mutation","cancer_gene_census",0.35884804025686,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000080824","somatic_mutation","cancer_gene_census",0.35884804025686,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000080824","affected_pathway","slapenrich",0.944785594634895,11,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000080824","affected_pathway","slapenrich",0.944785594634895,11,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000080824","affected_pathway","slapenrich",0.944785594634895,11,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000080824","literature","europepmc",0.79636060888746,24,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000080824","literature","europepmc",0.79636060888746,24,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000080824","literature","europepmc",0.79636060888746,24,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000085733","literature","europepmc",0.193072066534811,5,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000085733","literature","europepmc",0.193072066534811,5,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000085733","literature","europepmc",0.193072066534811,5,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000175793","literature","europepmc",0.0486344638089297,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000175793","literature","europepmc",0.0486344638089297,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000175793","literature","europepmc",0.0486344638089297,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000080824","known_drug","chembl",0.281932434788242,17,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000080824","known_drug","chembl",0.281932434788242,17,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000080824","known_drug","chembl",0.281932434788242,17,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000175793","rna_expression","expression_atlas",0.116528189906605,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000175793","rna_expression","expression_atlas",0.116528189906605,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000175793","rna_expression","expression_atlas",0.116528189906605,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000157168","affected_pathway","cancer_biomarkers",0.759913497014526,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000157168","affected_pathway","cancer_biomarkers",0.759913497014526,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000157168","affected_pathway","cancer_biomarkers",0.759913497014526,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000157168","somatic_mutation","cancer_gene_census",0.821677577355207,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000157168","somatic_mutation","cancer_gene_census",0.821677577355207,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000157168","somatic_mutation","cancer_gene_census",0.821677577355207,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000137462","affected_pathway","slapenrich",0.908734298750292,8,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000137462","affected_pathway","slapenrich",0.908734298750292,8,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000137462","affected_pathway","slapenrich",0.908734298750292,8,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000157168","affected_pathway","slapenrich",0.959877476978866,15,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000157168","affected_pathway","slapenrich",0.959877476978866,15,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000157168","affected_pathway","slapenrich",0.959877476978866,15,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000157168","genetic_association","ot_genetics_portal",0.703686161984373,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000157168","genetic_association","ot_genetics_portal",0.703686161984373,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000157168","genetic_association","ot_genetics_portal",0.703686161984373,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000111669","literature","europepmc",0.498840993373536,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000111669","literature","europepmc",0.498840993373536,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000111669","literature","europepmc",0.498840993373536,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000137462","literature","europepmc",0.654885749202557,8,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000137462","literature","europepmc",0.654885749202557,8,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000137462","literature","europepmc",0.654885749202557,8,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000157168","literature","europepmc",0.764879738025635,17,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000157168","literature","europepmc",0.764879738025635,17,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000157168","literature","europepmc",0.764879738025635,17,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000173020","literature","europepmc",0.0972689276178594,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000173020","literature","europepmc",0.0972689276178594,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000173020","literature","europepmc",0.0972689276178594,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000111669","rna_expression","expression_atlas",0.0119314898106737,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000111669","rna_expression","expression_atlas",0.0119314898106737,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000111669","rna_expression","expression_atlas",0.0119314898106737,1,NA,NA
"Praluent","Alirocumab","ALIROCUMAB","CHEMBL2109540","Sanofi","PCSK9 inhibitor","Other indication","LDL lowering","low density lipoprotein cholesterol measurement","EFO_0004611","Not serious","P",2015,"ENSG00000169174","ENSG00000169174","genetic_association","ot_genetics_portal",0.801727437567137,46,NA,NA
"Praluent","Alirocumab","ALIROCUMAB","CHEMBL2109540","Sanofi","PCSK9 inhibitor","Other indication","LDL lowering","low density lipoprotein cholesterol measurement","EFO_0004611","Not serious","P",2015,"ENSG00000169174","ENSG00000169174","genetic_association","gene_burden",0.97610152074843,27,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000067225","literature","europepmc",0.896208683560675,50,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000067225","literature","europepmc",0.896208683560675,50,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000067225","literature","europepmc",0.896208683560675,50,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000067225","literature","europepmc",0.896208683560675,50,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000067225","literature","europepmc",0.896208683560675,50,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000067225","rna_expression","expression_atlas",0.0130812540428936,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000067225","rna_expression","expression_atlas",0.0130812540428936,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000067225","rna_expression","expression_atlas",0.0130812540428936,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000067225","rna_expression","expression_atlas",0.0130812540428936,1,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000067225","rna_expression","expression_atlas",0.0130812540428936,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000123908","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000123908","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000123908","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000123908","literature","europepmc",0.747988559761141,17,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000123908","literature","europepmc",0.747988559761141,17,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000123908","literature","europepmc",0.747988559761141,17,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000250722","literature","europepmc",0.0730783479628969,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000250722","literature","europepmc",0.0730783479628969,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000250722","literature","europepmc",0.0730783479628969,4,NA,NA
"Xpovio","Selinexor","SELINEXOR","CHEMBL3545185","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019,"ENSG00000082898","ENSG00000162692","literature","europepmc",0.615196589115083,26,"MONDO_0004095","multiple myeloma -> B-cell neoplasm (parent)"
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000100351","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000100351","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000100351","affected_pathway","slapenrich",0.330206106514326,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000085063","literature","europepmc",0.186364460011571,7,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000085063","literature","europepmc",0.186364460011571,7,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000085063","literature","europepmc",0.186364460011571,7,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000100351","literature","europepmc",0.250771454014794,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000100351","literature","europepmc",0.250771454014794,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000100351","literature","europepmc",0.250771454014794,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000107263","affected_pathway","slapenrich",0.749160923564138,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000107263","affected_pathway","slapenrich",0.749160923564138,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000107263","affected_pathway","slapenrich",0.749160923564138,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000107263","literature","europepmc",0.0607930797611621,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000107263","literature","europepmc",0.0607930797611621,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000107263","literature","europepmc",0.0607930797611621,1,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000196396","literature","europepmc",0.332126104308509,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000196396","literature","europepmc",0.332126104308509,6,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000196396","literature","europepmc",0.332126104308509,6,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000196396","literature","europepmc",0.332126104308509,6,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000196396","literature","europepmc",0.332126104308509,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000039068","somatic_mutation","cancer_gene_census",0.649092778699908,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000039068","somatic_mutation","cancer_gene_census",0.649092778699908,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000039068","somatic_mutation","cancer_gene_census",0.649092778699908,4,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000039068","affected_pathway","slapenrich",0.31398878388363,1,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000039068","affected_pathway","slapenrich",0.31398878388363,1,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000039068","affected_pathway","slapenrich",0.31398878388363,1,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000039068","literature","europepmc",0.964844937661788,339,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000039068","literature","europepmc",0.964844937661788,339,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000039068","literature","europepmc",0.964844937661788,339,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000136235","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000136235","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000136235","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000160293","affected_pathway","slapenrich",0.690482324240203,2,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000160293","affected_pathway","slapenrich",0.690482324240203,2,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000136235","literature","europepmc",0.628870636196021,3,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000136235","literature","europepmc",0.628870636196021,3,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000136235","literature","europepmc",0.628870636196021,3,NA,NA
"Tepmetko","Tepotinib","Tepotinib","CHEMBL3402762","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021,"ENSG00000105976","ENSG00000160293","literature","europepmc",0.296937043306756,6,NA,NA
"Tabrecta","Capmatinib","CAPMATINIB","CHEMBL3188267","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020,"ENSG00000105976","ENSG00000160293","literature","europepmc",0.296937043306756,6,NA,NA
"Tagrisso","Osimertinib","OSIMERTINIB","CHEMBL3353410","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015,"ENSG00000146648","ENSG00000133056","literature","europepmc",0.216110955067631,4,NA,NA
"Portrazza","Necitumumab","NECITUMUMAB","CHEMBL1743047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015,"ENSG00000146648","ENSG00000133056","literature","europepmc",0.216110955067631,4,NA,NA
"Exkivity","Mobocertinib","Mobocertinib","CHEMBL4650319","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021,"ENSG00000146648","ENSG00000133056","literature","europepmc",0.216110955067631,4,NA,NA
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000115263","literature","europepmc",0.975836380874382,1884,"Orphanet_79161","type 2 diabetes mellitus -> Disorder of carbohydrate metabolism"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000115263","literature","europepmc",0.975836380874382,1884,"HP_0003076","type 2 diabetes mellitus -> Glycosuria"
"Ubrelvy","Ubrogepant","UBROGEPANT","CHEMBL2364638","Allergan","CGRP receptor antagonist","Other indication","Migraine with or without aura","migraine disorder","MONDO_0005277","Not serious","S",2019,"ENSG00000064989","ENSG00000148926","literature","europepmc",0.0507892407471309,5,NA,NA
"Nurtec ODT","Rimegepant","RIMEGEPANT","CHEMBL2178422","Biohaven","CGRP receptor antagonist","Other indication","Migraine","migraine disorder","MONDO_0005277","Not serious","S",2020,"ENSG00000064989","ENSG00000148926","literature","europepmc",0.0507892407471309,5,NA,NA
"Aimovig","Erenumab","ERENUMAB","CHEMBL3833329","Amgen/Novartis","CGRP receptor antibody","Other indication","Migraine","migraine disorder","MONDO_0005277","Not serious","S",2018,"ENSG00000064989","ENSG00000148926","literature","europepmc",0.0507892407471309,5,NA,NA
"Qulipta","Atogepant","Atogepant","CHEMBL3991065","AbbVie","CGRP receptor antagonist","Other indication","Episodic migraine","migraine disorder","MONDO_0005277","Not serious","S",2021,"ENSG00000064989","ENSG00000148926","literature","europepmc",0.0507892407471309,5,NA,NA
"Bevyxxa","Betrixaban","BETRIXABAN","CHEMBL512351","Portola Pharmaceuticals","FXa inhibitor","Other indication","Prophylaxis of venous thromboembolism","venous thromboembolism","EFO_0004286","Serious","P,F",2017,"ENSG00000126218","ENSG00000117601","literature","europepmc",0.861289071851818,30,NA,NA
"Bevyxxa","Betrixaban","BETRIXABAN","CHEMBL512351","Portola Pharmaceuticals","FXa inhibitor","Other indication","Prophylaxis of venous thromboembolism","venous thromboembolism","EFO_0004286","Serious","P,F",2017,"ENSG00000126218","ENSG00000117601","known_drug","chembl",0.979178134344507,74,NA,NA
"Bevyxxa","Betrixaban","BETRIXABAN","CHEMBL512351","Portola Pharmaceuticals","FXa inhibitor","Other indication","Prophylaxis of venous thromboembolism","venous thromboembolism","EFO_0004286","Serious","P,F",2017,"ENSG00000126218","ENSG00000117601","genetic_association","gene_burden",0.400931647971613,3,NA,NA
"Adlyxin","Lixisenatide","LIXISENATIDE","CHEMBL2108336","Sanofi","GLP1 receptor agonist","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2016,"ENSG00000112164","ENSG00000254997","rna_expression","expression_atlas",0.0373144559616683,1,NA,NA
"Ongentys","Opicapone","OPICAPONE","CHEMBL1089318","Neurocrine","COMT inhibitor","Other indication","Parkinson disease","parkinson disease","MONDO_0005180","Serious","S",2020,"ENSG00000093010","ENSG00000103266","literature","europepmc",0.351014917409708,8,NA,NA
"Ongentys","Opicapone","OPICAPONE","CHEMBL1089318","Neurocrine","COMT inhibitor","Other indication","Parkinson disease","parkinson disease","MONDO_0005180","Serious","S",2020,"ENSG00000093010","ENSG00000103266","animal_model","impc",0.402700115124578,4,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000127329","literature","europepmc",0.488171807875452,5,NA,NA
"Xadago","Safinamide","SAFINAMIDE","CHEMBL396778","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017,"ENSG00000069535","ENSG00000005893","literature","europepmc",0.0892423973083388,8,NA,NA
"Nourianz","Istradefylline","ISTRADEFYLLINE","CHEMBL431770","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019,"ENSG00000128271","ENSG00000170775","literature","europepmc",0.222409748157976,27,NA,NA
"Klisyri","Tirbanibulin","TIRBANIBULIN","CHEMBL571546","Athenex","Microtubule inhibitor","Other indication","Actinic keratosis","actinic keratosis","EFO_0002496","Not serious","S",2020,"ENSG00000197122","ENSG00000039068","literature","europepmc",0.0741456042520374,6,"EFO_0003784","actinic keratosis -> skin pigmentation"
"Klisyri","Tirbanibulin","TIRBANIBULIN","CHEMBL571546","Athenex","Microtubule inhibitor","Other indication","Actinic keratosis","actinic keratosis","EFO_0002496","Not serious","S",2020,"ENSG00000197122","ENSG00000241794","rna_expression","expression_atlas",0.403240498055788,1,"EFO_0003784","actinic keratosis -> skin pigmentation"
"Ingrezza","Valbenazine","VALBENAZINE","CHEMBL2364639","Neurocrine Biosciences","VMAT2 inhibitor","Other indication","Tardive dyskinesia","movement disorder","EFO_0004280","Not concordant","P,B,F",2017,"ENSG00000165646","ENSG00000139514","animal_model","impc",0.257093934309955,1,NA,NA
"Ingrezza","Valbenazine","VALBENAZINE","CHEMBL2364639","Neurocrine Biosciences","VMAT2 inhibitor","Other indication","Tardive dyskinesia","movement disorder","EFO_0004280","Not concordant","P,B,F",2017,"ENSG00000165646","ENSG00000139514","literature","europepmc",0.0243172319044648,1,NA,NA
"Rezlidhia","Olutasidenib","Olutasidenib","CHEMBL4297610","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022,"ENSG00000138413","ENSG00000114062","literature","europepmc",0.108414325574072,3,NA,NA
"Ubrelvy","Ubrogepant","UBROGEPANT","CHEMBL2364638","Allergan","CGRP receptor antagonist","Other indication","Migraine with or without aura","migraine disorder","MONDO_0005277","Not serious","S",2019,"ENSG00000064989","ENSG00000110680","genetic_association","ot_genetics_portal",0.318132052235735,2,NA,NA
"Nurtec ODT","Rimegepant","RIMEGEPANT","CHEMBL2178422","Biohaven","CGRP receptor antagonist","Other indication","Migraine","migraine disorder","MONDO_0005277","Not serious","S",2020,"ENSG00000064989","ENSG00000110680","genetic_association","ot_genetics_portal",0.318132052235735,2,NA,NA
"Aimovig","Erenumab","ERENUMAB","CHEMBL3833329","Amgen/Novartis","CGRP receptor antibody","Other indication","Migraine","migraine disorder","MONDO_0005277","Not serious","S",2018,"ENSG00000064989","ENSG00000110680","genetic_association","ot_genetics_portal",0.318132052235735,2,NA,NA
"Qulipta","Atogepant","Atogepant","CHEMBL3991065","AbbVie","CGRP receptor antagonist","Other indication","Episodic migraine","migraine disorder","MONDO_0005277","Not serious","S",2021,"ENSG00000064989","ENSG00000110680","genetic_association","ot_genetics_portal",0.318132052235735,2,NA,NA
"Ubrelvy","Ubrogepant","UBROGEPANT","CHEMBL2364638","Allergan","CGRP receptor antagonist","Other indication","Migraine with or without aura","migraine disorder","MONDO_0005277","Not serious","S",2019,"ENSG00000064989","ENSG00000110680","literature","europepmc",0.973431421774547,287,NA,NA
"Nurtec ODT","Rimegepant","RIMEGEPANT","CHEMBL2178422","Biohaven","CGRP receptor antagonist","Other indication","Migraine","migraine disorder","MONDO_0005277","Not serious","S",2020,"ENSG00000064989","ENSG00000110680","literature","europepmc",0.973431421774547,287,NA,NA
"Aimovig","Erenumab","ERENUMAB","CHEMBL3833329","Amgen/Novartis","CGRP receptor antibody","Other indication","Migraine","migraine disorder","MONDO_0005277","Not serious","S",2018,"ENSG00000064989","ENSG00000110680","literature","europepmc",0.973431421774547,287,NA,NA
"Qulipta","Atogepant","Atogepant","CHEMBL3991065","AbbVie","CGRP receptor antagonist","Other indication","Episodic migraine","migraine disorder","MONDO_0005277","Not serious","S",2021,"ENSG00000064989","ENSG00000110680","literature","europepmc",0.973431421774547,287,NA,NA
"Ubrelvy","Ubrogepant","UBROGEPANT","CHEMBL2364638","Allergan","CGRP receptor antagonist","Other indication","Migraine with or without aura","migraine disorder","MONDO_0005277","Not serious","S",2019,"ENSG00000064989","ENSG00000110680","known_drug","chembl",0.979771667324388,58,NA,NA
"Nurtec ODT","Rimegepant","RIMEGEPANT","CHEMBL2178422","Biohaven","CGRP receptor antagonist","Other indication","Migraine","migraine disorder","MONDO_0005277","Not serious","S",2020,"ENSG00000064989","ENSG00000110680","known_drug","chembl",0.979771667324388,58,NA,NA
"Aimovig","Erenumab","ERENUMAB","CHEMBL3833329","Amgen/Novartis","CGRP receptor antibody","Other indication","Migraine","migraine disorder","MONDO_0005277","Not serious","S",2018,"ENSG00000064989","ENSG00000110680","known_drug","chembl",0.979771667324388,58,NA,NA
"Qulipta","Atogepant","Atogepant","CHEMBL3991065","AbbVie","CGRP receptor antagonist","Other indication","Episodic migraine","migraine disorder","MONDO_0005277","Not serious","S",2021,"ENSG00000064989","ENSG00000110680","known_drug","chembl",0.979771667324388,58,NA,NA
"Xadago","Safinamide","SAFINAMIDE","CHEMBL396778","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017,"ENSG00000069535","ENSG00000068078","literature","europepmc",0.328052347792527,49,NA,NA
"Ongentys","Opicapone","OPICAPONE","CHEMBL1089318","Neurocrine","COMT inhibitor","Other indication","Parkinson disease","parkinson disease","MONDO_0005180","Serious","S",2020,"ENSG00000093010","ENSG00000068078","literature","europepmc",0.328052347792527,49,NA,NA
"Daurismo","Glasdegib","GLASDEGIB","CHEMBL2043437","Pfizer","Hedgehog pathway inhibitor","Oncology","AML","acute myeloid leukemia","EFO_0000222","Serious","P,O",2018,"ENSG00000128602","ENSG00000185920","literature","europepmc",0.0848570071666221,4,NA,NA
"Daurismo","Glasdegib","GLASDEGIB","CHEMBL2043437","Pfizer","Hedgehog pathway inhibitor","Oncology","AML","acute myeloid leukemia","EFO_0000222","Serious","P,O",2018,"ENSG00000128602","ENSG00000185920","somatic_mutation","cancer_gene_census",0.531939447910168,2,NA,NA
"Daurismo","Glasdegib","GLASDEGIB","CHEMBL2043437","Pfizer","Hedgehog pathway inhibitor","Oncology","AML","acute myeloid leukemia","EFO_0000222","Serious","P,O",2018,"ENSG00000128602","ENSG00000185920","genetic_association","eva",0.194537855235719,1,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000141480","literature","europepmc",0.0370668916877086,4,NA,NA
"Xadago","Safinamide","SAFINAMIDE","CHEMBL396778","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017,"ENSG00000069535","ENSG00000135018","literature","europepmc",0.0895009229817109,3,NA,NA
"Adlyxin","Lixisenatide","LIXISENATIDE","CHEMBL2108336","Sanofi","GLP1 receptor agonist","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2016,"ENSG00000112164","ENSG00000221880","rna_expression","expression_atlas",0.0212329338425574,1,NA,NA
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000172156","literature","europepmc",0.0227974049104358,2,"Orphanet_79161","type 2 diabetes mellitus -> Disorder of carbohydrate metabolism"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000172156","literature","europepmc",0.0227974049104358,2,"HP_0003076","type 2 diabetes mellitus -> Glycosuria"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000120937","literature","europepmc",0.874766828592728,127,"Orphanet_79161","type 2 diabetes mellitus -> Disorder of carbohydrate metabolism"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000120937","literature","europepmc",0.874766828592728,127,"HP_0003076","type 2 diabetes mellitus -> Glycosuria"
"Scemblix","Asciminib","Asciminib","CHEMBL4208229","Novartis","ABL/BCR-ABL1  kinase inhibitor","Oncology","Ph+ CML","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive","EFO_1000131","Serious","P,O,B,A,F",2021,"ENSG00000097007","ENSG00000122025","somatic_mutation","cancer_gene_census",0.455948098208716,1,"EFO_0000339","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive -> chronic myelogenous leukemia"
"Scemblix","Asciminib","Asciminib","CHEMBL4208229","Novartis","ABL/BCR-ABL1  kinase inhibitor","Oncology","Ph+ CML","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive","EFO_1000131","Serious","P,O,B,A,F",2021,"ENSG00000097007","ENSG00000122025","known_drug","chembl",0.151982699402905,2,"EFO_0000339","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive -> chronic myelogenous leukemia"
"Scemblix","Asciminib","Asciminib","CHEMBL4208229","Novartis","ABL/BCR-ABL1  kinase inhibitor","Oncology","Ph+ CML","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive","EFO_1000131","Serious","P,O,B,A,F",2021,"ENSG00000097007","ENSG00000122025","literature","europepmc",0.114282546467685,4,"EFO_0000339","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive -> chronic myelogenous leukemia"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000141433","literature","europepmc",0.185169655429803,7,"Orphanet_79161","type 2 diabetes mellitus -> Disorder of carbohydrate metabolism"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000141433","literature","europepmc",0.185169655429803,7,"HP_0003076","type 2 diabetes mellitus -> Glycosuria"
"Ongentys","Opicapone","OPICAPONE","CHEMBL1089318","Neurocrine","COMT inhibitor","Other indication","Parkinson disease","parkinson disease","MONDO_0005180","Serious","S",2020,"ENSG00000093010","ENSG00000109501","literature","europepmc",0.0759913497014526,2,NA,NA
"Ongentys","Opicapone","OPICAPONE","CHEMBL1089318","Neurocrine","COMT inhibitor","Other indication","Parkinson disease","parkinson disease","MONDO_0005180","Serious","S",2020,"ENSG00000093010","ENSG00000109501","animal_model","impc",0.252777625646912,1,NA,NA
"Xadago","Safinamide","SAFINAMIDE","CHEMBL396778","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017,"ENSG00000069535","ENSG00000189221","literature","europepmc",0.182951030620389,59,NA,NA
"Nourianz","Istradefylline","ISTRADEFYLLINE","CHEMBL431770","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019,"ENSG00000128271","ENSG00000116729","literature","europepmc",0.0243172319044648,1,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000149177","genetic_association","ot_genetics_portal",0.162495451148813,1,NA,NA
"Adlyxin","Lixisenatide","LIXISENATIDE","CHEMBL2108336","Sanofi","GLP1 receptor agonist","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2016,"ENSG00000112164","ENSG00000272804","rna_expression","expression_atlas",0.0251846879080131,1,NA,NA
"Striverdi Respimat","Olodaterol","OLODATEROL","CHEMBL605846","Boehringer Ingelheim","Long-acting beta2-adrenoceptor agonist","Other indication","COPD","chronic obstructive pulmonary disease","EFO_0000341","Serious","S",2014,"ENSG00000169252","ENSG00000106462","literature","europepmc",0.0896697926477141,2,NA,NA
"Striverdi Respimat","Olodaterol","OLODATEROL","CHEMBL605846","Boehringer Ingelheim","Long-acting beta2-adrenoceptor agonist","Other indication","COPD","chronic obstructive pulmonary disease","EFO_0000341","Serious","S",2014,"ENSG00000169252","ENSG00000197971","literature","europepmc",0.0243172319044648,1,NA,NA
"Xadago","Safinamide","SAFINAMIDE","CHEMBL396778","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017,"ENSG00000069535","ENSG00000138794","literature","europepmc",0.0165492272683164,3,NA,NA
"Ongentys","Opicapone","OPICAPONE","CHEMBL1089318","Neurocrine","COMT inhibitor","Other indication","Parkinson disease","parkinson disease","MONDO_0005180","Serious","S",2020,"ENSG00000093010","ENSG00000126895","literature","europepmc",0.130136030712068,6,NA,NA
"Ongentys","Opicapone","OPICAPONE","CHEMBL1089318","Neurocrine","COMT inhibitor","Other indication","Parkinson disease","parkinson disease","MONDO_0005180","Serious","S",2020,"ENSG00000093010","ENSG00000126895","known_drug","chembl",0.759913497014526,2,NA,NA
"Klisyri","Tirbanibulin","TIRBANIBULIN","CHEMBL571546","Athenex","Microtubule inhibitor","Other indication","Actinic keratosis","actinic keratosis","EFO_0002496","Not serious","S",2020,"ENSG00000197122","ENSG00000146648","literature","europepmc",0.0653525607432493,2,"EFO_0003784","actinic keratosis -> skin pigmentation"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000102962","literature","europepmc",0.0547137717850459,1,"Orphanet_79161","type 2 diabetes mellitus -> Disorder of carbohydrate metabolism"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000102962","literature","europepmc",0.0547137717850459,1,"HP_0003076","type 2 diabetes mellitus -> Glycosuria"
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000140443","literature","europepmc",0.860962689119042,126,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000140443","genetic_association","ot_genetics_portal",0.731267090277705,3,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000140443","known_drug","chembl",0.425551558328135,1,NA,NA
"Rezlidhia","Olutasidenib","Olutasidenib","CHEMBL4297610","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022,"ENSG00000138413","ENSG00000072062","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Rezlidhia","Olutasidenib","Olutasidenib","CHEMBL4297610","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022,"ENSG00000138413","ENSG00000261371","literature","europepmc",0.495745599100563,44,NA,NA
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000118702","literature","europepmc",0.191643086443074,9,"Orphanet_79161","type 2 diabetes mellitus -> Disorder of carbohydrate metabolism"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000118702","literature","europepmc",0.191643086443074,9,"HP_0003076","type 2 diabetes mellitus -> Glycosuria"
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000127947","literature","europepmc",0.0212775779164067,2,NA,NA
"Klisyri","Tirbanibulin","TIRBANIBULIN","CHEMBL571546","Athenex","Microtubule inhibitor","Other indication","Actinic keratosis","actinic keratosis","EFO_0002496","Not serious","S",2020,"ENSG00000197122","ENSG00000168036","literature","europepmc",0.0653525607432493,2,"EFO_0003784","actinic keratosis -> skin pigmentation"
"Tzield","Teplizumab","Teplizumab","CHEMBL1743078","Provention Bio","CD3-targeted antibody","Other indication","Delay onset of type 1 diabetes","type 1 diabetes mellitus","MONDO_0005147","Not concordant","P,B",2022,"ENSG00000198851","ENSG00000115085","literature","europepmc",0.0607930797611621,1,NA,NA
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000131096","literature","europepmc",0.317340492451625,33,"Orphanet_79161","type 2 diabetes mellitus -> Disorder of carbohydrate metabolism"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000131096","literature","europepmc",0.317340492451625,33,"HP_0003076","type 2 diabetes mellitus -> Glycosuria"
"Ubrelvy","Ubrogepant","UBROGEPANT","CHEMBL2364638","Allergan","CGRP receptor antagonist","Other indication","Migraine with or without aura","migraine disorder","MONDO_0005277","Not serious","S",2019,"ENSG00000064989","ENSG00000132329","literature","europepmc",0.457619302641202,21,NA,NA
"Nurtec ODT","Rimegepant","RIMEGEPANT","CHEMBL2178422","Biohaven","CGRP receptor antagonist","Other indication","Migraine","migraine disorder","MONDO_0005277","Not serious","S",2020,"ENSG00000064989","ENSG00000132329","literature","europepmc",0.457619302641202,21,NA,NA
"Aimovig","Erenumab","ERENUMAB","CHEMBL3833329","Amgen/Novartis","CGRP receptor antibody","Other indication","Migraine","migraine disorder","MONDO_0005277","Not serious","S",2018,"ENSG00000064989","ENSG00000132329","literature","europepmc",0.457619302641202,21,NA,NA
"Qulipta","Atogepant","Atogepant","CHEMBL3991065","AbbVie","CGRP receptor antagonist","Other indication","Episodic migraine","migraine disorder","MONDO_0005277","Not serious","S",2021,"ENSG00000064989","ENSG00000132329","literature","europepmc",0.457619302641202,21,NA,NA
"Bevyxxa","Betrixaban","BETRIXABAN","CHEMBL512351","Portola Pharmaceuticals","FXa inhibitor","Other indication","Prophylaxis of venous thromboembolism","venous thromboembolism","EFO_0004286","Serious","P,F",2017,"ENSG00000126218","ENSG00000140093","literature","europepmc",0.0529625933485924,5,NA,NA
"Yupelri","Revefenacin","REVEFENACIN","CHEMBL3833319","Theravance Biopharma/Mylan","Long-acting muscarinic receptor antagonist","Other indication","COPD","chronic obstructive pulmonary disease","EFO_0000341","Serious","S",2018,"ENSG00000133019","ENSG00000184984","known_drug","chembl",0.189892370044607,20,NA,NA
"Nourianz","Istradefylline","ISTRADEFYLLINE","CHEMBL431770","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019,"ENSG00000128271","ENSG00000170425","literature","europepmc",0.0151982699402905,2,NA,NA
"Nourianz","Istradefylline","ISTRADEFYLLINE","CHEMBL431770","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019,"ENSG00000128271","ENSG00000170425","known_drug","chembl",0.473257238974047,4,NA,NA
"Striverdi Respimat","Olodaterol","OLODATEROL","CHEMBL605846","Boehringer Ingelheim","Long-acting beta2-adrenoceptor agonist","Other indication","COPD","chronic obstructive pulmonary disease","EFO_0000341","Serious","S",2014,"ENSG00000169252","ENSG00000113369","genetic_association","ot_genetics_portal",0.109305887229655,1,NA,NA
"Ongentys","Opicapone","OPICAPONE","CHEMBL1089318","Neurocrine","COMT inhibitor","Other indication","Parkinson disease","parkinson disease","MONDO_0005180","Serious","S",2020,"ENSG00000093010","ENSG00000185897","literature","europepmc",0.0121586159522324,1,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000169047","literature","europepmc",0.948995846131313,381,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000169047","animal_model","impc",0.662540971063934,29,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000169047","genetic_association","ot_genetics_portal",0.433009903324502,28,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000169047","genetic_association","uniprot_literature",0.303965398805811,1,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000169047","genetic_association","uniprot_variants",0.303965398805811,1,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000169047","genetic_association","eva",0.745977424438019,8,NA,NA
"Adlyxin","Lixisenatide","LIXISENATIDE","CHEMBL2108336","Sanofi","GLP1 receptor agonist","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2016,"ENSG00000112164","ENSG00000188581","rna_expression","expression_atlas",0.0251846879080131,1,NA,NA
"Tzield","Teplizumab","Teplizumab","CHEMBL1743078","Provention Bio","CD3-targeted antibody","Other indication","Delay onset of type 1 diabetes","type 1 diabetes mellitus","MONDO_0005147","Not concordant","P,B",2022,"ENSG00000198851","ENSG00000149451","literature","europepmc",0.0334361938686392,2,NA,NA
"Xadago","Safinamide","SAFINAMIDE","CHEMBL396778","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017,"ENSG00000069535","ENSG00000174775","literature","europepmc",0.0182379239283486,1,NA,NA
"Klisyri","Tirbanibulin","TIRBANIBULIN","CHEMBL571546","Athenex","Microtubule inhibitor","Other indication","Actinic keratosis","actinic keratosis","EFO_0002496","Not serious","S",2020,"ENSG00000197122","ENSG00000168610","literature","europepmc",0.0607930797611621,1,"EFO_0003784","actinic keratosis -> skin pigmentation"
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000135439","animal_model","impc",0.803293820791995,15,NA,NA
"Adlyxin","Lixisenatide","LIXISENATIDE","CHEMBL2108336","Sanofi","GLP1 receptor agonist","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2016,"ENSG00000112164","ENSG00000187766","rna_expression","expression_atlas",0.0200165085240602,1,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000081237","literature","europepmc",0.456224939434435,47,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000081237","animal_model","impc",0.251865729450495,1,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000081237","genetic_association","ot_genetics_portal",0.481934422723938,1,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000081237","rna_expression","expression_atlas",0.015388973958969,1,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000144724","literature","europepmc",0.0303965398805811,1,NA,NA
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000197635","literature","europepmc",0.983052558808706,2002,"Orphanet_79161","type 2 diabetes mellitus -> Disorder of carbohydrate metabolism"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000197635","literature","europepmc",0.983052558808706,2002,"HP_0003076","type 2 diabetes mellitus -> Glycosuria"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000197635","known_drug","chembl",0.998365083402234,692,"Orphanet_79161","type 2 diabetes mellitus -> Disorder of carbohydrate metabolism"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000197635","known_drug","chembl",0.998365083402234,692,"HP_0003076","type 2 diabetes mellitus -> Glycosuria"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000197635","animal_model","impc",0.783966768744062,5,"Orphanet_79161","type 2 diabetes mellitus -> Disorder of carbohydrate metabolism"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000197635","animal_model","impc",0.783966768744062,5,"HP_0003076","type 2 diabetes mellitus -> Glycosuria"
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000171105","somatic_mutation","eva_somatic",0.194537855235719,1,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000171105","literature","europepmc",0.894384571408984,957,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000171105","genetic_association","genomics_england",0.971735321876137,21,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000171105","animal_model","impc",0.837842484360576,80,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000171105","genetic_association","orphanet",0.827461363415818,3,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000171105","genetic_association","ot_genetics_portal",0.672992499067393,8,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000171105","known_drug","chembl",0.999434300845564,1908,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000171105","genetic_association","uniprot_literature",0.877615654218776,5,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000171105","genetic_association","uniprot_variants",0.990276903600932,63,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000171105","genetic_association","eva",0.909266195576847,1104,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000171105","genetic_association","gene2phenotype",0.607930797611621,1,NA,NA
"Ingrezza","Valbenazine","VALBENAZINE","CHEMBL2364639","Neurocrine Biosciences","VMAT2 inhibitor","Other indication","Tardive dyskinesia","movement disorder","EFO_0004280","Not concordant","P,B,F",2017,"ENSG00000165646","ENSG00000180871","animal_model","impc",0.378968860961144,3,NA,NA
"Ingrezza","Valbenazine","VALBENAZINE","CHEMBL2364639","Neurocrine Biosciences","VMAT2 inhibitor","Other indication","Tardive dyskinesia","movement disorder","EFO_0004280","Not concordant","P,B,F",2017,"ENSG00000165646","ENSG00000180871","literature","europepmc",0.0607930797611621,1,NA,NA
"Xadago","Safinamide","SAFINAMIDE","CHEMBL396778","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017,"ENSG00000069535","ENSG00000163050","animal_model","impc",0.262382932249176,1,NA,NA
"Tzield","Teplizumab","Teplizumab","CHEMBL1743078","Provention Bio","CD3-targeted antibody","Other indication","Delay onset of type 1 diabetes","type 1 diabetes mellitus","MONDO_0005147","Not concordant","P,B",2022,"ENSG00000198851","ENSG00000176171","rna_expression","expression_atlas",0.0116356624437126,1,NA,NA
"Klisyri","Tirbanibulin","TIRBANIBULIN","CHEMBL571546","Athenex","Microtubule inhibitor","Other indication","Actinic keratosis","actinic keratosis","EFO_0002496","Not serious","S",2020,"ENSG00000197122","ENSG00000197122","known_drug","chembl",0.887083048679182,9,"EFO_0003784","actinic keratosis -> skin pigmentation"
"Klisyri","Tirbanibulin","TIRBANIBULIN","CHEMBL571546","Athenex","Microtubule inhibitor","Other indication","Actinic keratosis","actinic keratosis","EFO_0002496","Not serious","S",2020,"ENSG00000197122","ENSG00000197122","literature","europepmc",0.0151982699402905,2,"EFO_0003784","actinic keratosis -> skin pigmentation"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000138755","literature","europepmc",0.0325293637622018,5,"Orphanet_79161","type 2 diabetes mellitus -> Disorder of carbohydrate metabolism"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000138755","literature","europepmc",0.0325293637622018,5,"HP_0003076","type 2 diabetes mellitus -> Glycosuria"
"Rezlidhia","Olutasidenib","Olutasidenib","CHEMBL4297610","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022,"ENSG00000138413","ENSG00000179218","literature","europepmc",0.738768901536213,33,NA,NA
"Rezlidhia","Olutasidenib","Olutasidenib","CHEMBL4297610","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022,"ENSG00000138413","ENSG00000179218","somatic_mutation","cancer_gene_census",0.620596022561863,3,NA,NA
"Rezlidhia","Olutasidenib","Olutasidenib","CHEMBL4297610","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022,"ENSG00000138413","ENSG00000179218","affected_pathway","slapenrich",0.76516056090965,3,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000254647","somatic_mutation","eva_somatic",0.182379239283486,1,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000254647","literature","europepmc",0.982231112916358,1292,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000254647","genetic_association","genomics_england",0.960798322092247,15,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000254647","animal_model","impc",0.928050464798592,93,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000254647","genetic_association","orphanet",0.759913497014526,2,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000254647","genetic_association","ot_genetics_portal",0.783827842110812,47,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000254647","genetic_association","clingen",0.759913497014526,2,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000254647","genetic_association","uniprot_literature",0.607930797611621,1,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000254647","genetic_association","uniprot_variants",0.965276618544161,17,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000254647","genetic_association","eva",0.924267144412298,167,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000185950","literature","europepmc",0.701448599807835,193,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000185950","animal_model","impc",0.738094491276353,29,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000185950","genetic_association","ot_genetics_portal",0.155438395651423,5,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000124181","literature","europepmc",0.0465455460404697,6,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000124181","genetic_association","ot_genetics_portal",0.343555548859017,2,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000153233","literature","europepmc",0.0212775779164067,2,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000153233","genetic_association","ot_genetics_portal",0.4793862852273,19,NA,NA
"Ponvory","Ponesimod","Ponesimod","CHEMBL1096146","J&J","S1P receptor modulator","Other indication","Relapsing multiple sclerosis","multiple sclerosis","MONDO_0005301","Serious","S",2021,"ENSG00000170989","ENSG00000110848","genetic_association","ot_genetics_portal",0.359604770092846,2,NA,NA
"Zeposia","Ozanimod","OZANIMOD","CHEMBL3707247","Celgene/Bristol Myers Squibb","S1P receptor modulator","Other indication","Multiple sclerosis","multiple sclerosis","MONDO_0005301","Serious","S",2020,"ENSG00000170989","ENSG00000110848","genetic_association","ot_genetics_portal",0.359604770092846,2,NA,NA
"Ponvory","Ponesimod","Ponesimod","CHEMBL1096146","J&J","S1P receptor modulator","Other indication","Relapsing multiple sclerosis","multiple sclerosis","MONDO_0005301","Serious","S",2021,"ENSG00000170989","ENSG00000110848","literature","europepmc",0.0328671030942083,6,NA,NA
"Zeposia","Ozanimod","OZANIMOD","CHEMBL3707247","Celgene/Bristol Myers Squibb","S1P receptor modulator","Other indication","Multiple sclerosis","multiple sclerosis","MONDO_0005301","Serious","S",2020,"ENSG00000170989","ENSG00000110848","literature","europepmc",0.0328671030942083,6,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000178188","literature","europepmc",0.187938623933791,13,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000178188","animal_model","impc",0.930210515061305,32,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000178188","genetic_association","ot_genetics_portal",0.180066677089914,3,NA,NA
"Nourianz","Istradefylline","ISTRADEFYLLINE","CHEMBL431770","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019,"ENSG00000128271","ENSG00000160014","literature","europepmc",0.0121586159522324,1,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000106070","literature","europepmc",0.133543580217986,15,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000106070","animal_model","impc",0.414563209161305,2,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000106070","genetic_association","ot_genetics_portal",0.532158649676059,5,NA,NA
"Idhifa","Enasidenib mesylate","ENASIDENIBMESYLATE","CHEMBL3989931","Celgene/Agios","IDH2 inhibitor","Oncology","IDH2-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","P,O,F",2017,"ENSG00000182054","ENSG00000182054","literature","europepmc",0.977675456198809,335,NA,NA
"Idhifa","Enasidenib mesylate","ENASIDENIBMESYLATE","CHEMBL3989931","Celgene/Agios","IDH2 inhibitor","Oncology","IDH2-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","P,O,F",2017,"ENSG00000182054","ENSG00000182054","affected_pathway","cancer_biomarkers",0.607930797611621,1,NA,NA
"Idhifa","Enasidenib mesylate","ENASIDENIBMESYLATE","CHEMBL3989931","Celgene/Agios","IDH2 inhibitor","Oncology","IDH2-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","P,O,F",2017,"ENSG00000182054","ENSG00000182054","somatic_mutation","cancer_gene_census",0.855958119553862,4,NA,NA
"Idhifa","Enasidenib mesylate","ENASIDENIBMESYLATE","CHEMBL3989931","Celgene/Agios","IDH2 inhibitor","Oncology","IDH2-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","P,O,F",2017,"ENSG00000182054","ENSG00000182054","somatic_mutation","intogen",0.827461363415818,3,NA,NA
"Idhifa","Enasidenib mesylate","ENASIDENIBMESYLATE","CHEMBL3989931","Celgene/Agios","IDH2 inhibitor","Oncology","IDH2-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","P,O,F",2017,"ENSG00000182054","ENSG00000182054","somatic_mutation","eva_somatic",0.831329081873242,8,NA,NA
"Idhifa","Enasidenib mesylate","ENASIDENIBMESYLATE","CHEMBL3989931","Celgene/Agios","IDH2 inhibitor","Oncology","IDH2-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","P,O,F",2017,"ENSG00000182054","ENSG00000182054","genetic_association","gene_burden",0.252106390366084,2,NA,NA
"Idhifa","Enasidenib mesylate","ENASIDENIBMESYLATE","CHEMBL3989931","Celgene/Agios","IDH2 inhibitor","Oncology","IDH2-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","P,O,F",2017,"ENSG00000182054","ENSG00000182054","affected_pathway","slapenrich",0.759690205721964,2,NA,NA
"Idhifa","Enasidenib mesylate","ENASIDENIBMESYLATE","CHEMBL3989931","Celgene/Agios","IDH2 inhibitor","Oncology","IDH2-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","P,O,F",2017,"ENSG00000182054","ENSG00000182054","known_drug","chembl",0.798952078586095,23,NA,NA
"Scemblix","Asciminib","Asciminib","CHEMBL4208229","Novartis","ABL/BCR-ABL1  kinase inhibitor","Oncology","Ph+ CML","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive","EFO_1000131","Serious","P,O,B,A,F",2021,"ENSG00000097007","ENSG00000197122","known_drug","chembl",0.0759913497014526,2,"EFO_0000339","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive -> chronic myelogenous leukemia"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000146469","literature","europepmc",0.0243172319044648,1,"Orphanet_79161","type 2 diabetes mellitus -> Disorder of carbohydrate metabolism"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000146469","literature","europepmc",0.0243172319044648,1,"HP_0003076","type 2 diabetes mellitus -> Glycosuria"
"Scemblix","Asciminib","Asciminib","CHEMBL4208229","Novartis","ABL/BCR-ABL1  kinase inhibitor","Oncology","Ph+ CML","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive","EFO_1000131","Serious","P,O,B,A,F",2021,"ENSG00000097007","ENSG00000157404","somatic_mutation","cancer_gene_census",0.303965398805811,1,"EFO_0000339","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive -> chronic myelogenous leukemia"
"Scemblix","Asciminib","Asciminib","CHEMBL4208229","Novartis","ABL/BCR-ABL1  kinase inhibitor","Oncology","Ph+ CML","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive","EFO_1000131","Serious","P,O,B,A,F",2021,"ENSG00000097007","ENSG00000157404","known_drug","chembl",0.121586159522324,1,"EFO_0000339","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive -> chronic myelogenous leukemia"
"Scemblix","Asciminib","Asciminib","CHEMBL4208229","Novartis","ABL/BCR-ABL1  kinase inhibitor","Oncology","Ph+ CML","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive","EFO_1000131","Serious","P,O,B,A,F",2021,"ENSG00000097007","ENSG00000157404","literature","europepmc",0.0303965398805811,1,"EFO_0000339","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive -> chronic myelogenous leukemia"
"Xadago","Safinamide","SAFINAMIDE","CHEMBL396778","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017,"ENSG00000069535","ENSG00000097033","literature","europepmc",0.14961852407886,3,NA,NA
"Nourianz","Istradefylline","ISTRADEFYLLINE","CHEMBL431770","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019,"ENSG00000128271","ENSG00000149295","literature","europepmc",0.82679830692779,232,NA,NA
"Nourianz","Istradefylline","ISTRADEFYLLINE","CHEMBL431770","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019,"ENSG00000128271","ENSG00000149295","known_drug","chembl",0.996296778138121,249,NA,NA
"Nourianz","Istradefylline","ISTRADEFYLLINE","CHEMBL431770","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019,"ENSG00000128271","ENSG00000149295","animal_model","impc",0.645973883966075,28,NA,NA
"Striverdi Respimat","Olodaterol","OLODATEROL","CHEMBL605846","Boehringer Ingelheim","Long-acting beta2-adrenoceptor agonist","Other indication","COPD","chronic obstructive pulmonary disease","EFO_0000341","Serious","S",2014,"ENSG00000169252","ENSG00000163485","genetic_association","ot_genetics_portal",0.154586854144512,1,NA,NA
"Striverdi Respimat","Olodaterol","OLODATEROL","CHEMBL605846","Boehringer Ingelheim","Long-acting beta2-adrenoceptor agonist","Other indication","COPD","chronic obstructive pulmonary disease","EFO_0000341","Serious","S",2014,"ENSG00000169252","ENSG00000163485","known_drug","chembl",0.921495233486897,12,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000094796","literature","europepmc",0.0607930797611621,1,NA,NA
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000271503","literature","europepmc",0.425381550259263,17,"Orphanet_79161","type 2 diabetes mellitus -> Disorder of carbohydrate metabolism"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000271503","literature","europepmc",0.425381550259263,17,"HP_0003076","type 2 diabetes mellitus -> Glycosuria"
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000075624","literature","europepmc",0.208654671845255,48,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000075624","animal_model","impc",0.383258150477626,3,NA,NA
"Nourianz","Istradefylline","ISTRADEFYLLINE","CHEMBL431770","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019,"ENSG00000128271","ENSG00000128271","literature","europepmc",0.347779846568408,217,NA,NA
"Nourianz","Istradefylline","ISTRADEFYLLINE","CHEMBL431770","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019,"ENSG00000128271","ENSG00000128271","known_drug","chembl",0.930308173432758,43,NA,NA
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000107562","literature","europepmc",0.284497405710077,31,"Orphanet_79161","type 2 diabetes mellitus -> Disorder of carbohydrate metabolism"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000107562","literature","europepmc",0.284497405710077,31,"HP_0003076","type 2 diabetes mellitus -> Glycosuria"
"Ongentys","Opicapone","OPICAPONE","CHEMBL1089318","Neurocrine","COMT inhibitor","Other indication","Parkinson disease","parkinson disease","MONDO_0005180","Serious","S",2020,"ENSG00000093010","ENSG00000099377","genetic_association","ot_genetics_portal",0.210581786267836,2,NA,NA
"Rezlidhia","Olutasidenib","Olutasidenib","CHEMBL4297610","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022,"ENSG00000138413","ENSG00000163513","literature","europepmc",0.650872322262233,9,NA,NA
"Rezlidhia","Olutasidenib","Olutasidenib","CHEMBL4297610","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022,"ENSG00000138413","ENSG00000163513","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Klisyri","Tirbanibulin","TIRBANIBULIN","CHEMBL571546","Athenex","Microtubule inhibitor","Other indication","Actinic keratosis","actinic keratosis","EFO_0002496","Not serious","S",2020,"ENSG00000197122","ENSG00000174775","literature","europepmc",0.0759913497014526,2,"EFO_0003784","actinic keratosis -> skin pigmentation"
"Klisyri","Tirbanibulin","TIRBANIBULIN","CHEMBL571546","Athenex","Microtubule inhibitor","Other indication","Actinic keratosis","actinic keratosis","EFO_0002496","Not serious","S",2020,"ENSG00000197122","ENSG00000174775","somatic_mutation","cancer_gene_census",0.455948098208716,1,"EFO_0003784","actinic keratosis -> skin pigmentation"
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000179295","literature","europepmc",0.463473170570515,19,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000179295","animal_model","impc",0.434700629964366,9,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000179295","genetic_association","ot_genetics_portal",0.156872810875711,4,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000160691","literature","europepmc",0.30763341733216,12,NA,NA
"Tzield","Teplizumab","Teplizumab","CHEMBL1743078","Provention Bio","CD3-targeted antibody","Other indication","Delay onset of type 1 diabetes","type 1 diabetes mellitus","MONDO_0005147","Not concordant","P,B",2022,"ENSG00000198851","ENSG00000165025","genetic_association","ot_genetics_portal",0.0350141613553195,1,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000011465","literature","europepmc",0.321516282901724,11,NA,NA
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000169248","genetic_association","ot_genetics_portal",0.0379449406223534,1,"Orphanet_79161","type 2 diabetes mellitus -> Disorder of carbohydrate metabolism"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000169248","genetic_association","ot_genetics_portal",0.0379449406223534,1,"HP_0003076","type 2 diabetes mellitus -> Glycosuria"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000169248","literature","europepmc",0.0227974049104358,2,"Orphanet_79161","type 2 diabetes mellitus -> Disorder of carbohydrate metabolism"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000169248","literature","europepmc",0.0227974049104358,2,"HP_0003076","type 2 diabetes mellitus -> Glycosuria"
"Rezlidhia","Olutasidenib","Olutasidenib","CHEMBL4297610","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022,"ENSG00000138413","ENSG00000138413","literature","europepmc",0.985000841010706,458,NA,NA
"Rezlidhia","Olutasidenib","Olutasidenib","CHEMBL4297610","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022,"ENSG00000138413","ENSG00000138413","affected_pathway","cancer_biomarkers",0.827461363415818,3,NA,NA
"Rezlidhia","Olutasidenib","Olutasidenib","CHEMBL4297610","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022,"ENSG00000138413","ENSG00000138413","somatic_mutation","cancer_gene_census",0.639593859987226,4,NA,NA
"Rezlidhia","Olutasidenib","Olutasidenib","CHEMBL4297610","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022,"ENSG00000138413","ENSG00000138413","somatic_mutation","intogen",0.801779693110174,4,NA,NA
"Rezlidhia","Olutasidenib","Olutasidenib","CHEMBL4297610","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022,"ENSG00000138413","ENSG00000138413","somatic_mutation","eva_somatic",0.832123889357364,7,NA,NA
"Rezlidhia","Olutasidenib","Olutasidenib","CHEMBL4297610","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022,"ENSG00000138413","ENSG00000138413","genetic_association","eva",0.559296333802691,1,NA,NA
"Rezlidhia","Olutasidenib","Olutasidenib","CHEMBL4297610","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022,"ENSG00000138413","ENSG00000138413","affected_pathway","slapenrich",0.76516056090965,3,NA,NA
"Rezlidhia","Olutasidenib","Olutasidenib","CHEMBL4297610","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022,"ENSG00000138413","ENSG00000138413","known_drug","chembl",0.657835459760078,13,NA,NA
"Nourianz","Istradefylline","ISTRADEFYLLINE","CHEMBL431770","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019,"ENSG00000128271","ENSG00000163485","literature","europepmc",0.0968687065094317,6,NA,NA
"Nourianz","Istradefylline","ISTRADEFYLLINE","CHEMBL431770","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019,"ENSG00000128271","ENSG00000163485","known_drug","chembl",0.473257238974047,4,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000145675","literature","europepmc",0.764615552905667,43,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000145675","genetic_association","genomics_england",0.947175754388692,11,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000145675","animal_model","impc",0.858773748803583,34,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000145675","genetic_association","orphanet",0.607930797611621,1,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000145675","genetic_association","ot_genetics_portal",0.423421724057184,3,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000145675","genetic_association","clingen",0.607930797611621,1,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000145675","genetic_association","uniprot_literature",0.607930797611621,1,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000145675","genetic_association","uniprot_variants",0.759913497014526,2,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000145675","genetic_association","eva",0.9297734874989,254,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000145675","genetic_association","gene2phenotype",0.759913497014526,2,NA,NA
"Scemblix","Asciminib","Asciminib","CHEMBL4208229","Novartis","ABL/BCR-ABL1  kinase inhibitor","Oncology","Ph+ CML","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive","EFO_1000131","Serious","P,O,B,A,F",2021,"ENSG00000097007","ENSG00000149311","somatic_mutation","cancer_gene_census",0.303965398805811,1,"EFO_0000339","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive -> chronic myelogenous leukemia"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000169245","literature","europepmc",0.287806814439449,22,"Orphanet_79161","type 2 diabetes mellitus -> Disorder of carbohydrate metabolism"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000169245","literature","europepmc",0.287806814439449,22,"HP_0003076","type 2 diabetes mellitus -> Glycosuria"
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000017427","literature","europepmc",0.967105596161085,1406,NA,NA
"Xadago","Safinamide","SAFINAMIDE","CHEMBL396778","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017,"ENSG00000069535","ENSG00000070748","literature","europepmc",0.10850101291396,14,NA,NA
"Ongentys","Opicapone","OPICAPONE","CHEMBL1089318","Neurocrine","COMT inhibitor","Other indication","Parkinson disease","parkinson disease","MONDO_0005180","Serious","S",2020,"ENSG00000093010","ENSG00000188822","literature","europepmc",0.0933004904667835,4,NA,NA
"Xadago","Safinamide","SAFINAMIDE","CHEMBL396778","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017,"ENSG00000069535","ENSG00000148180","literature","europepmc",0.0182379239283486,1,NA,NA
"Ongentys","Opicapone","OPICAPONE","CHEMBL1089318","Neurocrine","COMT inhibitor","Other indication","Parkinson disease","parkinson disease","MONDO_0005180","Serious","S",2020,"ENSG00000093010","ENSG00000148180","literature","europepmc",0.0182379239283486,1,NA,NA
"Lupkynis","Voclosporin","Voclosporin","CHEMBL2218919","Aurinia","Calcineurin inhibitor","Other indication","Lupus nephritis","lupus nephritis","EFO_0005761","Serious","P,F",2021,"ENSG00000138814","ENSG00000101096","literature","europepmc",0.0182379239283486,1,"MONDO_0007915","lupus nephritis -> systemic lupus erythematosus"
"Striverdi Respimat","Olodaterol","OLODATEROL","CHEMBL605846","Boehringer Ingelheim","Long-acting beta2-adrenoceptor agonist","Other indication","COPD","chronic obstructive pulmonary disease","EFO_0000341","Serious","S",2014,"ENSG00000169252","ENSG00000197122","literature","europepmc",0.238443968396558,3,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000196396","literature","europepmc",0.91934109845429,614,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000196396","animal_model","impc",0.658699403091538,17,NA,NA
"Daurismo","Glasdegib","GLASDEGIB","CHEMBL2043437","Pfizer","Hedgehog pathway inhibitor","Oncology","AML","acute myeloid leukemia","EFO_0000222","Serious","P,O",2018,"ENSG00000128602","ENSG00000186469","literature","europepmc",0.0911896196417432,1,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000152894","literature","europepmc",0.0121586159522324,1,NA,NA
"Nourianz","Istradefylline","ISTRADEFYLLINE","CHEMBL431770","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019,"ENSG00000128271","ENSG00000118432","literature","europepmc",0.154122906837196,25,NA,NA
"Nourianz","Istradefylline","ISTRADEFYLLINE","CHEMBL431770","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019,"ENSG00000128271","ENSG00000118432","known_drug","chembl",0.477056806459119,4,NA,NA
"Lupkynis","Voclosporin","Voclosporin","CHEMBL2218919","Aurinia","Calcineurin inhibitor","Other indication","Lupus nephritis","lupus nephritis","EFO_0005761","Serious","P,F",2021,"ENSG00000138814","ENSG00000002834","literature","europepmc",0.0607930797611621,1,"MONDO_0007915","lupus nephritis -> systemic lupus erythematosus"
"Vyvgart","Efgartigimod alfa","Efgartigimodalfa","CHEMBL4297551","Argenx","FcRn-binding Fc fragment","Other indication","Myasthenia gravis","Myasthenia gravis","EFO_0004991","Serious","S,O,F",2021,"ENSG00000104870","ENSG00000163631","literature","europepmc",0.266788638445608,7,NA,NA
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000159224","genetic_association","ot_genetics_portal",0.396388573220861,9,"Orphanet_79161","type 2 diabetes mellitus -> Disorder of carbohydrate metabolism"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000159224","genetic_association","ot_genetics_portal",0.396388573220861,9,"HP_0003076","type 2 diabetes mellitus -> Glycosuria"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000159224","literature","europepmc",0.46994766893856,116,"Orphanet_79161","type 2 diabetes mellitus -> Disorder of carbohydrate metabolism"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000159224","literature","europepmc",0.46994766893856,116,"HP_0003076","type 2 diabetes mellitus -> Glycosuria"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000122585","literature","europepmc",0.681971638589217,40,"Orphanet_79161","type 2 diabetes mellitus -> Disorder of carbohydrate metabolism"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000122585","literature","europepmc",0.681971638589217,40,"HP_0003076","type 2 diabetes mellitus -> Glycosuria"
"Xadago","Safinamide","SAFINAMIDE","CHEMBL396778","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017,"ENSG00000069535","ENSG00000102466","literature","europepmc",0.0364758478566973,1,NA,NA
"Xadago","Safinamide","SAFINAMIDE","CHEMBL396778","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017,"ENSG00000069535","ENSG00000102466","animal_model","impc",0.334179559447108,2,NA,NA
"Striverdi Respimat","Olodaterol","OLODATEROL","CHEMBL605846","Boehringer Ingelheim","Long-acting beta2-adrenoceptor agonist","Other indication","COPD","chronic obstructive pulmonary disease","EFO_0000341","Serious","S",2014,"ENSG00000169252","ENSG00000141480","literature","europepmc",0.123671596507873,7,NA,NA
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000006128","literature","europepmc",0.0928184204993592,12,"Orphanet_79161","type 2 diabetes mellitus -> Disorder of carbohydrate metabolism"
"Nesina","Alogliptin","ALOGLIPTIN","CHEMBL376359","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013,"ENSG00000197635","ENSG00000006128","literature","europepmc",0.0928184204993592,12,"HP_0003076","type 2 diabetes mellitus -> Glycosuria"
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000027644","literature","europepmc",0.0606242100951589,3,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000197594","somatic_mutation","eva_somatic",0.244523276372674,3,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000197594","literature","europepmc",0.607375687634921,95,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000197594","genetic_association","ot_genetics_portal",0.240000285182508,1,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000197594","genetic_association","uniprot_literature",0.607930797611621,1,NA,NA
"Tresiba","Insulin degludec","INSULINDEGLUDEC","CHEMBL2107869","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015,"ENSG00000171105","ENSG00000197594","genetic_association","eva",0.808860557470626,29,NA,NA
"Ingrezza","Valbenazine","VALBENAZINE","CHEMBL2364639","Neurocrine Biosciences","VMAT2 inhibitor","Other indication","Tardive dyskinesia","movement disorder","EFO_0004280","Not concordant","P,B,F",2017,"ENSG00000165646","ENSG00000173250","literature","europepmc",0.0547137717850459,1,NA,NA
"Ingrezza","Valbenazine","VALBENAZINE","CHEMBL2364639","Neurocrine Biosciences","VMAT2 inhibitor","Other indication","Tardive dyskinesia","movement disorder","EFO_0004280","Not concordant","P,B,F",2017,"ENSG00000165646","ENSG00000173250","genetic_association","eva",0.425551558328135,1,NA,NA
"Striverdi Respimat","Olodaterol","OLODATEROL","CHEMBL605846","Boehringer Ingelheim","Long-acting beta2-adrenoceptor agonist","Other indication","COPD","chronic obstructive pulmonary disease","EFO_0000341","Serious","S",2014,"ENSG00000169252","ENSG00000169252","literature","europepmc",0.833354920795771,125,NA,NA
"Striverdi Respimat","Olodaterol","OLODATEROL","CHEMBL605846","Boehringer Ingelheim","Long-acting beta2-adrenoceptor agonist","Other indication","COPD","chronic obstructive pulmonary disease","EFO_0000341","Serious","S",2014,"ENSG00000169252","ENSG00000169252","known_drug","chembl",0.999076989623257,982,NA,NA
"Tepezza","Teprotumumab","TEPROTUMUMAB","CHEMBL1743079","Horizon Therapeutics","IGF1R-directed mAb","Other indication","Thyroid eye disease","Graves disease","EFO_0004237","Not concordant","P,O,B,F",2020,"ENSG00000140443","ENSG00000150093","literature","europepmc",0.126145640504411,2,NA,NA
"Briumvi","Ublituximab","Ublituximab","CHEMBL2108354","TG Therapeutics","CD20-targeted mAb","Other indication","Relapsing forms of multiple sclerosis","relapsing-remitting multiple sclerosis","EFO_0003929","Serious","S",2022,"ENSG00000156738","ENSG00000144648","literature","europepmc",0.0243172319044648,1,"MONDO_0005301","relapsing-remitting multiple sclerosis -> multiple sclerosis (parent)"
"Winlevi","Clascoterone","CLASCOTERONE","CHEMBL3590187","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020,"ENSG00000169083","ENSG00000000938","rna_expression","expression_atlas",0.0299440676558243,1,NA,NA
"Winlevi","Clascoterone","CLASCOTERONE","CHEMBL3590187","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020,"ENSG00000169083","ENSG00000000938","literature","europepmc",0.0182379239283486,1,NA,NA
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000138207","animal_model","impc",0.59717854512483,6,NA,NA
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000138207","literature","europepmc",0.131887209148521,3,NA,NA
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000118271","somatic_mutation","eva_somatic",0.559296333802691,1,NA,NA
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000118271","genetic_association","eva",0.944371101297926,300,NA,NA
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000118271","genetic_association","genomics_england",0.759913497014526,2,NA,NA
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000118271","known_drug","chembl",0.920570637175102,12,NA,NA
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000118271","genetic_association","orphanet",0.607930797611621,1,NA,NA
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000118271","affected_pathway","reactome",0.759913497014526,2,NA,NA
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000118271","literature","europepmc",0.783086230922133,190,NA,NA
"Kynamro","Mipomersen","MIPOMERSEN","CHEMBL2219536","Genzyme","Oligonucleotide inhibitor of apolipoprotein B100 synthesis","Other indication","Homozygous familial hypercholesterolaemia","homozygous familial hypercholesterolemia","MONDO_0018328","Serious","S,O",2013,"ENSG00000084674","ENSG00000130164","animal_model","impc",0.822032053587636,19,"EFO_0004611","homozygous familial hypercholesterolemia -> low density lipoprotein cholesterol measurement"
"Kynamro","Mipomersen","MIPOMERSEN","CHEMBL2219536","Genzyme","Oligonucleotide inhibitor of apolipoprotein B100 synthesis","Other indication","Homozygous familial hypercholesterolaemia","homozygous familial hypercholesterolemia","MONDO_0018328","Serious","S,O",2013,"ENSG00000084674","ENSG00000130164","genetic_association","eva",0.909612974165809,60,"EFO_0004611","homozygous familial hypercholesterolemia -> low density lipoprotein cholesterol measurement"
"Kynamro","Mipomersen","MIPOMERSEN","CHEMBL2219536","Genzyme","Oligonucleotide inhibitor of apolipoprotein B100 synthesis","Other indication","Homozygous familial hypercholesterolaemia","homozygous familial hypercholesterolemia","MONDO_0018328","Serious","S,O",2013,"ENSG00000084674","ENSG00000130164","genetic_association","orphanet",0.607930797611621,1,"EFO_0004611","homozygous familial hypercholesterolemia -> low density lipoprotein cholesterol measurement"
"Kynamro","Mipomersen","MIPOMERSEN","CHEMBL2219536","Genzyme","Oligonucleotide inhibitor of apolipoprotein B100 synthesis","Other indication","Homozygous familial hypercholesterolaemia","homozygous familial hypercholesterolemia","MONDO_0018328","Serious","S,O",2013,"ENSG00000084674","ENSG00000130164","literature","europepmc",0.6140635865314,41,"EFO_0004611","homozygous familial hypercholesterolemia -> low density lipoprotein cholesterol measurement"
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000166595","animal_model","impc",0.330714353900722,1,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000087088","literature","europepmc",0.169651949935794,25,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000087088","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000197153","literature","europepmc",0.134315554945648,6,NA,NA
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000159459","literature","europepmc",0.0607930797611621,1,NA,NA
"Imjudo","Tremelimumab","Tremelimumab","CHEMBL2108658","AstraZeneca","CTLA4-targeted mAb","Oncology","Hepatocellular carcinoma","hepatocellular carcinoma","EFO_0000182","Serious","S,O",2022,"ENSG00000163599","ENSG00000114013","literature","europepmc",0.778364930160538,21,"MONDO_0018531","hepatocellular carcinoma -> carcinoma of liver and intrahepatic biliary tract"
"Evenity","Romosozumab","ROMOSOZUMAB","CHEMBL2107874","Amgen","Sclerostin inhibitor","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2019,"ENSG00000167941","ENSG00000134569","literature","europepmc",0.0243172319044648,1,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000015475","literature","europepmc",0.395155018447554,1,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000015475","rna_expression","expression_atlas",0.0655349399825327,1,NA,NA
"Winlevi","Clascoterone","CLASCOTERONE","CHEMBL3590187","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020,"ENSG00000169083","ENSG00000110092","genetic_association","ot_genetics_portal",0.0521184335027596,1,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000198625","literature","europepmc",0.0506608998009684,3,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000198625","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Winlevi","Clascoterone","CLASCOTERONE","CHEMBL3590187","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020,"ENSG00000169083","ENSG00000107338","genetic_association","ot_genetics_portal",0.461358638013185,1,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000100030","somatic_mutation","intogen",0.342543193468965,1,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000100030","affected_pathway","slapenrich",0.684438701090125,5,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000100030","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Keytruda","Pembrolizumab","PEMBROLIZUMAB","CHEMBL3137343","Merck & Co.","PD1-specific antibody","Oncology","Metastatic melanoma *and others (2021 approval)","metastatic melanoma","EFO_0002617","Serious","P,O,B,A",2014,"ENSG00000188389","ENSG00000121594","literature","europepmc",0.0780177856934914,3,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Opdivo","Nivolumab","NIVOLUMAB","CHEMBL2108738","Bristol-Myers Squibb","PD1 inhibitor","Oncology","Unresectable or metastatic melanoma","metastatic melanoma","EFO_0002617","Serious","P,O,B,A,F",2014,"ENSG00000188389","ENSG00000121594","literature","europepmc",0.0780177856934914,3,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Tafinlar","Dabrafenib","DABRAFENIB","CHEMBL2028663","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013,"ENSG00000157764","ENSG00000174775","literature","europepmc",0.0182379239283486,1,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Tafinlar","Dabrafenib","DABRAFENIB","CHEMBL2028663","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013,"ENSG00000157764","ENSG00000132155","known_drug","chembl",0.0607930797611621,1,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Tafinlar","Dabrafenib","DABRAFENIB","CHEMBL2028663","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013,"ENSG00000157764","ENSG00000132155","literature","europepmc",0.0986840554189664,6,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Tymlos","Abaloparatide","ABALOPARATIDE","CHEMBL3301581","Radius Health","Parathyroid hormone-related protein","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2017,"ENSG00000160801","ENSG00000152266","literature","europepmc",0.913188638950141,829,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000171552","literature","europepmc",0.226310783376048,26,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000171552","known_drug","chembl",0.178825968550806,15,NA,NA
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000142192","animal_model","impc",0.437576767244225,3,NA,NA
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000142192","affected_pathway","reactome",0.759913497014526,2,NA,NA
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000142192","literature","europepmc",0.0667035180712751,3,NA,NA
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000204305","literature","europepmc",0.181690147656602,7,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000141510","literature","europepmc",0.934217106486735,261,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000141510","somatic_mutation","intogen",0.827461363415818,3,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000141510","known_drug","chembl",0.121586159522324,1,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000141510","affected_pathway","slapenrich",0.977086804651432,40,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000141510","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000141510","animal_model","impc",0.604369758529778,4,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000141510","somatic_mutation","eva_somatic",0.844586244748924,57,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000141510","genetic_association","gene_burden",0.660780562474682,4,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000142168","literature","europepmc",0.111713935458184,7,NA,NA
"Imjudo","Tremelimumab","Tremelimumab","CHEMBL2108658","AstraZeneca","CTLA4-targeted mAb","Oncology","Hepatocellular carcinoma","hepatocellular carcinoma","EFO_0000182","Serious","S,O",2022,"ENSG00000163599","ENSG00000121594","literature","europepmc",0.739632825966616,33,"MONDO_0018531","hepatocellular carcinoma -> carcinoma of liver and intrahepatic biliary tract"
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000070061","literature","europepmc",0.941329085326353,84,NA,NA
"Tafinlar","Dabrafenib","DABRAFENIB","CHEMBL2028663","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013,"ENSG00000157764","ENSG00000133703","literature","europepmc",0.0364758478566973,2,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000169136","literature","europepmc",0.0121586159522324,1,NA,NA
"Evkeeza","Evinacumab","Evinacumab","CHEMBL3545191","Regeneron","ANGPTL3-targeted mAb","Other indication","HoFH","homozygous familial hypercholesterolemia","MONDO_0018328","Serious","P,O,B",2021,"ENSG00000132855","ENSG00000175445","animal_model","impc",0.6141468900172,4,"EFO_0004611","homozygous familial hypercholesterolemia -> low density lipoprotein cholesterol measurement"
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000165637","literature","europepmc",0.0243172319044648,1,NA,NA
"Winlevi","Clascoterone","CLASCOTERONE","CHEMBL3590187","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020,"ENSG00000169083","ENSG00000254087","rna_expression","expression_atlas",0.0769200850369284,2,NA,NA
"Winlevi","Clascoterone","CLASCOTERONE","CHEMBL3590187","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020,"ENSG00000169083","ENSG00000254087","literature","europepmc",0.0182379239283486,1,NA,NA
"Tafinlar","Dabrafenib","DABRAFENIB","CHEMBL2028663","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013,"ENSG00000157764","ENSG00000187555","literature","europepmc",0.151982699402905,1,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000113575","literature","europepmc",0.0182379239283486,1,NA,NA
"Qelbree","Viloxazine","Viloxazine","CHEMBL306700","Supernus","SNRI","Other indication","ADHD","attention deficit hyperactivity disorder","EFO_0003888","Not serious","S",2021,"ENSG00000103546","ENSG00000100151","literature","europepmc",0.0516741177969878,2,NA,NA
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000198959","animal_model","impc",0.492949546215172,22,NA,NA
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000198959","literature","europepmc",0.272823988613768,8,NA,NA
"Winlevi","Clascoterone","CLASCOTERONE","CHEMBL3590187","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020,"ENSG00000169083","ENSG00000142515","literature","europepmc",0.0121586159522324,1,NA,NA
"Korsuva","Difelikefalin","Difelikefalin","CHEMBL3989915","Cara Therapeutics","kappa-Opioid receptor agonist","Other indication","Pruritus associated with CKD","chronic kidney disease","EFO_0003884","Serious","P,B",2021,"ENSG00000082556","ENSG00000198932","rna_expression","expression_atlas",0.0774503836157205,1,"HP_0012594","chronic kidney disease -> Moderate albuminuria"
"Tecfidera","Dimethyl fumarate","DIMETHYLFUMARATE","CHEMBL2107333","Biogen Idec","MOA unknown; activates NRF2 pathway","Other indication","Relapsing forms of multiple sclerosis","relapsing-remitting multiple sclerosis","EFO_0003929","Serious","S",2013,"ENSG00000079999","ENSG00000090339","literature","europepmc",0.0594218580732159,5,"MONDO_0005301","relapsing-remitting multiple sclerosis -> multiple sclerosis (parent)"
"Briumvi","Ublituximab","Ublituximab","CHEMBL2108354","TG Therapeutics","CD20-targeted mAb","Other indication","Relapsing forms of multiple sclerosis","relapsing-remitting multiple sclerosis","EFO_0003929","Serious","S",2022,"ENSG00000156738","ENSG00000168685","literature","europepmc",0.083021393897167,5,"MONDO_0005301","relapsing-remitting multiple sclerosis -> multiple sclerosis (parent)"
"Tecfidera","Dimethyl fumarate","DIMETHYLFUMARATE","CHEMBL2107333","Biogen Idec","MOA unknown; activates NRF2 pathway","Other indication","Relapsing forms of multiple sclerosis","relapsing-remitting multiple sclerosis","EFO_0003929","Serious","S",2013,"ENSG00000079999","ENSG00000116044","literature","europepmc",0.0303965398805811,2,"MONDO_0005301","relapsing-remitting multiple sclerosis -> multiple sclerosis (parent)"
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000170035","literature","europepmc",0.0243172319044648,1,NA,NA
"Tafinlar","Dabrafenib","DABRAFENIB","CHEMBL2028663","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013,"ENSG00000157764","ENSG00000169032","known_drug","chembl",0.886511900854954,28,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Tafinlar","Dabrafenib","DABRAFENIB","CHEMBL2028663","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013,"ENSG00000157764","ENSG00000169032","literature","europepmc",0.308680543188166,18,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Gazyva","Obinutuzumab","OBINUTUZUMAB","CHEMBL1743048","Genentech","Humanized CD20-specific monoclonal antibody","Oncology","Previously untreated chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B",2013,"ENSG00000156738","ENSG00000157613","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000141682","literature","europepmc",0.187367760836439,14,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000141682","genetic_association","ot_genetics_portal",0.484290817239493,1,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000141682","rna_expression","expression_atlas",0.040844915504829,1,NA,NA
"Tymlos","Abaloparatide","ABALOPARATIDE","CHEMBL3301581","Radius Health","Parathyroid hormone-related protein","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2017,"ENSG00000160801","ENSG00000198668","literature","europepmc",0.0121586159522324,1,NA,NA
"Winlevi","Clascoterone","CLASCOTERONE","CHEMBL3590187","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020,"ENSG00000169083","ENSG00000169083","known_drug","chembl",0.812979755660126,8,NA,NA
"Winlevi","Clascoterone","CLASCOTERONE","CHEMBL3590187","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020,"ENSG00000169083","ENSG00000169083","literature","europepmc",0.28584678804685,75,NA,NA
"Winlevi","Clascoterone","CLASCOTERONE","CHEMBL3590187","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020,"ENSG00000169083","ENSG00000101336","rna_expression","expression_atlas",0.0622556537421232,3,NA,NA
"Winlevi","Clascoterone","CLASCOTERONE","CHEMBL3590187","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020,"ENSG00000169083","ENSG00000101336","literature","europepmc",0.0182379239283486,1,NA,NA
"Briumvi","Ublituximab","Ublituximab","CHEMBL2108354","TG Therapeutics","CD20-targeted mAb","Other indication","Relapsing forms of multiple sclerosis","relapsing-remitting multiple sclerosis","EFO_0003929","Serious","S",2022,"ENSG00000156738","ENSG00000156738","known_drug","chembl",0.927495523917799,15,"MONDO_0005301","relapsing-remitting multiple sclerosis -> multiple sclerosis (parent)"
"Evenity","Romosozumab","ROMOSOZUMAB","CHEMBL2107874","Amgen","Sclerostin inhibitor","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2019,"ENSG00000167941","ENSG00000162337","genetic_association","ot_genetics_portal",0.442433074080183,6,NA,NA
"Evenity","Romosozumab","ROMOSOZUMAB","CHEMBL2107874","Amgen","Sclerostin inhibitor","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2019,"ENSG00000167941","ENSG00000162337","animal_model","impc",0.776891357338,34,NA,NA
"Evenity","Romosozumab","ROMOSOZUMAB","CHEMBL2107874","Amgen","Sclerostin inhibitor","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2019,"ENSG00000167941","ENSG00000162337","genetic_association","uniprot_literature",0.759913497014526,2,NA,NA
"Evenity","Romosozumab","ROMOSOZUMAB","CHEMBL2107874","Amgen","Sclerostin inhibitor","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2019,"ENSG00000167941","ENSG00000162337","genetic_association","eva",0.873627899970689,514,NA,NA
"Evenity","Romosozumab","ROMOSOZUMAB","CHEMBL2107874","Amgen","Sclerostin inhibitor","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2019,"ENSG00000167941","ENSG00000162337","genetic_association","gene_burden",0.532141635685504,19,NA,NA
"Evenity","Romosozumab","ROMOSOZUMAB","CHEMBL2107874","Amgen","Sclerostin inhibitor","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2019,"ENSG00000167941","ENSG00000162337","genetic_association","genomics_england",0.607930797611621,1,NA,NA
"Evenity","Romosozumab","ROMOSOZUMAB","CHEMBL2107874","Amgen","Sclerostin inhibitor","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2019,"ENSG00000167941","ENSG00000162337","literature","europepmc",0.786887200334706,168,NA,NA
"Tymlos","Abaloparatide","ABALOPARATIDE","CHEMBL3301581","Radius Health","Parathyroid hormone-related protein","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2017,"ENSG00000160801","ENSG00000087494","animal_model","impc",0.468577860529097,2,NA,NA
"Tymlos","Abaloparatide","ABALOPARATIDE","CHEMBL3301581","Radius Health","Parathyroid hormone-related protein","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2017,"ENSG00000160801","ENSG00000087494","literature","europepmc",0.546152869804716,84,NA,NA
"Winlevi","Clascoterone","CLASCOTERONE","CHEMBL3590187","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020,"ENSG00000169083","ENSG00000132437","rna_expression","expression_atlas",0.00927593129072799,1,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000171791","literature","europepmc",0.570347373933888,326,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000171791","genetic_association","ot_genetics_portal",0.708563911102623,4,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000171791","known_drug","chembl",0.931937448907452,102,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000171791","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000171791","rna_expression","expression_atlas",0.0430531040350025,2,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000123358","literature","europepmc",0.0182379239283486,1,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000123358","affected_pathway","slapenrich",0.405141245893539,2,NA,NA
"Winlevi","Clascoterone","CLASCOTERONE","CHEMBL3590187","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020,"ENSG00000169083","ENSG00000116288","genetic_association","ot_genetics_portal",0.123664683923735,1,NA,NA
"Tafinlar","Dabrafenib","DABRAFENIB","CHEMBL2028663","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013,"ENSG00000157764","ENSG00000171132","literature","europepmc",0.0486344638089297,1,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Korsuva","Difelikefalin","Difelikefalin","CHEMBL3989915","Cara Therapeutics","kappa-Opioid receptor agonist","Other indication","Pruritus associated with CKD","chronic kidney disease","EFO_0003884","Serious","P,B",2021,"ENSG00000082556","ENSG00000134817","literature","europepmc",0.0750692179354836,7,"HP_0012594","chronic kidney disease -> Moderate albuminuria"
"Keytruda","Pembrolizumab","PEMBROLIZUMAB","CHEMBL3137343","Merck & Co.","PD1-specific antibody","Oncology","Metastatic melanoma *and others (2021 approval)","metastatic melanoma","EFO_0002617","Serious","P,O,B,A",2014,"ENSG00000188389","ENSG00000120217","known_drug","chembl",0.165492272683163,3,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Opdivo","Nivolumab","NIVOLUMAB","CHEMBL2108738","Bristol-Myers Squibb","PD1 inhibitor","Oncology","Unresectable or metastatic melanoma","metastatic melanoma","EFO_0002617","Serious","P,O,B,A,F",2014,"ENSG00000188389","ENSG00000120217","known_drug","chembl",0.165492272683163,3,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Keytruda","Pembrolizumab","PEMBROLIZUMAB","CHEMBL3137343","Merck & Co.","PD1-specific antibody","Oncology","Metastatic melanoma *and others (2021 approval)","metastatic melanoma","EFO_0002617","Serious","P,O,B,A",2014,"ENSG00000188389","ENSG00000120217","literature","europepmc",0.412943474387337,132,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Opdivo","Nivolumab","NIVOLUMAB","CHEMBL2108738","Bristol-Myers Squibb","PD1 inhibitor","Oncology","Unresectable or metastatic melanoma","metastatic melanoma","EFO_0002617","Serious","P,O,B,A,F",2014,"ENSG00000188389","ENSG00000120217","literature","europepmc",0.412943474387337,132,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Tymlos","Abaloparatide","ABALOPARATIDE","CHEMBL3301581","Radius Health","Parathyroid hormone-related protein","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2017,"ENSG00000160801","ENSG00000168036","genetic_association","ot_genetics_portal",0.145214981369966,3,NA,NA
"Tymlos","Abaloparatide","ABALOPARATIDE","CHEMBL3301581","Radius Health","Parathyroid hormone-related protein","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2017,"ENSG00000160801","ENSG00000168036","literature","europepmc",0.527150842600814,16,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000100290","literature","europepmc",0.0121586159522324,1,NA,NA
"Tafinlar","Dabrafenib","DABRAFENIB","CHEMBL2028663","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013,"ENSG00000157764","ENSG00000140575","rna_expression","expression_atlas",0.0372401659333984,2,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Tafinlar","Dabrafenib","DABRAFENIB","CHEMBL2028663","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013,"ENSG00000157764","ENSG00000170027","rna_expression","expression_atlas",0.0341993949323694,2,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000153094","literature","europepmc",0.102792254190842,13,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000153094","genetic_association","ot_genetics_portal",0.67350600917398,10,NA,NA
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000119614","animal_model","impc",0.256425210432582,1,NA,NA
"Gazyva","Obinutuzumab","OBINUTUZUMAB","CHEMBL1743048","Genentech","Humanized CD20-specific monoclonal antibody","Oncology","Previously untreated chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B",2013,"ENSG00000156738","ENSG00000156738","literature","europepmc",0.172215545054554,24,NA,NA
"Gazyva","Obinutuzumab","OBINUTUZUMAB","CHEMBL1743048","Genentech","Humanized CD20-specific monoclonal antibody","Oncology","Previously untreated chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B",2013,"ENSG00000156738","ENSG00000156738","known_drug","chembl",0.97353740219826,320,NA,NA
"Gazyva","Obinutuzumab","OBINUTUZUMAB","CHEMBL1743048","Genentech","Humanized CD20-specific monoclonal antibody","Oncology","Previously untreated chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B",2013,"ENSG00000156738","ENSG00000156738","rna_expression","expression_atlas",0.039794405403221,1,NA,NA
"Keytruda","Pembrolizumab","PEMBROLIZUMAB","CHEMBL3137343","Merck & Co.","PD1-specific antibody","Oncology","Metastatic melanoma *and others (2021 approval)","metastatic melanoma","EFO_0002617","Serious","P,O,B,A",2014,"ENSG00000188389","ENSG00000179295","literature","europepmc",0.0729516957133945,1,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Opdivo","Nivolumab","NIVOLUMAB","CHEMBL2108738","Bristol-Myers Squibb","PD1 inhibitor","Oncology","Unresectable or metastatic melanoma","metastatic melanoma","EFO_0002617","Serious","P,O,B,A,F",2014,"ENSG00000188389","ENSG00000179295","literature","europepmc",0.0729516957133945,1,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000029363","literature","europepmc",0.303965398805811,1,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000029363","somatic_mutation","cancer_gene_census",0.303965398805811,1,NA,NA
"Tafinlar","Dabrafenib","DABRAFENIB","CHEMBL2028663","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013,"ENSG00000157764","ENSG00000096384","known_drug","chembl",0.158737486043034,3,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Imjudo","Tremelimumab","Tremelimumab","CHEMBL2108658","AstraZeneca","CTLA4-targeted mAb","Oncology","Hepatocellular carcinoma","hepatocellular carcinoma","EFO_0000182","Serious","S,O",2022,"ENSG00000163599","ENSG00000145675","literature","europepmc",0.669936698246038,22,"MONDO_0018531","hepatocellular carcinoma -> carcinoma of liver and intrahepatic biliary tract"
"Imjudo","Tremelimumab","Tremelimumab","CHEMBL2108658","AstraZeneca","CTLA4-targeted mAb","Oncology","Hepatocellular carcinoma","hepatocellular carcinoma","EFO_0000182","Serious","S,O",2022,"ENSG00000163599","ENSG00000145675","known_drug","chembl",0.0607930797611621,1,"MONDO_0018531","hepatocellular carcinoma -> carcinoma of liver and intrahepatic biliary tract"
"Imjudo","Tremelimumab","Tremelimumab","CHEMBL2108658","AstraZeneca","CTLA4-targeted mAb","Oncology","Hepatocellular carcinoma","hepatocellular carcinoma","EFO_0000182","Serious","S,O",2022,"ENSG00000163599","ENSG00000145675","somatic_mutation","cancer_gene_census",0.531939447910168,2,"MONDO_0018531","hepatocellular carcinoma -> carcinoma of liver and intrahepatic biliary tract"
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000128609","known_drug","chembl",0.0607930797611621,1,NA,NA
"Winlevi","Clascoterone","CLASCOTERONE","CHEMBL3590187","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020,"ENSG00000169083","ENSG00000184557","rna_expression","expression_atlas",0.0658082022309441,1,NA,NA
"Korsuva","Difelikefalin","Difelikefalin","CHEMBL3989915","Cara Therapeutics","kappa-Opioid receptor agonist","Other indication","Pruritus associated with CKD","chronic kidney disease","EFO_0003884","Serious","P,B",2021,"ENSG00000082556","ENSG00000105374","literature","europepmc",0.0182379239283486,1,"HP_0012594","chronic kidney disease -> Moderate albuminuria"
"Tafinlar","Dabrafenib","DABRAFENIB","CHEMBL2028663","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013,"ENSG00000157764","ENSG00000044574","literature","europepmc",0.0121586159522324,1,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Zynlonta","Loncastuximab tesirine","Loncastuximabtesirine","CHEMBL4297778","ADC Therapeutics","CD19-targeted ADC","Oncology","B-cell lymphoma","B-cell non-Hodgkins lymphoma","EFO_1001938","Serious","P,O,A",2021,"ENSG00000177455","ENSG00000211899","animal_model","impc",0.712192926375492,13,NA,NA
"Tafinlar","Dabrafenib","DABRAFENIB","CHEMBL2028663","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013,"ENSG00000157764","ENSG00000213281","literature","europepmc",0.378291025481527,50,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000105327","literature","europepmc",0.100308581605917,2,NA,NA
"Kynamro","Mipomersen","MIPOMERSEN","CHEMBL2219536","Genzyme","Oligonucleotide inhibitor of apolipoprotein B100 synthesis","Other indication","Homozygous familial hypercholesterolaemia","homozygous familial hypercholesterolemia","MONDO_0018328","Serious","S,O",2013,"ENSG00000084674","ENSG00000138823","animal_model","impc",0.332477353213796,1,"EFO_0004611","homozygous familial hypercholesterolemia -> low density lipoprotein cholesterol measurement"
"Kynamro","Mipomersen","MIPOMERSEN","CHEMBL2219536","Genzyme","Oligonucleotide inhibitor of apolipoprotein B100 synthesis","Other indication","Homozygous familial hypercholesterolaemia","homozygous familial hypercholesterolemia","MONDO_0018328","Serious","S,O",2013,"ENSG00000084674","ENSG00000138823","known_drug","chembl",0.586822089361217,4,"EFO_0004611","homozygous familial hypercholesterolemia -> low density lipoprotein cholesterol measurement"
"Kynamro","Mipomersen","MIPOMERSEN","CHEMBL2219536","Genzyme","Oligonucleotide inhibitor of apolipoprotein B100 synthesis","Other indication","Homozygous familial hypercholesterolaemia","homozygous familial hypercholesterolemia","MONDO_0018328","Serious","S,O",2013,"ENSG00000084674","ENSG00000138823","literature","europepmc",0.167988427646631,13,"EFO_0004611","homozygous familial hypercholesterolemia -> low density lipoprotein cholesterol measurement"
"Tafinlar","Dabrafenib","DABRAFENIB","CHEMBL2028663","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013,"ENSG00000157764","ENSG00000157764","known_drug","chembl",0.906569821941886,32,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Tafinlar","Dabrafenib","DABRAFENIB","CHEMBL2028663","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013,"ENSG00000157764","ENSG00000157764","literature","europepmc",0.944614946105741,865,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000187678","literature","europepmc",0.142694867772728,3,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000030110","literature","europepmc",0.64816399553689,4,NA,NA
"Venclexta","Venetoclax","VENETOCLAX","CHEMBL3137309","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016,"ENSG00000171791","ENSG00000030110","genetic_association","ot_genetics_portal",0.636774476697188,4,NA,NA
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000132016","animal_model","impc",0.431646064574191,2,NA,NA
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000139372","animal_model","impc",0.267975895587203,1,NA,NA
"Keytruda","Pembrolizumab","PEMBROLIZUMAB","CHEMBL3137343","Merck & Co.","PD1-specific antibody","Oncology","Metastatic melanoma *and others (2021 approval)","metastatic melanoma","EFO_0002617","Serious","P,O,B,A",2014,"ENSG00000188389","ENSG00000197646","literature","europepmc",0.0303965398805811,1,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Opdivo","Nivolumab","NIVOLUMAB","CHEMBL2108738","Bristol-Myers Squibb","PD1 inhibitor","Oncology","Unresectable or metastatic melanoma","metastatic melanoma","EFO_0002617","Serious","P,O,B,A,F",2014,"ENSG00000188389","ENSG00000197646","literature","europepmc",0.0303965398805811,1,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Gazyva","Obinutuzumab","OBINUTUZUMAB","CHEMBL1743048","Genentech","Humanized CD20-specific monoclonal antibody","Oncology","Previously untreated chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B",2013,"ENSG00000156738","ENSG00000168685","literature","europepmc",0.0911896196417432,1,NA,NA
"Gazyva","Obinutuzumab","OBINUTUZUMAB","CHEMBL1743048","Genentech","Humanized CD20-specific monoclonal antibody","Oncology","Previously untreated chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B",2013,"ENSG00000156738","ENSG00000168685","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Gazyva","Obinutuzumab","OBINUTUZUMAB","CHEMBL1743048","Genentech","Humanized CD20-specific monoclonal antibody","Oncology","Previously untreated chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B",2013,"ENSG00000156738","ENSG00000168685","rna_expression","expression_atlas",0.0255973890437662,1,NA,NA
"Tafinlar","Dabrafenib","DABRAFENIB","CHEMBL2028663","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013,"ENSG00000157764","ENSG00000078061","known_drug","chembl",0.0607930797611621,1,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Tafinlar","Dabrafenib","DABRAFENIB","CHEMBL2028663","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013,"ENSG00000157764","ENSG00000078061","literature","europepmc",0.0121586159522324,1,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000128272","animal_model","impc",0.249737971658854,1,NA,NA
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000128272","literature","europepmc",0.0874863078662924,5,NA,NA
"Tepezza","Teprotumumab","TEPROTUMUMAB","CHEMBL1743079","Horizon Therapeutics","IGF1R-directed mAb","Other indication","Thyroid eye disease","Graves disease","EFO_0004237","Not concordant","P,O,B,F",2020,"ENSG00000140443","ENSG00000140443","literature","europepmc",0.135231710318673,21,NA,NA
"Tepezza","Teprotumumab","TEPROTUMUMAB","CHEMBL1743079","Horizon Therapeutics","IGF1R-directed mAb","Other indication","Thyroid eye disease","Graves disease","EFO_0004237","Not concordant","P,O,B,F",2020,"ENSG00000140443","ENSG00000140443","known_drug","chembl",0.896781327414228,7,NA,NA
"Tepezza","Teprotumumab","TEPROTUMUMAB","CHEMBL1743079","Horizon Therapeutics","IGF1R-directed mAb","Other indication","Thyroid eye disease","Graves disease","EFO_0004237","Not concordant","P,O,B,F",2020,"ENSG00000140443","ENSG00000171105","literature","europepmc",0.0408664591727812,3,NA,NA
"Tafinlar","Dabrafenib","DABRAFENIB","CHEMBL2028663","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013,"ENSG00000157764","ENSG00000126934","known_drug","chembl",0.886511900854954,28,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Tafinlar","Dabrafenib","DABRAFENIB","CHEMBL2028663","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013,"ENSG00000157764","ENSG00000126934","literature","europepmc",0.0407094103833982,6,"EFO_0000756","metastatic melanoma -> melanoma (parent)"
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000130294","literature","europepmc",0.0243172319044648,1,NA,NA
"Evenity","Romosozumab","ROMOSOZUMAB","CHEMBL2107874","Amgen","Sclerostin inhibitor","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2019,"ENSG00000167941","ENSG00000070018","animal_model","impc",0.572064569249195,3,NA,NA
"Winlevi","Clascoterone","CLASCOTERONE","CHEMBL3590187","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020,"ENSG00000169083","ENSG00000163565","rna_expression","expression_atlas",0.0378536348770146,1,NA,NA
"Evenity","Romosozumab","ROMOSOZUMAB","CHEMBL2107874","Amgen","Sclerostin inhibitor","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2019,"ENSG00000167941","ENSG00000070018","literature","europepmc",0.28541665056756,27,NA,NA
"Tecfidera","Dimethyl fumarate","DIMETHYLFUMARATE","CHEMBL2107333","Biogen Idec","MOA unknown; activates NRF2 pathway","Other indication","Relapsing forms of multiple sclerosis","relapsing-remitting multiple sclerosis","EFO_0003929","Serious","S",2013,"ENSG00000079999","ENSG00000030582","literature","europepmc",0.0486344638089297,1,"MONDO_0005301","relapsing-remitting multiple sclerosis -> multiple sclerosis (parent)"
"Mayzent","Siponimod","SIPONIMOD","CHEMBL2336071","Novartis","S1P receptor modulator","Other indication","Relapsing forms of multiple sclerosis","relapsing-remitting multiple sclerosis","EFO_0003929","Serious","S",2019,"ENSG00000170989","ENSG00000110848","literature","europepmc",0.0182379239283486,1,"MONDO_0005301","relapsing-remitting multiple sclerosis -> multiple sclerosis (parent)"
"Vyndaqel","Tafamidis","TAFAMIDIS","CHEMBL2103837","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019,"ENSG00000118271","ENSG00000026025","literature","europepmc",0.558300452708411,19,NA,NA
"Tepezza","Teprotumumab","TEPROTUMUMAB","CHEMBL1743079","Horizon Therapeutics","IGF1R-directed mAb","Other indication","Thyroid eye disease","Graves disease","EFO_0004237","Not concordant","P,O,B,F",2020,"ENSG00000140443","ENSG00000017427","literature","europepmc",0.17185659618604,21,NA,NA
"Welireg","Belzutifan","Belzutifan","CHEMBL4585668","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021,"ENSG00000116016","ENSG00000134086","literature","europepmc",0.920580911402914,423,"EFO_0000681","von Hippel-Lindau disease -> renal cell carcinoma"
"Welireg","Belzutifan","Belzutifan","CHEMBL4585668","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021,"ENSG00000116016","ENSG00000134086","somatic_mutation","eva_somatic",0.857627153045302,10,"EFO_0000681","von Hippel-Lindau disease -> renal cell carcinoma"
"Welireg","Belzutifan","Belzutifan","CHEMBL4585668","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021,"ENSG00000116016","ENSG00000134086","genetic_association","gene2phenotype",0.827461363415818,3,"EFO_0000681","von Hippel-Lindau disease -> renal cell carcinoma"
"Welireg","Belzutifan","Belzutifan","CHEMBL4585668","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021,"ENSG00000116016","ENSG00000134086","genetic_association","clingen",0.607930797611621,1,"EFO_0000681","von Hippel-Lindau disease -> renal cell carcinoma"
"Welireg","Belzutifan","Belzutifan","CHEMBL4585668","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021,"ENSG00000116016","ENSG00000134086","genetic_association","orphanet",0.607930797611621,1,"EFO_0000681","von Hippel-Lindau disease -> renal cell carcinoma"
"Welireg","Belzutifan","Belzutifan","CHEMBL4585668","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021,"ENSG00000116016","ENSG00000134086","genetic_association","genomics_england",0.951397496038773,12,"EFO_0000681","von Hippel-Lindau disease -> renal cell carcinoma"
"Welireg","Belzutifan","Belzutifan","CHEMBL4585668","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021,"ENSG00000116016","ENSG00000134086","genetic_association","eva",0.948159837661053,1549,"EFO_0000681","von Hippel-Lindau disease -> renal cell carcinoma"
"Welireg","Belzutifan","Belzutifan","CHEMBL4585668","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021,"ENSG00000116016","ENSG00000134086","genetic_association","uniprot_literature",0.607930797611621,1,"EFO_0000681","von Hippel-Lindau disease -> renal cell carcinoma"
"Welireg","Belzutifan","Belzutifan","CHEMBL4585668","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021,"ENSG00000116016","ENSG00000134086","genetic_association","uniprot_variants",0.989788995428024,59,"EFO_0000681","von Hippel-Lindau disease -> renal cell carcinoma"
"Cibinqo","Abrocitinib","Abrocitinib","CHEMBL3655081","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022,"ENSG00000162434","ENSG00000096968","literature","europepmc",0.10680741377304,18,"MONDO_0002406","atopic eczema -> dermatitis"
"Cibinqo","Abrocitinib","Abrocitinib","CHEMBL3655081","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022,"ENSG00000162434","ENSG00000096968","literature","europepmc",0.10680741377304,18,"HP_0000964","atopic eczema -> eczema"
"Cibinqo","Abrocitinib","Abrocitinib","CHEMBL3655081","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022,"ENSG00000162434","ENSG00000096968","known_drug","chembl",0.680703665261627,38,"MONDO_0002406","atopic eczema -> dermatitis"
"Cibinqo","Abrocitinib","Abrocitinib","CHEMBL3655081","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022,"ENSG00000162434","ENSG00000096968","known_drug","chembl",0.680703665261627,38,"HP_0000964","atopic eczema -> eczema"
"Ocrevus","Ocrelizumab","OCRELIZUMAB","CHEMBL2108041","Roche/Genentech","CD20-directed cytolytic antibody","Other indication","Relapsing or primary progressive forms of multiple sclerosis","chronic progressive multiple sclerosis","EFO_0003840","Serious","P,B,F",2017,"ENSG00000156738","ENSG00000168685","literature","europepmc",0.122768247184347,3,NA,NA
"Empaveli","Pegcetacoplan","Pegcetacoplan","CHEMBL4298211","Apellis","Complement protein C3 inhibitor","Other indication","PNH","paroxysmal nocturnal hemoglobinuria","MONDO_0100244","Serious","P,O,F",2021,"ENSG00000125730","ENSG00000000971","literature","europepmc",0.182379239283486,1,NA,NA
"Cablivi","Caplacizumab","CAPLACIZUMAB","CHEMBL2109624","Sanofi/Ablynx","vWF-directed nanobody","Other indication","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Serious","P,O,F",2019,"ENSG00000110799","ENSG00000185245","known_drug","chembl",0.121586159522324,1,NA,NA
"Emflaza","Deflazacort","DEFLAZACORT","CHEMBL1201891","PTC Therapeutics","Corticosteroid","Other indication","Duchenne muscular dystrophy","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,F",2017,"ENSG00000113580","ENSG00000146648","literature","europepmc",0.0121586159522324,1,NA,NA
"Cablivi","Caplacizumab","CAPLACIZUMAB","CHEMBL2109624","Sanofi/Ablynx","vWF-directed nanobody","Other indication","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Serious","P,O,F",2019,"ENSG00000110799","ENSG00000160323","genetic_association","genomics_england",0.904421128957003,7,NA,NA
"Cablivi","Caplacizumab","CAPLACIZUMAB","CHEMBL2109624","Sanofi/Ablynx","vWF-directed nanobody","Other indication","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Serious","P,O,F",2019,"ENSG00000110799","ENSG00000160323","literature","europepmc",0.625652642340236,133,NA,NA
"Cablivi","Caplacizumab","CAPLACIZUMAB","CHEMBL2109624","Sanofi/Ablynx","vWF-directed nanobody","Other indication","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Serious","P,O,F",2019,"ENSG00000110799","ENSG00000160323","genetic_association","clingen",0.607930797611621,1,NA,NA
"Cablivi","Caplacizumab","CAPLACIZUMAB","CHEMBL2109624","Sanofi/Ablynx","vWF-directed nanobody","Other indication","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Serious","P,O,F",2019,"ENSG00000110799","ENSG00000160323","genetic_association","orphanet",0.607930797611621,1,NA,NA
"Cablivi","Caplacizumab","CAPLACIZUMAB","CHEMBL2109624","Sanofi/Ablynx","vWF-directed nanobody","Other indication","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Serious","P,O,F",2019,"ENSG00000110799","ENSG00000160323","genetic_association","eva",0.926797591578576,193,NA,NA
"Cablivi","Caplacizumab","CAPLACIZUMAB","CHEMBL2109624","Sanofi/Ablynx","vWF-directed nanobody","Other indication","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Serious","P,O,F",2019,"ENSG00000110799","ENSG00000160323","genetic_association","uniprot_literature",0.607930797611621,1,NA,NA
"Cablivi","Caplacizumab","CAPLACIZUMAB","CHEMBL2109624","Sanofi/Ablynx","vWF-directed nanobody","Other indication","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Serious","P,O,F",2019,"ENSG00000110799","ENSG00000160323","genetic_association","uniprot_variants",0.985702485030815,42,NA,NA
"Cablivi","Caplacizumab","CAPLACIZUMAB","CHEMBL2109624","Sanofi/Ablynx","vWF-directed nanobody","Other indication","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Serious","P,O,F",2019,"ENSG00000110799","ENSG00000185010","literature","europepmc",0.0243172319044648,1,NA,NA
"Viltepso","Viltolarsen","VILTOLARSEN","CHEMBL4298062","Nippon Shinyaku","Dystrophin splicing modifier","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2020,"ENSG00000198947","ENSG00000101400","literature","europepmc",0.0607930797611621,1,NA,NA
"Vyondys 53","Golodirsen","GOLODIRSEN","CHEMBL4297762","Sarepta","Exon 53 skipping antisense","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2019,"ENSG00000198947","ENSG00000101400","literature","europepmc",0.0607930797611621,1,NA,NA
"Exondys 51","Eteplirsen","ETEPLIRSEN","CHEMBL2108278","Sarepta Therapeutics","ASO designed to target dystrophin pre-mRNA","Other indication","Duchenne muscular dystrophy","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2016,"ENSG00000198947","ENSG00000101400","literature","europepmc",0.0607930797611621,1,NA,NA
"Amondys 45","Casimersen","Casimersen","CHEMBL4297566","Sarepta","Exon 45-skipping ASO","Other indication","DMD","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2021,"ENSG00000198947","ENSG00000101400","literature","europepmc",0.0607930797611621,1,NA,NA
"Viltepso","Viltolarsen","VILTOLARSEN","CHEMBL4298062","Nippon Shinyaku","Dystrophin splicing modifier","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2020,"ENSG00000198947","ENSG00000101400","genetic_association","eva",0.194537855235719,1,NA,NA
"Vyondys 53","Golodirsen","GOLODIRSEN","CHEMBL4297762","Sarepta","Exon 53 skipping antisense","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2019,"ENSG00000198947","ENSG00000101400","genetic_association","eva",0.194537855235719,1,NA,NA
"Exondys 51","Eteplirsen","ETEPLIRSEN","CHEMBL2108278","Sarepta Therapeutics","ASO designed to target dystrophin pre-mRNA","Other indication","Duchenne muscular dystrophy","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2016,"ENSG00000198947","ENSG00000101400","genetic_association","eva",0.194537855235719,1,NA,NA
"Amondys 45","Casimersen","Casimersen","CHEMBL4297566","Sarepta","Exon 45-skipping ASO","Other indication","DMD","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2021,"ENSG00000198947","ENSG00000101400","genetic_association","eva",0.194537855235719,1,NA,NA
"Welireg","Belzutifan","Belzutifan","CHEMBL4585668","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021,"ENSG00000116016","ENSG00000152256","literature","europepmc",0.121586159522324,1,"EFO_0000681","von Hippel-Lindau disease -> renal cell carcinoma"
"Adbry","Tralokinumab","Tralokinumab","CHEMBL1743081","LEO Pharma","IL-13-targeted mAb","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","S",2021,"ENSG00000169194","ENSG00000123496","animal_model","impc",0.32749232067338,1,"MONDO_0002406","atopic eczema -> dermatitis"
"Adbry","Tralokinumab","Tralokinumab","CHEMBL1743081","LEO Pharma","IL-13-targeted mAb","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","S",2021,"ENSG00000169194","ENSG00000123496","animal_model","impc",0.32749232067338,1,"HP_0000964","atopic eczema -> eczema"
"Adbry","Tralokinumab","Tralokinumab","CHEMBL1743081","LEO Pharma","IL-13-targeted mAb","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","S",2021,"ENSG00000169194","ENSG00000123496","rna_expression","expression_atlas",0.0136557767872104,1,"MONDO_0002406","atopic eczema -> dermatitis"
"Adbry","Tralokinumab","Tralokinumab","CHEMBL1743081","LEO Pharma","IL-13-targeted mAb","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","S",2021,"ENSG00000169194","ENSG00000123496","rna_expression","expression_atlas",0.0136557767872104,1,"HP_0000964","atopic eczema -> eczema"
"Adbry","Tralokinumab","Tralokinumab","CHEMBL1743081","LEO Pharma","IL-13-targeted mAb","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","S",2021,"ENSG00000169194","ENSG00000123496","literature","europepmc",0.0226285352444326,3,"MONDO_0002406","atopic eczema -> dermatitis"
"Adbry","Tralokinumab","Tralokinumab","CHEMBL1743081","LEO Pharma","IL-13-targeted mAb","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","S",2021,"ENSG00000169194","ENSG00000123496","literature","europepmc",0.0226285352444326,3,"HP_0000964","atopic eczema -> eczema"
"Viltepso","Viltolarsen","VILTOLARSEN","CHEMBL4298062","Nippon Shinyaku","Dystrophin splicing modifier","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2020,"ENSG00000198947","ENSG00000171873","known_drug","chembl",0.759913497014526,2,NA,NA
"Vyondys 53","Golodirsen","GOLODIRSEN","CHEMBL4297762","Sarepta","Exon 53 skipping antisense","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2019,"ENSG00000198947","ENSG00000171873","known_drug","chembl",0.759913497014526,2,NA,NA
"Exondys 51","Eteplirsen","ETEPLIRSEN","CHEMBL2108278","Sarepta Therapeutics","ASO designed to target dystrophin pre-mRNA","Other indication","Duchenne muscular dystrophy","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2016,"ENSG00000198947","ENSG00000171873","known_drug","chembl",0.759913497014526,2,NA,NA
"Amondys 45","Casimersen","Casimersen","CHEMBL4297566","Sarepta","Exon 45-skipping ASO","Other indication","DMD","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2021,"ENSG00000198947","ENSG00000171873","known_drug","chembl",0.759913497014526,2,NA,NA
"Cibinqo","Abrocitinib","Abrocitinib","CHEMBL3655081","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022,"ENSG00000162434","ENSG00000141736","literature","europepmc",0.0607930797611621,1,"MONDO_0002406","atopic eczema -> dermatitis"
"Cibinqo","Abrocitinib","Abrocitinib","CHEMBL3655081","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022,"ENSG00000162434","ENSG00000141736","literature","europepmc",0.0607930797611621,1,"HP_0000964","atopic eczema -> eczema"
"Viltepso","Viltolarsen","VILTOLARSEN","CHEMBL4298062","Nippon Shinyaku","Dystrophin splicing modifier","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2020,"ENSG00000198947","ENSG00000138101","literature","europepmc",0.0182379239283486,1,NA,NA
"Vyondys 53","Golodirsen","GOLODIRSEN","CHEMBL4297762","Sarepta","Exon 53 skipping antisense","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2019,"ENSG00000198947","ENSG00000138101","literature","europepmc",0.0182379239283486,1,NA,NA
"Exondys 51","Eteplirsen","ETEPLIRSEN","CHEMBL2108278","Sarepta Therapeutics","ASO designed to target dystrophin pre-mRNA","Other indication","Duchenne muscular dystrophy","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2016,"ENSG00000198947","ENSG00000138101","literature","europepmc",0.0182379239283486,1,NA,NA
"Amondys 45","Casimersen","Casimersen","CHEMBL4297566","Sarepta","Exon 45-skipping ASO","Other indication","DMD","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2021,"ENSG00000198947","ENSG00000138101","literature","europepmc",0.0182379239283486,1,NA,NA
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000111679","animal_model","impc",0.252595246407629,1,"MONDO_0002406","atopic eczema -> dermatitis"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000111679","animal_model","impc",0.252595246407629,1,"HP_0000964","atopic eczema -> eczema"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000111679","literature","europepmc",0.0243172319044648,1,"MONDO_0002406","atopic eczema -> dermatitis"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000111679","literature","europepmc",0.0243172319044648,1,"HP_0000964","atopic eczema -> eczema"
"Cibinqo","Abrocitinib","Abrocitinib","CHEMBL3655081","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022,"ENSG00000162434","ENSG00000134352","literature","europepmc",0.0547137717850459,2,"MONDO_0002406","atopic eczema -> dermatitis"
"Cibinqo","Abrocitinib","Abrocitinib","CHEMBL3655081","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022,"ENSG00000162434","ENSG00000134352","literature","europepmc",0.0547137717850459,2,"HP_0000964","atopic eczema -> eczema"
"Emflaza","Deflazacort","DEFLAZACORT","CHEMBL1201891","PTC Therapeutics","Corticosteroid","Other indication","Duchenne muscular dystrophy","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,F",2017,"ENSG00000113580","ENSG00000142208","literature","europepmc",0.173054138670013,16,NA,NA
"Galafold","Migalastat","MIGALASTAT","CHEMBL110458","Amicus Therapeutics","beta-galactosidase regulator","Other indication","Fabry disease","fabry disease","MONDO_0010526","Serious","P,O,A,F",2018,"ENSG00000102393","ENSG00000134243","literature","europepmc",0.343480900650566,2,NA,NA
"Viltepso","Viltolarsen","VILTOLARSEN","CHEMBL4298062","Nippon Shinyaku","Dystrophin splicing modifier","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2020,"ENSG00000198947","ENSG00000173402","literature","europepmc",0.121520692302493,16,NA,NA
"Vyondys 53","Golodirsen","GOLODIRSEN","CHEMBL4297762","Sarepta","Exon 53 skipping antisense","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2019,"ENSG00000198947","ENSG00000173402","literature","europepmc",0.121520692302493,16,NA,NA
"Exondys 51","Eteplirsen","ETEPLIRSEN","CHEMBL2108278","Sarepta Therapeutics","ASO designed to target dystrophin pre-mRNA","Other indication","Duchenne muscular dystrophy","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2016,"ENSG00000198947","ENSG00000173402","literature","europepmc",0.121520692302493,16,NA,NA
"Amondys 45","Casimersen","Casimersen","CHEMBL4297566","Sarepta","Exon 45-skipping ASO","Other indication","DMD","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2021,"ENSG00000198947","ENSG00000173402","literature","europepmc",0.121520692302493,16,NA,NA
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000077238","genetic_association","eva",0.243172319044648,2,"MONDO_0002406","atopic eczema -> dermatitis"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000077238","genetic_association","eva",0.243172319044648,2,"HP_0000964","atopic eczema -> eczema"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000077238","animal_model","impc",0.570491683406108,6,"MONDO_0002406","atopic eczema -> dermatitis"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000077238","animal_model","impc",0.570491683406108,6,"HP_0000964","atopic eczema -> eczema"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000077238","rna_expression","expression_atlas",0.032518017878998,1,"MONDO_0002406","atopic eczema -> dermatitis"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000077238","rna_expression","expression_atlas",0.032518017878998,1,"HP_0000964","atopic eczema -> eczema"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000077238","literature","europepmc",0.782991758507173,61,"MONDO_0002406","atopic eczema -> dermatitis"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000077238","literature","europepmc",0.782991758507173,61,"HP_0000964","atopic eczema -> eczema"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000077238","known_drug","chembl",0.971226422377876,39,"MONDO_0002406","atopic eczema -> dermatitis"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000077238","known_drug","chembl",0.971226422377876,39,"HP_0000964","atopic eczema -> eczema"
"Repatha","Evolocumab","EVOLOCUMAB","CHEMBL2364655","Amgen","PCSK9 inhibitor","Other indication","LDL lowering","LDL cholesterol change measurement","EFO_0007804","Not serious","S,O",2015,"ENSG00000169174","ENSG00000130164","genetic_association","ot_genetics_portal",0.395006583348468,1,NA,NA
"Welireg","Belzutifan","Belzutifan","CHEMBL4585668","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021,"ENSG00000116016","ENSG00000135766","literature","europepmc",0.0121586159522324,1,"EFO_0000681","von Hippel-Lindau disease -> renal cell carcinoma"
"Cablivi","Caplacizumab","CAPLACIZUMAB","CHEMBL2109624","Sanofi/Ablynx","vWF-directed nanobody","Other indication","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Serious","P,O,F",2019,"ENSG00000110799","ENSG00000110799","known_drug","chembl",0.798921355965358,7,NA,NA
"Cablivi","Caplacizumab","CAPLACIZUMAB","CHEMBL2109624","Sanofi/Ablynx","vWF-directed nanobody","Other indication","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Serious","P,O,F",2019,"ENSG00000110799","ENSG00000110799","literature","europepmc",0.17360126088247,37,NA,NA
"Cibinqo","Abrocitinib","Abrocitinib","CHEMBL3655081","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022,"ENSG00000162434","ENSG00000115415","animal_model","impc",0.285970647196507,1,"MONDO_0002406","atopic eczema -> dermatitis"
"Cibinqo","Abrocitinib","Abrocitinib","CHEMBL3655081","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022,"ENSG00000162434","ENSG00000115415","animal_model","impc",0.285970647196507,1,"HP_0000964","atopic eczema -> eczema"
"Cibinqo","Abrocitinib","Abrocitinib","CHEMBL3655081","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022,"ENSG00000162434","ENSG00000115415","literature","europepmc",0.640872203358871,5,"MONDO_0002406","atopic eczema -> dermatitis"
"Cibinqo","Abrocitinib","Abrocitinib","CHEMBL3655081","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022,"ENSG00000162434","ENSG00000115415","literature","europepmc",0.640872203358871,5,"HP_0000964","atopic eczema -> eczema"
"Cibinqo","Abrocitinib","Abrocitinib","CHEMBL3655081","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022,"ENSG00000162434","ENSG00000159110","animal_model","impc",0.306701087395063,1,"MONDO_0002406","atopic eczema -> dermatitis"
"Cibinqo","Abrocitinib","Abrocitinib","CHEMBL3655081","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022,"ENSG00000162434","ENSG00000159110","animal_model","impc",0.306701087395063,1,"HP_0000964","atopic eczema -> eczema"
"Cibinqo","Abrocitinib","Abrocitinib","CHEMBL3655081","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022,"ENSG00000162434","ENSG00000159110","literature","europepmc",0.0182379239283486,1,"MONDO_0002406","atopic eczema -> dermatitis"
"Cibinqo","Abrocitinib","Abrocitinib","CHEMBL3655081","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022,"ENSG00000162434","ENSG00000159110","literature","europepmc",0.0182379239283486,1,"HP_0000964","atopic eczema -> eczema"
"Viltepso","Viltolarsen","VILTOLARSEN","CHEMBL4298062","Nippon Shinyaku","Dystrophin splicing modifier","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2020,"ENSG00000198947","ENSG00000134769","literature","europepmc",0.138917253344235,5,NA,NA
"Vyondys 53","Golodirsen","GOLODIRSEN","CHEMBL4297762","Sarepta","Exon 53 skipping antisense","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2019,"ENSG00000198947","ENSG00000134769","literature","europepmc",0.138917253344235,5,NA,NA
"Exondys 51","Eteplirsen","ETEPLIRSEN","CHEMBL2108278","Sarepta Therapeutics","ASO designed to target dystrophin pre-mRNA","Other indication","Duchenne muscular dystrophy","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2016,"ENSG00000198947","ENSG00000134769","literature","europepmc",0.138917253344235,5,NA,NA
"Amondys 45","Casimersen","Casimersen","CHEMBL4297566","Sarepta","Exon 45-skipping ASO","Other indication","DMD","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2021,"ENSG00000198947","ENSG00000134769","literature","europepmc",0.138917253344235,5,NA,NA
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000147168","literature","europepmc",0.0182379239283486,1,"MONDO_0002406","atopic eczema -> dermatitis"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000147168","literature","europepmc",0.0182379239283486,1,"HP_0000964","atopic eczema -> eczema"
"Kevzara","Sarilumab","SARILUMAB","CHEMBL2108730","Sanofi/Regeneron","IL-6 receptor antagonist","Other indication","Rheumatoid arthritis","rheumatoid arthritis","EFO_0000685","Serious","S",2017,"ENSG00000160712","ENSG00000136244","literature","europepmc",0.987637940198162,1655,NA,NA
"Kevzara","Sarilumab","SARILUMAB","CHEMBL2108730","Sanofi/Regeneron","IL-6 receptor antagonist","Other indication","Rheumatoid arthritis","rheumatoid arthritis","EFO_0000685","Serious","S",2017,"ENSG00000160712","ENSG00000136244","genetic_association","uniprot_literature",0.607930797611621,1,NA,NA
"Kevzara","Sarilumab","SARILUMAB","CHEMBL2108730","Sanofi/Regeneron","IL-6 receptor antagonist","Other indication","Rheumatoid arthritis","rheumatoid arthritis","EFO_0000685","Serious","S",2017,"ENSG00000160712","ENSG00000136244","known_drug","chembl",0.662050545013308,22,NA,NA
"Kevzara","Sarilumab","SARILUMAB","CHEMBL2108730","Sanofi/Regeneron","IL-6 receptor antagonist","Other indication","Rheumatoid arthritis","rheumatoid arthritis","EFO_0000685","Serious","S",2017,"ENSG00000160712","ENSG00000137642","literature","europepmc",0.194537855235719,1,NA,NA
"Kevzara","Sarilumab","SARILUMAB","CHEMBL2108730","Sanofi/Regeneron","IL-6 receptor antagonist","Other indication","Rheumatoid arthritis","rheumatoid arthritis","EFO_0000685","Serious","S",2017,"ENSG00000160712","ENSG00000137642","rna_expression","expression_atlas",0.0407069010925391,1,NA,NA
"Empaveli","Pegcetacoplan","Pegcetacoplan","CHEMBL4298211","Apellis","Complement protein C3 inhibitor","Other indication","PNH","paroxysmal nocturnal hemoglobinuria","MONDO_0100244","Serious","P,O,F",2021,"ENSG00000125730","ENSG00000155659","animal_model","impc",0.25162255713145,1,NA,NA
"Empaveli","Pegcetacoplan","Pegcetacoplan","CHEMBL4298211","Apellis","Complement protein C3 inhibitor","Other indication","PNH","paroxysmal nocturnal hemoglobinuria","MONDO_0100244","Serious","P,O,F",2021,"ENSG00000125730","ENSG00000155659","literature","europepmc",0.0364758478566973,1,NA,NA
"Emflaza","Deflazacort","DEFLAZACORT","CHEMBL1201891","PTC Therapeutics","Corticosteroid","Other indication","Duchenne muscular dystrophy","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,F",2017,"ENSG00000113580","ENSG00000204389","literature","europepmc",0.0121586159522324,1,NA,NA
"Ocrevus","Ocrelizumab","OCRELIZUMAB","CHEMBL2108041","Roche/Genentech","CD20-directed cytolytic antibody","Other indication","Relapsing or primary progressive forms of multiple sclerosis","chronic progressive multiple sclerosis","EFO_0003840","Serious","P,B,F",2017,"ENSG00000156738","ENSG00000156738","known_drug","chembl",0.881612405228157,12,NA,NA
"Adbry","Tralokinumab","Tralokinumab","CHEMBL1743081","LEO Pharma","IL-13-targeted mAb","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","S",2021,"ENSG00000169194","ENSG00000131724","animal_model","impc",0.266516861672935,1,"MONDO_0002406","atopic eczema -> dermatitis"
"Adbry","Tralokinumab","Tralokinumab","CHEMBL1743081","LEO Pharma","IL-13-targeted mAb","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","S",2021,"ENSG00000169194","ENSG00000131724","animal_model","impc",0.266516861672935,1,"HP_0000964","atopic eczema -> eczema"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000131724","animal_model","impc",0.266516861672935,1,"MONDO_0002406","atopic eczema -> dermatitis"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000131724","animal_model","impc",0.266516861672935,1,"HP_0000964","atopic eczema -> eczema"
"Adbry","Tralokinumab","Tralokinumab","CHEMBL1743081","LEO Pharma","IL-13-targeted mAb","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","S",2021,"ENSG00000169194","ENSG00000131724","literature","europepmc",0.0212775779164067,2,"MONDO_0002406","atopic eczema -> dermatitis"
"Adbry","Tralokinumab","Tralokinumab","CHEMBL1743081","LEO Pharma","IL-13-targeted mAb","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","S",2021,"ENSG00000169194","ENSG00000131724","literature","europepmc",0.0212775779164067,2,"HP_0000964","atopic eczema -> eczema"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000131724","literature","europepmc",0.0212775779164067,2,"MONDO_0002406","atopic eczema -> dermatitis"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000131724","literature","europepmc",0.0212775779164067,2,"HP_0000964","atopic eczema -> eczema"
"Empaveli","Pegcetacoplan","Pegcetacoplan","CHEMBL4298211","Apellis","Complement protein C3 inhibitor","Other indication","PNH","paroxysmal nocturnal hemoglobinuria","MONDO_0100244","Serious","P,O,F",2021,"ENSG00000125730","ENSG00000203710","literature","europepmc",0.0749781317054333,3,NA,NA
"Empaveli","Pegcetacoplan","Pegcetacoplan","CHEMBL4298211","Apellis","Complement protein C3 inhibitor","Other indication","PNH","paroxysmal nocturnal hemoglobinuria","MONDO_0100244","Serious","P,O,F",2021,"ENSG00000125730","ENSG00000125730","literature","europepmc",0.311506089777438,33,NA,NA
"Cibinqo","Abrocitinib","Abrocitinib","CHEMBL3655081","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022,"ENSG00000162434","ENSG00000168610","literature","europepmc",0.210044312135417,27,"MONDO_0002406","atopic eczema -> dermatitis"
"Cibinqo","Abrocitinib","Abrocitinib","CHEMBL3655081","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022,"ENSG00000162434","ENSG00000168610","literature","europepmc",0.210044312135417,27,"HP_0000964","atopic eczema -> eczema"
"Welireg","Belzutifan","Belzutifan","CHEMBL4585668","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021,"ENSG00000116016","ENSG00000136878","literature","europepmc",0.0303965398805811,1,"EFO_0000681","von Hippel-Lindau disease -> renal cell carcinoma"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000166888","animal_model","impc",0.412526640989306,2,"MONDO_0002406","atopic eczema -> dermatitis"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000166888","animal_model","impc",0.412526640989306,2,"HP_0000964","atopic eczema -> eczema"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000166888","genetic_association","ot_genetics_portal",0.290262817944086,1,"MONDO_0002406","atopic eczema -> dermatitis"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000166888","genetic_association","ot_genetics_portal",0.290262817944086,1,"HP_0000964","atopic eczema -> eczema"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000166888","literature","europepmc",0.244424694780736,38,"MONDO_0002406","atopic eczema -> dermatitis"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000166888","literature","europepmc",0.244424694780736,38,"HP_0000964","atopic eczema -> eczema"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000113520","animal_model","impc",0.525563157468252,7,"MONDO_0002406","atopic eczema -> dermatitis"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000113520","animal_model","impc",0.525563157468252,7,"HP_0000964","atopic eczema -> eczema"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000113520","genetic_association","ot_genetics_portal",0.192796187212885,4,"MONDO_0002406","atopic eczema -> dermatitis"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000113520","genetic_association","ot_genetics_portal",0.192796187212885,4,"HP_0000964","atopic eczema -> eczema"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000113520","literature","europepmc",0.578029397213034,556,"MONDO_0002406","atopic eczema -> dermatitis"
"Dupixent","Dupilumab","DUPILUMAB","CHEMBL2108675","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017,"ENSG00000077238","ENSG00000113520","literature","europepmc",0.578029397213034,556,"HP_0000964","atopic eczema -> eczema"
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000111640","literature","europepmc",0.677363651556743,54,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000145675","literature","europepmc",0.0227974049104358,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000111640","rna_expression","expression_atlas",0.0339363295232049,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000176105","known_drug","chembl",0.493680024067221,13,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000176105","known_drug","chembl",0.493680024067221,13,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000170276","literature","europepmc",0.356580120642436,6,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000137801","literature","europepmc",0.162489382587566,12,NA,NA
"Tezspire","Tezepelumab","Tezepelumab","CHEMBL3707229","Astrazeneca/Amgen","TSLP-targeted mAb","Other indication","Serious asthma","asthma","MONDO_0004979","Serious","P",2021,"ENSG00000145777","ENSG00000269335","literature","europepmc",0.0182379239283486,1,"EFO_0004842","asthma -> eosinophil count (eosinophil asthma)"
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000068001","literature","europepmc",0.0653525607432493,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000147955","literature","europepmc",0.705893788776659,29,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000147955","known_drug","chembl",0.623129067551912,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000165025","literature","europepmc",0.133266770930176,7,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000012817","literature","europepmc",0.124625813510382,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000012817","literature","europepmc",0.124625813510382,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000134243","literature","europepmc",0.471006424596523,32,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000183098","literature","europepmc",0.0303965398805811,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000167548","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000167548","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000167548","somatic_mutation","intogen",0.876626199490514,7,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000167548","somatic_mutation","intogen",0.876626199490514,7,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000167548","literature","europepmc",0.197577509223777,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000167548","literature","europepmc",0.197577509223777,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000117450","literature","europepmc",0.0121586159522324,1,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000117450","literature","europepmc",0.0121586159522324,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000011132","literature","europepmc",0.0395155018447554,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000132589","literature","europepmc",0.0121586159522324,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000140941","literature","europepmc",0.178003671152956,8,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000140941","rna_expression","expression_atlas",0.0668339790559494,3,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000110092","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000110092","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000110092","literature","europepmc",0.270140663655365,27,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000110092","literature","europepmc",0.270140663655365,27,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000110092","genetic_association","ot_genetics_portal",0.487384278045082,1,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000110092","genetic_association","ot_genetics_portal",0.487384278045082,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000010017","literature","europepmc",0.305147486467833,4,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000160307","literature","europepmc",0.882539943098733,125,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000160307","rna_expression","expression_atlas",0.0301136643494677,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000117984","literature","europepmc",0.841949390857978,97,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000151694","literature","europepmc",0.501095798926949,31,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000188157","literature","europepmc",0.217988678471458,12,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000120899","literature","europepmc",0.730519235473087,20,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000124145","literature","europepmc",0.0545449021190427,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000124145","rna_expression","expression_atlas",0.0621772747806903,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000120899","genetic_association","ot_genetics_portal",0.490133993806759,3,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000145675","known_drug","chembl",0.175978092911601,9,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000145675","known_drug","chembl",0.175978092911601,9,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000145675","somatic_mutation","cancer_gene_census",0.620596022561863,3,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000145675","somatic_mutation","cancer_gene_census",0.620596022561863,3,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000145675","literature","europepmc",0.0349560208626682,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000145675","literature","europepmc",0.0349560208626682,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000145675","somatic_mutation","eva_somatic",0.248238409024745,3,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000145675","somatic_mutation","eva_somatic",0.248238409024745,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000277586","literature","europepmc",0.913222458025796,161,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000277586","rna_expression","expression_atlas",0.0405441904186178,6,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000115041","literature","europepmc",0.292064057892569,13,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000161011","literature","europepmc",0.51435465582455,24,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000169783","literature","europepmc",0.566994946791392,8,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000197122","known_drug","chembl",0.497528740059266,20,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000197122","known_drug","chembl",0.497528740059266,20,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000197122","somatic_mutation","cancer_gene_census",0.7219178221638,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000197122","somatic_mutation","cancer_gene_census",0.7219178221638,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000197122","literature","europepmc",0.111145456682411,12,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000197122","literature","europepmc",0.111145456682411,12,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000198400","literature","europepmc",0.512736561213593,60,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000278195","literature","europepmc",0.065183691077246,3,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000132437","literature","europepmc",0.065183691077246,3,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000132437","literature","europepmc",0.065183691077246,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000182240","literature","europepmc",0.372982487722815,37,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000198805","literature","europepmc",0.0972689276178594,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000125686","somatic_mutation","eva_somatic",0.248238409024745,3,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000125686","somatic_mutation","eva_somatic",0.248238409024745,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000002330","literature","europepmc",0.112407938090662,8,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000169884","literature","europepmc",0.0334361938686392,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000084234","literature","europepmc",0.421166858182963,27,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000113575","literature","europepmc",0.425158302614774,10,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000158828","literature","europepmc",0.69281312952963,24,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000256762","literature","europepmc",0.193007014314976,12,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000084234","rna_expression","expression_atlas",0.062290008964073,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000113575","rna_expression","expression_atlas",0.0477240148933432,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000158828","rna_expression","expression_atlas",0.0229815231626662,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000154096","literature","europepmc",0.173101103824604,15,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000154096","rna_expression","expression_atlas",0.049233255152471,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000137642","genetic_association","orphanet",0.607930797611621,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000122861","literature","europepmc",0.305490560508046,13,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000137642","literature","europepmc",0.954014931849339,164,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000184144","literature","europepmc",0.130885812029122,6,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000137642","rna_expression","expression_atlas",0.0476803620843016,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000137642","genetic_association","genomics_england",0.303965398805811,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000137642","animal_model","impc",0.515408796305112,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000137642","genetic_association","uniprot_literature",0.303965398805811,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000137642","genetic_association","uniprot_variants",0.413730681707909,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000137642","genetic_association","eva",0.316124014758043,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000137642","genetic_association","ot_genetics_portal",0.83865836635347,8,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000000938","known_drug","chembl",0.493680024067221,13,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000000938","known_drug","chembl",0.493680024067221,13,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000168036","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000168036","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000168036","somatic_mutation","intogen",0.765776450749866,6,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000168036","somatic_mutation","intogen",0.765776450749866,6,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000168036","literature","europepmc",0.213314618523721,14,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000168036","literature","europepmc",0.213314618523721,14,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000168036","somatic_mutation","eva_somatic",0.683448989988691,27,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000168036","somatic_mutation","eva_somatic",0.683448989988691,27,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000168036","affected_pathway","slapenrich",0.383569422097786,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000168036","affected_pathway","slapenrich",0.383569422097786,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000108468","literature","europepmc",0.0182379239283486,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000109971","literature","europepmc",0.689829287686682,9,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000163932","literature","europepmc",0.623868716689006,5,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000143933","literature","europepmc",0.0303965398805811,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000014216","literature","europepmc",0.290672532023813,10,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000120885","literature","europepmc",0.9431669224738,227,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000120885","rna_expression","expression_atlas",0.02558786498941,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000120885","genetic_association","ot_genetics_portal",0.721561069321916,13,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000014216","affected_pathway","reactome",0.607930797611621,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000072062","literature","europepmc",0.0182379239283486,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000132773","literature","europepmc",0.607930797611621,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000167004","literature","europepmc",0.243101947110703,10,NA,NA
"Motegrity","Prucalopride","PRUCALOPRIDE","CHEMBL117287","Shire/Takeda","5-HT4-receptor agonist","Other indication","Chronic idiopathic constipation","constipation disorder","MONDO_0002203","Not serious","S",2018,"ENSG00000164270","ENSG00000164270","known_drug","chembl",0.865457038266544,4,NA,NA
"Saphnelo","Anifrolumab","Anifrolumab","CHEMBL2364653","AstraZeneca","IFNAR-targeted mAb","Other indication","SLE","systemic lupus erythematosus","MONDO_0007915","Serious","S,F",2021,"ENSG00000142166","ENSG00000072803","literature","europepmc",0.0439061131608393,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000196531","literature","europepmc",0.0243172319044648,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000197386","literature","europepmc",0.444088981731058,34,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000196531","rna_expression","expression_atlas",0.0724296216382493,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000049540","literature","europepmc",0.0912740544747448,4,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000113140","literature","europepmc",0.0881499656536851,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000118271","literature","europepmc",0.412748442620447,71,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000142156","literature","europepmc",0.0516741177969878,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000196230","literature","europepmc",0.150824253494123,6,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000157450","rna_expression","expression_atlas",0.0271891878618962,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000196230","rna_expression","expression_atlas",0.0784437452222936,5,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000124214","literature","europepmc",0.0182379239283486,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000221914","literature","europepmc",0.127496597832437,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000113805","rna_expression","expression_atlas",0.0306481153355912,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000139318","rna_expression","expression_atlas",0.0155307408661964,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000123384","literature","europepmc",0.766520416292616,30,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000135218","literature","europepmc",0.0668723877372783,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000130522","literature","europepmc",0.0303965398805811,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000130522","rna_expression","expression_atlas",0.0650000798312654,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000170348","literature","europepmc",0.275618936670509,5,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000010671","known_drug","chembl",0.151982699402905,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000010671","known_drug","chembl",0.151982699402905,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000010671","somatic_mutation","cancer_gene_census",0.60370905596154,3,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000010671","somatic_mutation","cancer_gene_census",0.60370905596154,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000137463","literature","europepmc",0.0303965398805811,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000134853","known_drug","chembl",0.455948098208716,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000140396","somatic_mutation","cancer_gene_census",0.7219178221638,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000140396","somatic_mutation","cancer_gene_census",0.7219178221638,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000140396","literature","europepmc",0.0303965398805811,1,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000140396","literature","europepmc",0.0303965398805811,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000159593","literature","europepmc",0.124627502207042,5,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000159593","rna_expression","expression_atlas",0.0391405930267527,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000141433","literature","europepmc",0.536369640208172,8,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000160695","literature","europepmc",0.0607930797611621,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000141433","rna_expression","expression_atlas",0.0331533784879853,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000134954","literature","europepmc",0.101659538933943,3,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000134954","literature","europepmc",0.101659538933943,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000114646","literature","europepmc",0.0303965398805811,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000180210","literature","europepmc",0.137325449962972,8,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000114646","rna_expression","expression_atlas",0.0496655962654627,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000254087","known_drug","chembl",0.494492614988299,14,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000254087","known_drug","chembl",0.494492614988299,14,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000254087","somatic_mutation","cancer_gene_census",0.379956748507263,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000254087","somatic_mutation","cancer_gene_census",0.379956748507263,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000105851","literature","europepmc",0.0395155018447554,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000134318","literature","europepmc",0.52863765152766,10,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000151224","literature","europepmc",0.0972689276178594,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000121691","literature","europepmc",0.706090079646068,36,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000150093","literature","europepmc",0.281843472559388,4,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000121691","rna_expression","expression_atlas",0.0316884924156,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000150093","rna_expression","expression_atlas",0.0806168727840118,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000175344","literature","europepmc",0.390322667352344,39,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000179218","literature","europepmc",0.279310427569339,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000175344","known_drug","chembl",0.58175633992575,17,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000128482","literature","europepmc",0.0699120417253364,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000133858","rna_expression","expression_atlas",0.0326266007450034,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000123560","literature","europepmc",0.789997628013001,6,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000126214","literature","europepmc",0.702498753952025,12,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000137752","literature","europepmc",0.888290165886887,63,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000123560","rna_expression","expression_atlas",0.0520938071020561,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000126214","rna_expression","expression_atlas",0.137968138975634,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000185933","literature","europepmc",0.450652582238604,19,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000065320","literature","europepmc",0.10657180243359,8,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000141551","literature","europepmc",0.0638327337492202,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000101439","literature","europepmc",0.84638109341715,78,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000101439","rna_expression","expression_atlas",0.0513901243445316,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000101439","affected_pathway","sysbio",0.455948098208716,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000196549","literature","europepmc",0.770633738637652,122,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000204301","literature","europepmc",0.109427543570092,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000132703","literature","europepmc",0.0607930797611621,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000136156","literature","europepmc",0.318077016719129,30,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000182866","known_drug","chembl",0.497318383381892,20,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000182866","known_drug","chembl",0.497318383381892,20,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000182866","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000182866","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000124151","literature","europepmc",0.0638327337492202,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000124151","literature","europepmc",0.0638327337492202,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000182866","literature","europepmc",0.0182379239283486,1,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000182866","literature","europepmc",0.0182379239283486,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000232810","literature","europepmc",0.958791553833646,435,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000232810","known_drug","chembl",0.147338783587816,4,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000128989","literature","europepmc",0.136784429462615,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000136827","literature","europepmc",0.0364758478566973,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000166949","literature","europepmc",0.0742182182084187,4,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000186868","literature","europepmc",0.998438611519857,6600,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000128989","rna_expression","expression_atlas",0.039781921923049,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000186868","known_drug","chembl",0.180760857118737,10,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000186868","genetic_association","eva",0.437710174280367,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000105376","literature","europepmc",0.121586159522324,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000204305","literature","europepmc",0.471870042893203,62,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000204305","known_drug","chembl",0.291941878586381,5,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000144339","literature","europepmc",0.167180969343196,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000148082","literature","europepmc",0.0410353288387844,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000196776","literature","europepmc",0.0233884487414471,4,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000138095","rna_expression","expression_atlas",0.0373316056970911,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000144339","rna_expression","expression_atlas",0.0423433480975592,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000196776","rna_expression","expression_atlas",0.0254936827392368,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000132692","literature","europepmc",0.0790310036895107,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000080824","literature","europepmc",0.169524880307321,5,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000101204","literature","europepmc",0.828175239091771,191,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000102974","literature","europepmc",0.285389735545455,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000205302","literature","europepmc",0.0121586159522324,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000101204","known_drug","chembl",0.675761501327388,14,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000165025","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000165025","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000179295","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000179295","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000165025","literature","europepmc",0.0607930797611621,1,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000165025","literature","europepmc",0.0607930797611621,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000179295","literature","europepmc",0.197577509223777,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000179295","literature","europepmc",0.197577509223777,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000156475","literature","europepmc",0.638960598739714,4,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000156475","rna_expression","expression_atlas",0.0345999944587116,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000183775","rna_expression","expression_atlas",0.0203068149339058,1,NA,NA
"Tavalisse","Fostamatinib","FOSTAMATINIB","CHEMBL2103830","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018,"ENSG00000165025","ENSG00000157404","literature","europepmc",0.0547137717850459,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000163879","genetic_association","ot_genetics_portal",0.127908513123686,1,NA,NA
"Tavalisse","Fostamatinib","FOSTAMATINIB","CHEMBL2103830","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018,"ENSG00000165025","ENSG00000165025","literature","europepmc",0.228933548687899,24,NA,NA
"Tavalisse","Fostamatinib","FOSTAMATINIB","CHEMBL2103830","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018,"ENSG00000165025","ENSG00000165025","known_drug","chembl",0.889689037137977,13,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000054523","literature","europepmc",0.0835904846715979,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000130234","literature","europepmc",0.69167363524513,35,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000153234","literature","europepmc",0.200771181154491,10,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000196712","literature","europepmc",0.275088685919259,2,NA,NA
"Tezspire","Tezepelumab","Tezepelumab","CHEMBL3707229","Astrazeneca/Amgen","TSLP-targeted mAb","Other indication","Serious asthma","asthma","MONDO_0004979","Serious","P",2021,"ENSG00000145777","ENSG00000171867","literature","europepmc",0.364758478566973,1,"EFO_0004842","asthma -> eosinophil count (eosinophil asthma)"
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000054523","rna_expression","expression_atlas",0.0426937706715273,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000119912","literature","europepmc",0.8369493875519,137,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000123143","literature","europepmc",0.0607930797611621,1,NA,NA
"Saphnelo","Anifrolumab","Anifrolumab","CHEMBL2364653","AstraZeneca","IFNAR-targeted mAb","Other indication","SLE","systemic lupus erythematosus","MONDO_0007915","Serious","S,F",2021,"ENSG00000142166","ENSG00000105397","known_drug","chembl",0.187649450403945,14,NA,NA
"Saphnelo","Anifrolumab","Anifrolumab","CHEMBL2364653","AstraZeneca","IFNAR-targeted mAb","Other indication","SLE","systemic lupus erythematosus","MONDO_0007915","Serious","S,F",2021,"ENSG00000142166","ENSG00000105397","literature","europepmc",0.426248215439487,35,NA,NA
"Saphnelo","Anifrolumab","Anifrolumab","CHEMBL2364653","AstraZeneca","IFNAR-targeted mAb","Other indication","SLE","systemic lupus erythematosus","MONDO_0007915","Serious","S,F",2021,"ENSG00000142166","ENSG00000105397","genetic_association","ot_genetics_portal",0.429900012891983,6,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000165916","literature","europepmc",0.203656817199893,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000170315","literature","europepmc",0.680779876220077,27,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000165916","rna_expression","expression_atlas",0.0233797504055041,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000165916","genetic_association","ot_genetics_portal",0.0463396351504161,2,NA,NA
"Besponsa","Inotuzumab ozogamicin","INOTUZUMABOZOGAMICIN","CHEMBL2108611","Pfizer","CD22-directed antibodydrug conjugate","Oncology","B cell precursor ALL","precursor B-cell acute lymphoblastic leukemia","MONDO_0020511","Serious","P,O,B",2017,"ENSG00000012124","ENSG00000254087","known_drug","chembl",0.0607930797611621,1,"EFO_1001938","precursor B-cell acute lymphoblastic leukemia -> B-cell non-Hodgkins lymphoma"
"Besponsa","Inotuzumab ozogamicin","INOTUZUMABOZOGAMICIN","CHEMBL2108611","Pfizer","CD22-directed antibodydrug conjugate","Oncology","B cell precursor ALL","precursor B-cell acute lymphoblastic leukemia","MONDO_0020511","Serious","P,O,B",2017,"ENSG00000012124","ENSG00000254087","literature","europepmc",0.0182379239283486,1,"EFO_1001938","precursor B-cell acute lymphoblastic leukemia -> B-cell non-Hodgkins lymphoma"
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000188517","literature","europepmc",0.668940867108523,12,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000196924","literature","europepmc",0.0722339996328808,4,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000168610","literature","europepmc",0.786323413467127,50,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000204843","literature","europepmc",0.0243172319044648,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000168610","rna_expression","expression_atlas",0.0583042811441755,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000136826","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000136826","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Saphnelo","Anifrolumab","Anifrolumab","CHEMBL2364653","AstraZeneca","IFNAR-targeted mAb","Other indication","SLE","systemic lupus erythematosus","MONDO_0007915","Serious","S,F",2021,"ENSG00000142166","ENSG00000170581","literature","europepmc",0.618907325901831,3,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000136826","literature","europepmc",0.370668916877086,3,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000136826","literature","europepmc",0.370668916877086,3,NA,NA
"Saphnelo","Anifrolumab","Anifrolumab","CHEMBL2364653","AstraZeneca","IFNAR-targeted mAb","Other indication","SLE","systemic lupus erythematosus","MONDO_0007915","Serious","S,F",2021,"ENSG00000142166","ENSG00000170581","rna_expression","expression_atlas",0.0733321396732374,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000136826","genetic_association","ot_genetics_portal",0.528338163502701,5,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000136826","genetic_association","ot_genetics_portal",0.528338163502701,5,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000171132","literature","europepmc",0.322721752608789,5,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000176884","literature","europepmc",0.784125445560741,18,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000171132","rna_expression","expression_atlas",0.0409374563614573,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000176884","known_drug","chembl",0.985802656503549,52,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000141867","known_drug","chembl",0.0683922147313074,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000141867","known_drug","chembl",0.0683922147313074,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000141867","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000141867","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000141867","somatic_mutation","intogen",0.25606909530015,1,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000141867","somatic_mutation","intogen",0.25606909530015,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000130522","literature","europepmc",0.0759913497014526,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000130522","literature","europepmc",0.0759913497014526,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000141867","literature","europepmc",0.613841235921734,3,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000141867","literature","europepmc",0.613841235921734,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000144381","literature","europepmc",0.0545449021190427,3,NA,NA
"Lartruvo","Olaratumab","OLARATUMAB","CHEMBL1743049","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016,"ENSG00000134853","ENSG00000067225","literature","europepmc",0.117533287538247,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000196136","literature","europepmc",0.59279869153793,100,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000198959","literature","europepmc",0.66601729106516,27,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000075651","literature","europepmc",0.163634706357128,4,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000137845","literature","europepmc",0.881132422482106,130,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000137845","rna_expression","expression_atlas",0.0204031224220041,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000137845","genetic_association","eva",0.381307705835289,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000137845","genetic_association","ot_genetics_portal",0.650697570279872,6,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000143369","literature","europepmc",0.0121586159522324,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000157766","literature","europepmc",0.100055277106913,4,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000067560","literature","europepmc",0.315116089316547,19,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000067560","rna_expression","expression_atlas",0.0418727557264558,1,NA,NA
"Tavalisse","Fostamatinib","FOSTAMATINIB","CHEMBL2103830","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018,"ENSG00000165025","ENSG00000175104","literature","europepmc",0.121586159522324,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000078549","literature","europepmc",0.218855087140184,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000134259","literature","europepmc",0.903623665518685,330,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000158560","rna_expression","expression_atlas",0.0692182921951281,6,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000101266","literature","europepmc",0.309982225005506,6,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000167037","literature","europepmc",0.170220623331254,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000185345","literature","europepmc",0.79387153660908,36,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000134287","rna_expression","expression_atlas",0.0511430720538951,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000080815","genetic_association","orphanet",0.607930797611621,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000080815","literature","europepmc",0.981857938200171,1514,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000241837","literature","europepmc",0.607930797611621,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000080815","rna_expression","expression_atlas",0.0498809631145068,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000080815","animal_model","impc",0.403787635773639,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000080815","affected_pathway","sysbio",0.455948098208716,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000080815","known_drug","chembl",0.643222988430273,20,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000080815","genetic_association","eva",0.937563113223505,314,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000101213","known_drug","chembl",0.173091407653309,4,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000101213","known_drug","chembl",0.173091407653309,4,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000101213","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000101213","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000101213","literature","europepmc",0.092540576969769,3,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000101213","literature","europepmc",0.092540576969769,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000106211","literature","europepmc",0.246948910107648,9,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000113721","literature","europepmc",0.767659773158692,12,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000171049","literature","europepmc",0.730611398233811,32,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000106211","rna_expression","expression_atlas",0.0199208673664806,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000113721","known_drug","chembl",0.462702884848845,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000141646","literature","europepmc",0.067378996735288,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000181773","literature","europepmc",0.247248490064617,10,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000073060","literature","europepmc",0.0755489111765242,5,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000073060","genetic_association","ot_genetics_portal",0.513383683575529,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000128052","literature","europepmc",0.624307435103265,9,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000131508","literature","europepmc",0.0364758478566973,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000139182","literature","europepmc",0.0759913497014526,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000131508","rna_expression","expression_atlas",0.0255515686131471,1,NA,NA
"Lartruvo","Olaratumab","OLARATUMAB","CHEMBL1743049","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016,"ENSG00000134853","ENSG00000124181","somatic_mutation","intogen",0.367471510544945,2,NA,NA
"Lartruvo","Olaratumab","OLARATUMAB","CHEMBL1743049","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016,"ENSG00000134853","ENSG00000124181","literature","europepmc",0.114026373184426,11,NA,NA
"Lartruvo","Olaratumab","OLARATUMAB","CHEMBL1743049","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016,"ENSG00000134853","ENSG00000124181","somatic_mutation","cancer_gene_census",0.755691755364446,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000189403","literature","europepmc",0.383277767372979,28,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000239697","literature","europepmc",0.0486344638089297,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000157554","somatic_mutation","cancer_gene_census",0.906661236771331,6,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000157554","somatic_mutation","cancer_gene_census",0.906661236771331,6,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000157554","somatic_mutation","intogen",0.151982699402905,1,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000157554","somatic_mutation","intogen",0.151982699402905,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000157554","literature","europepmc",0.627342445175508,10,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000157554","literature","europepmc",0.627342445175508,10,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000136504","somatic_mutation","cancer_gene_census",0.379956748507263,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000136504","somatic_mutation","cancer_gene_census",0.379956748507263,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000136504","somatic_mutation","eva_somatic",0.248238409024745,3,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000136504","somatic_mutation","eva_somatic",0.248238409024745,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000143801","genetic_association","orphanet",0.607930797611621,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000076248","literature","europepmc",0.0303965398805811,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000108387","literature","europepmc",0.0309031488785907,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000124788","literature","europepmc",0.14521523317816,9,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000135823","literature","europepmc",0.118568458590847,5,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000143801","literature","europepmc",0.907142109891325,462,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000135823","rna_expression","expression_atlas",0.0255594212153961,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000143801","known_drug","chembl",0.643222988430273,20,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000143801","genetic_association","eva",0.885212505986947,149,NA,NA
"Tavalisse","Fostamatinib","FOSTAMATINIB","CHEMBL2103830","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018,"ENSG00000165025","ENSG00000110395","literature","europepmc",0.0303965398805811,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000141027","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000141027","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000141027","somatic_mutation","intogen",0.230750478474351,1,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000141027","somatic_mutation","intogen",0.230750478474351,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000141027","literature","europepmc",0.0121586159522324,1,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000141027","literature","europepmc",0.0121586159522324,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000130066","rna_expression","expression_atlas",0.0763895294370008,1,NA,NA
"Lartruvo","Olaratumab","OLARATUMAB","CHEMBL1743049","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016,"ENSG00000134853","ENSG00000113721","known_drug","chembl",0.893944764225223,72,NA,NA
"Lartruvo","Olaratumab","OLARATUMAB","CHEMBL1743049","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016,"ENSG00000134853","ENSG00000113721","literature","europepmc",0.823146015241377,64,NA,NA
"Lartruvo","Olaratumab","OLARATUMAB","CHEMBL1743049","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016,"ENSG00000134853","ENSG00000113721","somatic_mutation","cancer_gene_census",0.634865509339136,5,NA,NA
"Lartruvo","Olaratumab","OLARATUMAB","CHEMBL1743049","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016,"ENSG00000134853","ENSG00000113721","animal_model","impc",0.293873747565458,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000069329","literature","europepmc",0.857765654181351,22,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000088832","literature","europepmc",0.09834631608696,5,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000154277","literature","europepmc",0.723226927346266,45,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000162604","literature","europepmc",0.266751590508679,5,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000176697","literature","europepmc",0.981996306162032,410,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000275700","literature","europepmc",0.0324229758726198,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000154277","rna_expression","expression_atlas",0.120630733390539,5,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000176697","rna_expression","expression_atlas",0.0280255832194247,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000069696","literature","europepmc",0.188458547259603,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000120948","literature","europepmc",0.959540001023164,217,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000170345","literature","europepmc",0.352917674345708,25,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000120948","rna_expression","expression_atlas",0.0145889858744908,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000069696","known_drug","chembl",0.473257238974047,4,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000106462","known_drug","chembl",0.0759913497014526,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000106462","known_drug","chembl",0.0759913497014526,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000169083","known_drug","chembl",0.991713214872535,584,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000169083","known_drug","chembl",0.991713214872535,584,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000106462","somatic_mutation","cancer_gene_census",0.7219178221638,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000106462","somatic_mutation","cancer_gene_census",0.7219178221638,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000169083","somatic_mutation","cancer_gene_census",0.759913497014526,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000169083","somatic_mutation","cancer_gene_census",0.759913497014526,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000169083","somatic_mutation","intogen",0.865457038266544,4,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000169083","somatic_mutation","intogen",0.865457038266544,4,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000106462","literature","europepmc",0.167765679823815,37,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000106462","literature","europepmc",0.167765679823815,37,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000145715","literature","europepmc",0.0243172319044648,1,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000145715","literature","europepmc",0.0243172319044648,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000169083","literature","europepmc",0.6831193883306,412,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000169083","literature","europepmc",0.6831193883306,412,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000169083","somatic_mutation","eva_somatic",0.843319670593179,10,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000169083","somatic_mutation","eva_somatic",0.843319670593179,10,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000169083","affected_pathway","cancer_biomarkers",0.928566906455679,8,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000169083","affected_pathway","cancer_biomarkers",0.928566906455679,8,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000169083","genetic_association","eva",0.910667391298007,93,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000169083","genetic_association","eva",0.910667391298007,93,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000145715","genetic_association","ot_genetics_portal",0.145338848146315,1,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000145715","genetic_association","ot_genetics_portal",0.145338848146315,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000169083","genetic_association","ot_genetics_portal",0.47979640308018,4,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000169083","genetic_association","ot_genetics_portal",0.47979640308018,4,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000169083","affected_pathway","progeny",0.39886768568892,1,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000169083","affected_pathway","progeny",0.39886768568892,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000169083","animal_model","impc",0.567183258129765,13,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000169083","animal_model","impc",0.567183258129765,13,NA,NA
"Lartruvo","Olaratumab","OLARATUMAB","CHEMBL1743049","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016,"ENSG00000134853","ENSG00000096063","literature","europepmc",0.0547137717850459,1,NA,NA
"Lartruvo","Olaratumab","OLARATUMAB","CHEMBL1743049","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016,"ENSG00000134853","ENSG00000197461","literature","europepmc",0.043701677475384,7,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000160691","literature","europepmc",0.0334361938686392,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000160691","literature","europepmc",0.0334361938686392,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000160691","genetic_association","ot_genetics_portal",0.170621678561548,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000160691","genetic_association","ot_genetics_portal",0.170621678561548,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000126934","literature","europepmc",0.0212775779164067,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000157212","literature","europepmc",0.0607930797611621,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000147224","rna_expression","expression_atlas",0.023331933268027,1,NA,NA
"Sylvant","Siltuximab","SILTUXIMAB","CHEMBL1743070","Janssen Biotech","IL-6-specific antibody","Other indication","Multicentric Castleman's disease","Castleman disease","MONDO_0015564","Serious","P,O",2014,"ENSG00000136244","ENSG00000160712","known_drug","chembl",0.136784429462615,2,NA,NA
"Sylvant","Siltuximab","SILTUXIMAB","CHEMBL1743070","Janssen Biotech","IL-6-specific antibody","Other indication","Multicentric Castleman's disease","Castleman disease","MONDO_0015564","Serious","P,O",2014,"ENSG00000136244","ENSG00000160712","literature","europepmc",0.202889703390505,31,NA,NA
"Tazverik","Tazemetostat","TAZEMETOSTAT","CHEMBL3414621","Epizyme","EZH2 inhibitor","Oncology","Epithelioid sarcoma","epithelioid sarcoma","MONDO_0017387","Serious","P,O,A,F",2020,"ENSG00000106462","ENSG00000085224","literature","europepmc",0.243172319044648,1,"EFO_1001968","epithelioid sarcoma -> soft tissue sarcoma (parent)"
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000184203","literature","europepmc",0.0911896196417432,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000168077","literature","europepmc",0.0121586159522324,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000168077","genetic_association","ot_genetics_portal",0.400973881598755,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000198804","literature","europepmc",0.028876712886552,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000112592","literature","europepmc",0.225584786487414,9,NA,NA
"Saphnelo","Anifrolumab","Anifrolumab","CHEMBL2364653","AstraZeneca","IFNAR-targeted mAb","Other indication","SLE","systemic lupus erythematosus","MONDO_0007915","Serious","S,F",2021,"ENSG00000142166","ENSG00000115415","literature","europepmc",0.883097439157132,59,NA,NA
"Saphnelo","Anifrolumab","Anifrolumab","CHEMBL2364653","AstraZeneca","IFNAR-targeted mAb","Other indication","SLE","systemic lupus erythematosus","MONDO_0007915","Serious","S,F",2021,"ENSG00000142166","ENSG00000115415","genetic_association","ot_genetics_portal",0.282975386904817,27,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000101412","literature","europepmc",0.0303965398805811,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000116141","literature","europepmc",0.703233107935612,27,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000123416","literature","europepmc",0.0788621340235075,3,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000253729","known_drug","chembl",0.0759913497014526,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000253729","known_drug","chembl",0.0759913497014526,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000109501","literature","europepmc",0.319163668746101,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000109501","rna_expression","expression_atlas",0.017164253278774,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000184702","literature","europepmc",0.0729516957133945,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000148180","literature","europepmc",0.0638327337492202,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000148180","literature","europepmc",0.0638327337492202,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000097007","known_drug","chembl",0.499712468911638,32,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000097007","known_drug","chembl",0.499712468911638,32,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000097007","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000097007","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000097007","literature","europepmc",0.0121586159522324,1,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000097007","literature","europepmc",0.0121586159522324,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000266412","literature","europepmc",0.0607930797611621,1,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000266412","literature","europepmc",0.0607930797611621,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000266412","genetic_association","ot_genetics_portal",0.15180204080346,5,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000266412","genetic_association","ot_genetics_portal",0.15180204080346,5,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000142192","genetic_association","orphanet",0.607930797611621,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000121653","literature","europepmc",0.320515556857358,11,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000142192","literature","europepmc",0.995925840342694,6090,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000146072","literature","europepmc",0.81544093654524,12,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000142192","animal_model","impc",0.423938853017804,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000066027","affected_pathway","sysbio",0.455948098208716,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000142192","genetic_association","uniprot_literature",0.607930797611621,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000142192","genetic_association","uniprot_variants",0.951397496038773,12,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000142192","known_drug","chembl",0.912966726240277,77,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000142192","genetic_association","eva",0.874357153360333,212,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000121653","genetic_association","ot_genetics_portal",0.160007014474029,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000142192","genetic_association","ot_genetics_portal",0.582216982168431,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000142192","affected_pathway","reactome",0.607930797611621,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000184634","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000184634","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000184634","somatic_mutation","intogen",0.487793089692349,5,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000184634","somatic_mutation","intogen",0.487793089692349,5,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000184634","literature","europepmc",0.0775111766954817,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000184634","literature","europepmc",0.0775111766954817,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000184634","somatic_mutation","eva_somatic",0.531939447910168,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000184634","somatic_mutation","eva_somatic",0.531939447910168,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000116288","literature","europepmc",0.21184699600105,4,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000116288","literature","europepmc",0.21184699600105,4,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000087245","literature","europepmc",0.754467566526342,34,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000124222","literature","europepmc",0.121586159522324,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000172977","literature","europepmc",0.549842667182481,10,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000134709","literature","europepmc",0.277621730909307,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000148798","literature","europepmc",0.121586159522324,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000148798","rna_expression","expression_atlas",0.0999386357892368,4,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000141968","somatic_mutation","cancer_gene_census",0.379956748507263,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000141968","somatic_mutation","cancer_gene_census",0.379956748507263,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000062725","literature","europepmc",0.0303965398805811,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000198736","literature","europepmc",0.182379239283486,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000108179","literature","europepmc",0.130536251820495,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000116133","literature","europepmc",0.768762810396336,33,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000116133","rna_expression","expression_atlas",0.0624608581976494,5,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000158792","rna_expression","expression_atlas",0.0629856675654842,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000109685","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000109685","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000007047","literature","europepmc",0.398782311728041,22,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000163697","literature","europepmc",0.103450298352316,8,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000175582","literature","europepmc",0.122670199388474,7,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000102030","rna_expression","expression_atlas",0.0379518552222817,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000175582","rna_expression","expression_atlas",0.0117818389097602,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000007047","genetic_association","ot_genetics_portal",0.0814639427983697,1,NA,NA
"Gamifant","Emapalumab","EMAPALUMAB","CHEMBL3989977","Novimmune","Interferon--blocking antibody","Other indication","Primary haemophagocytic lymphohistiocytosis","genetic hemophagocytic lymphohistiocytosis","MONDO_0015541","Serious","P,O,B",2018,"ENSG00000111537","ENSG00000027697","animal_model","impc",0.251744143290972,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000044574","literature","europepmc",0.307945669378378,19,NA,NA
"Lartruvo","Olaratumab","OLARATUMAB","CHEMBL1743049","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016,"ENSG00000134853","ENSG00000145431","literature","europepmc",0.0303965398805811,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000167552","literature","europepmc",0.0121586159522324,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000177606","literature","europepmc",0.288934198640719,29,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000178127","literature","europepmc",0.0461014188188813,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000177606","affected_pathway","reactome",0.607930797611621,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000108578","literature","europepmc",0.138519731172515,11,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000177426","literature","europepmc",0.0790310036895107,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000063660","literature","europepmc",0.0653525607432493,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000092969","literature","europepmc",0.151512847319271,9,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000115414","literature","europepmc",0.118568129846989,15,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000115414","rna_expression","expression_atlas",0.0258867990916878,1,NA,NA
"Tavalisse","Fostamatinib","FOSTAMATINIB","CHEMBL2103830","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018,"ENSG00000165025","ENSG00000162711","literature","europepmc",0.204585600362911,4,NA,NA
"Tavalisse","Fostamatinib","FOSTAMATINIB","CHEMBL2103830","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018,"ENSG00000165025","ENSG00000162711","animal_model","impc",0.309801534462882,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000070748","literature","europepmc",0.788246185680343,161,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000127445","literature","europepmc",0.211593691502045,4,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000127445","rna_expression","expression_atlas",0.0805969995556453,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000101336","known_drug","chembl",0.493680024067221,13,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000101336","known_drug","chembl",0.493680024067221,13,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000168484","literature","europepmc",0.0227974049104358,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000171603","literature","europepmc",0.283491640499579,6,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000005339","somatic_mutation","cancer_gene_census",0.620596022561863,3,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000005339","somatic_mutation","cancer_gene_census",0.620596022561863,3,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000005339","literature","europepmc",0.0653525607432493,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000005339","literature","europepmc",0.0653525607432493,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000005339","affected_pathway","slapenrich",0.490305438523753,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000005339","affected_pathway","slapenrich",0.490305438523753,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000146731","literature","europepmc",0.0121586159522324,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000148400","literature","europepmc",0.154807521741775,18,NA,NA
"Tavalisse","Fostamatinib","FOSTAMATINIB","CHEMBL2103830","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018,"ENSG00000165025","ENSG00000135077","literature","europepmc",0.374406349132331,9,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000034053","literature","europepmc",0.371423799024225,11,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000132155","literature","europepmc",0.170220623331254,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000132155","rna_expression","expression_atlas",0.0208616920168371,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000118058","somatic_mutation","cancer_gene_census",0.620596022561863,3,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000118058","somatic_mutation","cancer_gene_census",0.620596022561863,3,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000118058","somatic_mutation","intogen",0.216933586011983,1,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000118058","somatic_mutation","intogen",0.216933586011983,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000118058","literature","europepmc",0.132837945368119,5,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000118058","literature","europepmc",0.132837945368119,5,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000104805","literature","europepmc",0.0516741177969878,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000166033","literature","europepmc",0.342785157626633,6,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000197442","literature","europepmc",0.350549026956032,11,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000166033","rna_expression","expression_atlas",0.011307434096368,1,NA,NA
"Tavalisse","Fostamatinib","FOSTAMATINIB","CHEMBL2103830","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018,"ENSG00000165025","ENSG00000168610","literature","europepmc",0.0938290525213736,5,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000072506","literature","europepmc",0.277132319964249,53,NA,NA
"Viberzi","Eluxadoline","ELUXADOLINE","CHEMBL2159122","Allergan","Mu-opioid receptor agonist","Other indication","Irritable bowel syndrome","irritable bowel syndrome","EFO_0000555","Not serious","P,F",2015,"ENSG00000112038","ENSG00000172243","literature","europepmc",0.085110311665627,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000105329","literature","europepmc",0.848376806769295,151,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000132535","literature","europepmc",0.886339413682525,56,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000132535","animal_model","impc",0.266516861672935,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000100285","literature","europepmc",0.361946213747513,21,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000100285","rna_expression","expression_atlas",0.0303078206093098,3,NA,NA
"Lartruvo","Olaratumab","OLARATUMAB","CHEMBL1743049","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016,"ENSG00000134853","ENSG00000100311","affected_pathway","cancer_biomarkers",0.607930797611621,1,NA,NA
"Lartruvo","Olaratumab","OLARATUMAB","CHEMBL1743049","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016,"ENSG00000134853","ENSG00000100311","literature","europepmc",0.316648485010326,77,NA,NA
"Lartruvo","Olaratumab","OLARATUMAB","CHEMBL1743049","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016,"ENSG00000134853","ENSG00000100311","somatic_mutation","cancer_gene_census",0.920715759356422,8,NA,NA
"Lartruvo","Olaratumab","OLARATUMAB","CHEMBL1743049","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016,"ENSG00000134853","ENSG00000100311","genetic_association","genomics_england",0.607930797611621,1,NA,NA
"Lartruvo","Olaratumab","OLARATUMAB","CHEMBL1743049","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016,"ENSG00000134853","ENSG00000100311","genetic_association","eva",0.18676985059957,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000171867","literature","europepmc",0.927511040652268,109,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000084676","somatic_mutation","cancer_gene_census",0.379956748507263,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000084676","somatic_mutation","cancer_gene_census",0.379956748507263,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000084676","literature","europepmc",0.0303965398805811,1,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000084676","literature","europepmc",0.0303965398805811,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000135018","literature","europepmc",0.747967122100944,39,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000135018","rna_expression","expression_atlas",0.0282375814821039,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000075624","literature","europepmc",0.408308057075251,73,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000100985","literature","europepmc",0.859545683878896,55,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000164402","literature","europepmc",0.0408664591727812,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000075624","rna_expression","expression_atlas",0.0743830886992825,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000102879","rna_expression","expression_atlas",0.097099026854522,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000164402","rna_expression","expression_atlas",0.0334676432948238,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000105974","literature","europepmc",0.659649342632169,18,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000178741","literature","europepmc",0.0212775779164067,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000105974","rna_expression","expression_atlas",0.0365193293227898,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000178741","rna_expression","expression_atlas",0.0330300449662103,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000065154","literature","europepmc",0.0664299492123499,5,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000103415","literature","europepmc",0.121417289856321,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000129219","literature","europepmc",0.057648726580182,6,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000143153","literature","europepmc",0.209736125176009,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000146648","literature","europepmc",0.755172045381078,37,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000065154","rna_expression","expression_atlas",0.0366969204906708,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000103415","rna_expression","expression_atlas",0.0577750464440489,5,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000143153","rna_expression","expression_atlas",0.0469779875444771,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000146648","rna_expression","expression_atlas",0.0718317282669527,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000129219","genetic_association","ot_genetics_portal",0.0494390266881073,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000159388","somatic_mutation","cancer_gene_census",0.379956748507263,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000159388","somatic_mutation","cancer_gene_census",0.379956748507263,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000159388","literature","europepmc",0.113733720053174,4,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000159388","literature","europepmc",0.113733720053174,4,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000102003","literature","europepmc",0.791711750158438,93,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000172115","literature","europepmc",0.31340139540802,25,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000169604","rna_expression","expression_atlas",0.0538908016947346,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000106617","rna_expression","expression_atlas",0.049124821535945,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000157168","literature","europepmc",0.868419069751252,13,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000204264","literature","europepmc",0.0243172319044648,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000157168","rna_expression","expression_atlas",0.0234583568242672,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000137312","literature","europepmc",0.129657176029519,13,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000147257","rna_expression","expression_atlas",0.0153467705281427,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000116288","literature","europepmc",0.663777663066795,28,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000116288","rna_expression","expression_atlas",0.0572345271623618,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000089280","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000089280","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000089280","literature","europepmc",0.119897462862292,3,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000089280","literature","europepmc",0.119897462862292,3,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000129514","somatic_mutation","cancer_gene_census",0.855958119553862,4,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000129514","somatic_mutation","cancer_gene_census",0.855958119553862,4,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000129514","somatic_mutation","intogen",0.927523962466422,11,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000129514","somatic_mutation","intogen",0.927523962466422,11,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000129514","literature","europepmc",0.28949611636636,12,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000129514","literature","europepmc",0.28949611636636,12,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000129514","genetic_association","ot_genetics_portal",0.23358174626019,1,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000129514","genetic_association","ot_genetics_portal",0.23358174626019,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000210082","literature","europepmc",0.790158693137096,36,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000125977","rna_expression","expression_atlas",0.0386966450827981,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000006125","literature","europepmc",0.0212775779164067,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000143514","literature","europepmc",0.0182379239283486,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000172059","literature","europepmc",0.0607930797611621,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000143514","rna_expression","expression_atlas",0.0118725039059844,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000164305","literature","europepmc",0.857653523765519,125,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000204209","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000204209","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000204209","literature","europepmc",0.118546505534266,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000204209","literature","europepmc",0.118546505534266,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000109846","literature","europepmc",0.263846446918212,20,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000113108","literature","europepmc",0.0469457671488974,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000100030","literature","europepmc",0.49104964911249,22,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000185825","literature","europepmc",0.234053357080474,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000185825","rna_expression","expression_atlas",0.0291766949774727,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000011465","literature","europepmc",0.669058084227082,8,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000172020","literature","europepmc",0.773007678082254,29,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000179399","literature","europepmc",0.121586159522324,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000242689","literature","europepmc",0.13080812460118,11,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000011465","rna_expression","expression_atlas",0.014015950419392,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000172020","rna_expression","expression_atlas",0.0422152475864,3,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000004478","literature","europepmc",0.0911896196417432,1,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000004478","literature","europepmc",0.0911896196417432,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000160691","literature","europepmc",0.145060389076084,10,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000138798","literature","europepmc",0.354750576724923,10,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000163956","literature","europepmc",0.545908418757191,12,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000168385","literature","europepmc",0.0408664591727812,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000152256","rna_expression","expression_atlas",0.017493146733261,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000163956","rna_expression","expression_atlas",0.0579833800175322,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000182511","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000182511","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000019169","literature","europepmc",0.0151982699402905,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000109099","literature","europepmc",0.0607930797611621,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000109099","rna_expression","expression_atlas",0.0107520768596799,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000124181","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000124181","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000124181","literature","europepmc",0.0729516957133945,1,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000124181","literature","europepmc",0.0729516957133945,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000120910","literature","europepmc",0.0349560208626682,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000115884","literature","europepmc",0.0916962286397529,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000100083","literature","europepmc",0.68000664563281,7,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000134215","literature","europepmc",0.0182379239283486,1,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000134215","literature","europepmc",0.0182379239283486,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000137947","literature","europepmc",0.0303965398805811,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000137947","rna_expression","expression_atlas",0.0205665005699479,1,NA,NA
"Tavalisse","Fostamatinib","FOSTAMATINIB","CHEMBL2103830","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018,"ENSG00000165025","ENSG00000169083","literature","europepmc",0.0364758478566973,1,NA,NA
"Tavalisse","Fostamatinib","FOSTAMATINIB","CHEMBL2103830","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018,"ENSG00000165025","ENSG00000169083","known_drug","chembl",0.175523130843755,5,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000064300","literature","europepmc",0.898703019034102,80,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000095970","literature","europepmc",0.983148285668479,380,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000171791","literature","europepmc",0.442855470555178,67,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000171791","rna_expression","expression_atlas",0.0451402599645235,2,NA,NA
"Lartruvo","Olaratumab","OLARATUMAB","CHEMBL1743049","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016,"ENSG00000134853","ENSG00000146648","known_drug","chembl",0.455948098208716,2,NA,NA
"Lartruvo","Olaratumab","OLARATUMAB","CHEMBL1743049","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016,"ENSG00000134853","ENSG00000146648","literature","europepmc",0.83858874782914,118,NA,NA
"Lartruvo","Olaratumab","OLARATUMAB","CHEMBL1743049","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016,"ENSG00000134853","ENSG00000146648","somatic_mutation","cancer_gene_census",0.689952136760982,11,NA,NA
"Tavalisse","Fostamatinib","FOSTAMATINIB","CHEMBL2103830","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018,"ENSG00000165025","ENSG00000012124","literature","europepmc",0.0182379239283486,1,NA,NA
"Tavalisse","Fostamatinib","FOSTAMATINIB","CHEMBL2103830","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018,"ENSG00000165025","ENSG00000012124","animal_model","impc",0.349560208626682,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000107959","literature","europepmc",0.642544047792408,11,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000071242","rna_expression","expression_atlas",0.0579275822641482,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000107959","rna_expression","expression_atlas",0.0653853961295859,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000196535","literature","europepmc",0.115929025711216,4,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000143870","literature","europepmc",0.152658178066918,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000166313","literature","europepmc",0.428161942870021,20,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000166598","literature","europepmc",0.0212775779164067,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000143870","rna_expression","expression_atlas",0.030335063579381,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000166598","rna_expression","expression_atlas",0.0527509044925376,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000107282","literature","europepmc",0.625795416188511,7,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000188313","literature","europepmc",0.0121586159522324,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000173020","literature","europepmc",0.425449022935053,12,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000170312","literature","europepmc",0.284334300132935,4,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000204463","rna_expression","expression_atlas",0.0400819244012036,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000117362","literature","europepmc",0.517156705387327,18,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000102466","rna_expression","expression_atlas",0.0418843324780657,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000117362","known_drug","chembl",0.643222988430273,20,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000127824","literature","europepmc",0.0957491006238303,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000127824","rna_expression","expression_atlas",0.0632091297228249,4,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000173406","rna_expression","expression_atlas",0.0435261555800153,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000122194","literature","europepmc",0.804317744832534,24,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000145335","literature","europepmc",0.924684185518159,244,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000145335","rna_expression","expression_atlas",0.0303648252890901,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000145335","affected_pathway","sysbio",0.455948098208716,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000105290","literature","europepmc",0.235746443682978,21,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000068024","known_drug","chembl",0.167898148475752,7,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000068024","known_drug","chembl",0.167898148475752,7,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000068024","literature","europepmc",0.0182379239283486,1,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000068024","literature","europepmc",0.0182379239283486,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000130203","genetic_association","orphanet",0.607930797611621,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000130203","literature","europepmc",0.996957694709366,4029,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000162236","literature","europepmc",0.0227974049104358,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000196262","literature","europepmc",0.107725416793595,9,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000130203","rna_expression","expression_atlas",0.0172515326790531,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000130203","genetic_association","eva",0.801734661372472,13,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000130203","genetic_association","ot_genetics_portal",0.710825407503134,68,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000138613","literature","europepmc",0.33674115719599,8,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000138613","known_drug","chembl",0.643222988430273,20,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000138613","genetic_association","ot_genetics_portal",0.671608760001574,3,NA,NA
"Tavalisse","Fostamatinib","FOSTAMATINIB","CHEMBL2103830","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018,"ENSG00000165025","ENSG00000142192","animal_model","impc",0.300986537897514,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000123080","literature","europepmc",0.0364758478566973,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000182871","literature","europepmc",0.243087884211647,4,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000157005","literature","europepmc",0.494056821222045,126,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000157005","rna_expression","expression_atlas",0.0686126302469696,9,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000117461","known_drug","chembl",0.175978092911601,9,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000117461","known_drug","chembl",0.175978092911601,9,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000142515","literature","europepmc",0.884394654508537,1103,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000142515","literature","europepmc",0.884394654508537,1103,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000142515","genetic_association","ot_genetics_portal",0.631770324405834,24,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000142515","genetic_association","ot_genetics_portal",0.631770324405834,24,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000167755","literature","europepmc",0.360186695264165,24,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000167772","literature","europepmc",0.0182379239283486,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000111237","literature","europepmc",0.0151982699402905,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000187554","literature","europepmc",0.649810474780422,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000111237","rna_expression","expression_atlas",0.0496963087756985,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000160014","literature","europepmc",0.120404071860302,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000166851","literature","europepmc",0.48391798098883,5,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000160014","rna_expression","expression_atlas",0.0602967492066371,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000143322","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000143322","somatic_mutation","cancer_gene_census",0.569935122760895,2,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000196363","literature","europepmc",0.0303965398805811,1,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000196363","literature","europepmc",0.0303965398805811,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000105723","literature","europepmc",0.444264877242597,29,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000197971","literature","europepmc",0.148397253676307,10,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000125848","rna_expression","expression_atlas",0.0329749961599272,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000197971","rna_expression","expression_atlas",0.0439083026359104,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000105723","known_drug","chembl",0.121586159522324,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000127022","literature","europepmc",0.040697589506778,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000136854","literature","europepmc",0.028876712886552,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000136854","rna_expression","expression_atlas",0.0422061316279394,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000172531","rna_expression","expression_atlas",0.0309324613505269,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000140564","literature","europepmc",0.278106808638728,15,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000105647","known_drug","chembl",0.175978092911601,9,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000105647","known_drug","chembl",0.175978092911601,9,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000064012","literature","europepmc",0.123872312082659,9,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000164885","literature","europepmc",0.90488221918624,232,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000164885","rna_expression","expression_atlas",0.0897798679319799,3,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000164885","affected_pathway","reactome",0.951397496038773,12,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000142875","literature","europepmc",0.0121586159522324,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000186318","literature","europepmc",0.981588263717222,1061,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000205155","literature","europepmc",0.51055970442909,29,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000186318","known_drug","chembl",0.532471506678716,20,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000205155","known_drug","chembl",0.643222988430273,20,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000070808","literature","europepmc",0.213219906385656,5,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000108443","literature","europepmc",0.295855387602134,18,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000070808","animal_model","impc",0.304026191885572,1,NA,NA
"Lartruvo","Olaratumab","OLARATUMAB","CHEMBL1743049","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016,"ENSG00000134853","ENSG00000167193","literature","europepmc",0.181842233745596,6,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000074317","literature","europepmc",0.18823803636133,14,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000141434","literature","europepmc",0.490968223490004,10,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000138449","literature","europepmc",0.634000896649199,5,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000138449","rna_expression","expression_atlas",0.0603246964199624,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000168702","literature","europepmc",0.175340751604472,6,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000168702","rna_expression","expression_atlas",0.0439702178094583,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000051128","literature","europepmc",0.0212775779164067,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000089685","literature","europepmc",0.0243172319044648,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000184937","literature","europepmc",0.152320438734912,4,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000010810","literature","europepmc",0.696232094126103,39,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000168615","literature","europepmc",0.0789685219130895,6,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000010810","known_drug","chembl",0.0607930797611621,1,NA,NA
"Nubeqa","Darolutamide","DAROLUTAMIDE","CHEMBL4297185","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019,"ENSG00000169083","ENSG00000136573","known_drug","chembl",0.493680024067221,13,NA,NA
"Erleada","Apalutamide","APALUTAMIDE","CHEMBL3183409","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018,"ENSG00000169083","ENSG00000136573","known_drug","chembl",0.493680024067221,13,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000082701","literature","europepmc",0.922095332365416,498,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000099250","literature","europepmc",0.292233635674507,12,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000082701","rna_expression","expression_atlas",0.0168778653229126,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000099250","rna_expression","expression_atlas",0.0171655556942171,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000082701","known_drug","chembl",0.158737486043034,3,NA,NA
"Lartruvo","Olaratumab","OLARATUMAB","CHEMBL1743049","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016,"ENSG00000134853","ENSG00000099942","literature","europepmc",0.148279387627454,6,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000131042","literature","europepmc",0.460296388718707,7,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000131042","genetic_association","ot_genetics_portal",0.0385776939689512,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000138685","literature","europepmc",0.236453791808631,27,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000144711","rna_expression","expression_atlas",0.0315690442781005,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000241563","literature","europepmc",0.0668723877372783,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000118137","literature","europepmc",0.827406397365485,61,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000131187","literature","europepmc",0.0607930797611621,1,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000133961","literature","europepmc",0.0820706576775689,2,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000254087","literature","europepmc",0.0887832269011972,4,NA,NA
"Aduhelm","Aducanumab","Aducanumab","CHEMBL3039540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021,"ENSG00000142192","ENSG00000254087","known_drug","chembl",0.0607930797611621,1,NA,NA
"Poteligeo","Mogamulizumab","MOGAMULIZUMAB","CHEMBL1743041","Kyowa Hakko Kirin","CCR4 antibody","Oncology","mycosis fungoides or Sezary syndrome","mycosis fungoides","EFO_1001051","Serious","P,O,B",2018,"ENSG00000183813","ENSG00000102970","literature","europepmc",0.67817728073246,9,NA,NA
"Leqvio","Inclisiran","Inclisiran","CHEMBL3990033","Novartis/Alnylam","PCSK9-targeted siRNA","Other indication","HeFH or ASCVD","coronary atherosclerosis","MONDO_0021661","Serious","S",2021,"ENSG00000169174","ENSG00000130164","literature","europepmc",0.191329331581657,3,NA,NA
"Leqvio","Inclisiran","Inclisiran","CHEMBL3990033","Novartis/Alnylam","PCSK9-targeted siRNA","Other indication","HeFH or ASCVD","coronary atherosclerosis","MONDO_0021661","Serious","S",2021,"ENSG00000169174","ENSG00000130164","genetic_association","ot_genetics_portal",0.31228063058258,2,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000100368","affected_pathway","slapenrich",0.954257352157711,17,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000197386","literature","europepmc",0.197261722948351,5,NA,NA
"Macrilen","Macimorelin","MACIMORELIN","CHEMBL278623","Aeterna Zentaris","Growth hormone secretagogue receptor agonist","Other indication","Diagnosis of adult growth hormone deficiency","short stature due to GHSR deficiency","MONDO_0014403","Not serious","S,O",2017,"ENSG00000121853","ENSG00000121853","animal_model","impc",0.250832247094555,1,NA,NA
"Macrilen","Macimorelin","MACIMORELIN","CHEMBL278623","Aeterna Zentaris","Growth hormone secretagogue receptor agonist","Other indication","Diagnosis of adult growth hormone deficiency","short stature due to GHSR deficiency","MONDO_0014403","Not serious","S,O",2017,"ENSG00000121853","ENSG00000121853","genetic_association","uniprot_literature",0.607930797611621,1,NA,NA
"Macrilen","Macimorelin","MACIMORELIN","CHEMBL278623","Aeterna Zentaris","Growth hormone secretagogue receptor agonist","Other indication","Diagnosis of adult growth hormone deficiency","short stature due to GHSR deficiency","MONDO_0014403","Not serious","S,O",2017,"ENSG00000121853","ENSG00000121853","genetic_association","uniprot_variants",0.759913497014526,2,NA,NA
"Macrilen","Macimorelin","MACIMORELIN","CHEMBL278623","Aeterna Zentaris","Growth hormone secretagogue receptor agonist","Other indication","Diagnosis of adult growth hormone deficiency","short stature due to GHSR deficiency","MONDO_0014403","Not serious","S,O",2017,"ENSG00000121853","ENSG00000121853","genetic_association","orphanet",0.607930797611621,1,NA,NA
"Macrilen","Macimorelin","MACIMORELIN","CHEMBL278623","Aeterna Zentaris","Growth hormone secretagogue receptor agonist","Other indication","Diagnosis of adult growth hormone deficiency","short stature due to GHSR deficiency","MONDO_0014403","Not serious","S,O",2017,"ENSG00000121853","ENSG00000121853","genetic_association","genomics_england",0.607930797611621,1,NA,NA
"Macrilen","Macimorelin","MACIMORELIN","CHEMBL278623","Aeterna Zentaris","Growth hormone secretagogue receptor agonist","Other indication","Diagnosis of adult growth hormone deficiency","short stature due to GHSR deficiency","MONDO_0014403","Not serious","S,O",2017,"ENSG00000121853","ENSG00000121853","genetic_association","eva",0.784927947143503,76,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000169047","literature","europepmc",0.810323155469194,31,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000169047","affected_pathway","slapenrich",0.970417022263519,25,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000169047","genetic_association","ot_genetics_portal",0.369114507366769,2,NA,NA
"Givlaari","Givosiran","GIVOSIRAN","CHEMBL4297760","Alnylam","ALAS1-directed siRNA","Other indication","Acute hepatic porphyria","acute hepatic porphyria","Orphanet_95157","Serious","P,O,B",2019,"ENSG00000023330","ENSG00000023330","literature","europepmc",0.0494630049732174,15,NA,NA
"Givlaari","Givosiran","GIVOSIRAN","CHEMBL4297760","Alnylam","ALAS1-directed siRNA","Other indication","Acute hepatic porphyria","acute hepatic porphyria","Orphanet_95157","Serious","P,O,B",2019,"ENSG00000023330","ENSG00000023330","known_drug","chembl",0.721073473833784,3,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000177885","literature","europepmc",0.176475213042664,9,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000177885","affected_pathway","slapenrich",0.985623845649296,72,NA,NA
"Myalept","Metreleptin","METRELEPTIN","CHEMBL2107857","Amylin","Leptin analogue","Other indication","Leptin deficiency in patients with congenital or acquired generalized lipodystrophy","congenital generalized lipodystrophy","EFO_1000681","Serious","P,O,F",2014,"ENSG00000116678","ENSG00000174697","literature","europepmc",0.0253946203735654,5,NA,NA
"Myalept","Metreleptin","METRELEPTIN","CHEMBL2107857","Amylin","Leptin analogue","Other indication","Leptin deficiency in patients with congenital or acquired generalized lipodystrophy","congenital generalized lipodystrophy","EFO_1000681","Serious","P,O,F",2014,"ENSG00000116678","ENSG00000174697","animal_model","impc",0.485019011211172,4,NA,NA
"Jemperli","Dostarlimab","Dostarlimab","CHEMBL4298124","GlaxoSmithKline","PD1-targeted mAb","Oncology","Endometrial cancer","endometrial cancer","MONDO_0011962","Serious","P,B,A",2021,"ENSG00000188389","ENSG00000179295","affected_pathway","slapenrich",0.972775676807847,22,NA,NA
"Jemperli","Dostarlimab","Dostarlimab","CHEMBL4298124","GlaxoSmithKline","PD1-targeted mAb","Oncology","Endometrial cancer","endometrial cancer","MONDO_0011962","Serious","P,B,A",2021,"ENSG00000188389","ENSG00000179295","somatic_mutation","cancer_gene_census",0.683922147313074,2,NA,NA
"Jemperli","Dostarlimab","Dostarlimab","CHEMBL4298124","GlaxoSmithKline","PD1-targeted mAb","Oncology","Endometrial cancer","endometrial cancer","MONDO_0011962","Serious","P,B,A",2021,"ENSG00000188389","ENSG00000179295","literature","europepmc",0.0182379239283486,1,NA,NA
"Jemperli","Dostarlimab","Dostarlimab","CHEMBL4298124","GlaxoSmithKline","PD1-targeted mAb","Oncology","Endometrial cancer","endometrial cancer","MONDO_0011962","Serious","P,B,A",2021,"ENSG00000188389","ENSG00000197646","somatic_mutation","cancer_gene_census",0.607930797611621,1,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000105647","literature","europepmc",0.085110311665627,2,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000105647","known_drug","chembl",0.591454109686285,50,NA,NA
"Mulpleta","Lusutrombopag","LUSUTROMBOPAG","CHEMBL2107831","Shionogi","Thrombopoietin receptor agonist","Other indication","Thrombocytopenia","thrombocytopenia","HP_0001873","Not concordant","P,F",2018,"ENSG00000117400","ENSG00000096968","literature","europepmc",0.6863159193577,32,NA,NA
"Doptelet","Avatrombopag","AVATROMBOPAG","CHEMBL2103883","Dova Pharmaceuticals","Thrombopoietin receptor agonist","Other indication","Thrombocytopenia","thrombocytopenia","HP_0001873","Not concordant","P",2018,"ENSG00000117400","ENSG00000096968","literature","europepmc",0.6863159193577,32,NA,NA
"Mulpleta","Lusutrombopag","LUSUTROMBOPAG","CHEMBL2107831","Shionogi","Thrombopoietin receptor agonist","Other indication","Thrombocytopenia","thrombocytopenia","HP_0001873","Not concordant","P,F",2018,"ENSG00000117400","ENSG00000096968","animal_model","impc",0.623421692749539,8,NA,NA
"Doptelet","Avatrombopag","AVATROMBOPAG","CHEMBL2103883","Dova Pharmaceuticals","Thrombopoietin receptor agonist","Other indication","Thrombocytopenia","thrombocytopenia","HP_0001873","Not concordant","P",2018,"ENSG00000117400","ENSG00000096968","animal_model","impc",0.623421692749539,8,NA,NA
"Mulpleta","Lusutrombopag","LUSUTROMBOPAG","CHEMBL2107831","Shionogi","Thrombopoietin receptor agonist","Other indication","Thrombocytopenia","thrombocytopenia","HP_0001873","Not concordant","P,F",2018,"ENSG00000117400","ENSG00000096968","genetic_association","gene_burden",0.759913497014526,2,NA,NA
"Doptelet","Avatrombopag","AVATROMBOPAG","CHEMBL2103883","Dova Pharmaceuticals","Thrombopoietin receptor agonist","Other indication","Thrombocytopenia","thrombocytopenia","HP_0001873","Not concordant","P",2018,"ENSG00000117400","ENSG00000096968","genetic_association","gene_burden",0.759913497014526,2,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000066427","affected_pathway","slapenrich",0.594672962316427,1,NA,NA
"Jemperli","Dostarlimab","Dostarlimab","CHEMBL4298124","GlaxoSmithKline","PD1-targeted mAb","Oncology","Endometrial cancer","endometrial cancer","MONDO_0011962","Serious","P,B,A",2021,"ENSG00000188389","ENSG00000120217","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Jemperli","Dostarlimab","Dostarlimab","CHEMBL4298124","GlaxoSmithKline","PD1-targeted mAb","Oncology","Endometrial cancer","endometrial cancer","MONDO_0011962","Serious","P,B,A",2021,"ENSG00000188389","ENSG00000120217","literature","europepmc",0.702975592836982,26,NA,NA
"Jemperli","Dostarlimab","Dostarlimab","CHEMBL4298124","GlaxoSmithKline","PD1-targeted mAb","Oncology","Endometrial cancer","endometrial cancer","MONDO_0011962","Serious","P,B,A",2021,"ENSG00000188389","ENSG00000120217","known_drug","chembl",0.489479420074581,9,NA,NA
"Takhzyro","Lanadelumab","LANADELUMAB","CHEMBL3545189","Dyax/Shire","Kallikrein antibody","Other indication","Hereditary angioedema","hereditary angioedema","MONDO_0019623","Serious","P,O,B,F",2018,"ENSG00000164344","ENSG00000113889","literature","europepmc",0.721639817840913,175,NA,NA
"Orladeyo","Berotralstatc","BEROTRALSTAT","CHEMBL4594271","BioCryst","Plasma kallikrein inhibitor","#N/A","Hereditary angioedema","hereditary angioedema","MONDO_0019623","Serious","S,O,F",2020,"ENSG00000164344","ENSG00000113889","literature","europepmc",0.721639817840913,175,NA,NA
"Jemperli","Dostarlimab","Dostarlimab","CHEMBL4298124","GlaxoSmithKline","PD1-targeted mAb","Oncology","Endometrial cancer","endometrial cancer","MONDO_0011962","Serious","P,B,A",2021,"ENSG00000188389","ENSG00000006125","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000170145","literature","europepmc",0.397265889272594,4,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000124788","genetic_association","ot_genetics_portal",0.322990231678107,1,NA,NA
"Jemperli","Dostarlimab","Dostarlimab","CHEMBL4298124","GlaxoSmithKline","PD1-targeted mAb","Oncology","Endometrial cancer","endometrial cancer","MONDO_0011962","Serious","P,B,A",2021,"ENSG00000188389","ENSG00000121594","literature","europepmc",0.126145640504411,2,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000121879","literature","europepmc",0.982554063996823,434,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000121879","somatic_mutation","eva_somatic",0.778911334439889,4,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000121879","affected_pathway","cancer_biomarkers",0.919067987742997,7,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000121879","genetic_association","clingen",0.00607930797611621,1,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000121879","affected_pathway","crispr",0.44834896323857,1,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000121879","affected_pathway","slapenrich",0.986533167177985,79,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000121879","genetic_association","uniprot_variants",0.954994719693279,13,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000121879","somatic_mutation","intogen",0.943491907351674,11,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000121879","known_drug","chembl",0.898481029072387,103,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000121879","genetic_association","eva",0.79530692477534,8,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000121879","affected_pathway","progeny",0.580735987426089,1,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000121879","somatic_mutation","cancer_gene_census",0.960751402505293,17,NA,NA
"Sogroya","Somapacitan","SOMAPACITAN","CHEMBL3707290","Novo Nordisk","Growth hormone analogue","Other indication","Growth hormone deficiency","short stature due to partial GHR deficiency","MONDO_0011420","Not serious","S",2020,"ENSG00000112964","ENSG00000112964","genetic_association","eva",0.823614105697743,17,NA,NA
"Sogroya","Somapacitan","SOMAPACITAN","CHEMBL3707290","Novo Nordisk","Growth hormone analogue","Other indication","Growth hormone deficiency","short stature due to partial GHR deficiency","MONDO_0011420","Not serious","S",2020,"ENSG00000112964","ENSG00000112964","animal_model","impc",0.549042658838132,8,NA,NA
"Sogroya","Somapacitan","SOMAPACITAN","CHEMBL3707290","Novo Nordisk","Growth hormone analogue","Other indication","Growth hormone deficiency","short stature due to partial GHR deficiency","MONDO_0011420","Not serious","S",2020,"ENSG00000112964","ENSG00000112964","genetic_association","uniprot_variants",0.759913497014526,2,NA,NA
"Sogroya","Somapacitan","SOMAPACITAN","CHEMBL3707290","Novo Nordisk","Growth hormone analogue","Other indication","Growth hormone deficiency","short stature due to partial GHR deficiency","MONDO_0011420","Not serious","S",2020,"ENSG00000112964","ENSG00000112964","genetic_association","genomics_england",0.889774270171009,5,NA,NA
"Sogroya","Somapacitan","SOMAPACITAN","CHEMBL3707290","Novo Nordisk","Growth hormone analogue","Other indication","Growth hormone deficiency","short stature due to partial GHR deficiency","MONDO_0011420","Not serious","S",2020,"ENSG00000112964","ENSG00000112964","genetic_association","orphanet",0.607930797611621,1,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000117461","literature","europepmc",0.0273568858925229,2,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000145675","literature","europepmc",0.36091890437348,11,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000117461","affected_pathway","slapenrich",0.973304521321589,29,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000145675","affected_pathway","slapenrich",0.986626203558145,80,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000145675","somatic_mutation","intogen",0.349256475899104,3,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000117461","known_drug","chembl",0.591454109686285,50,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000145675","known_drug","chembl",0.591454109686285,50,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000117461","genetic_association","eva",0.182379239283486,1,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000117461","genetic_association","ot_genetics_portal",0.288403479359913,2,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000145675","somatic_mutation","cancer_gene_census",0.707605933430524,11,NA,NA
"Myalept","Metreleptin","METRELEPTIN","CHEMBL2107857","Amylin","Leptin analogue","Other indication","Leptin deficiency in patients with congenital or acquired generalized lipodystrophy","congenital generalized lipodystrophy","EFO_1000681","Serious","P,O,F",2014,"ENSG00000116678","ENSG00000179295","animal_model","impc",0.287247301871491,1,NA,NA
"Myalept","Metreleptin","METRELEPTIN","CHEMBL2107857","Amylin","Leptin analogue","Other indication","Leptin deficiency in patients with congenital or acquired generalized lipodystrophy","congenital generalized lipodystrophy","EFO_1000681","Serious","P,O,F",2014,"ENSG00000116678","ENSG00000116678","animal_model","impc",0.431372141088967,6,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000170345","literature","europepmc",0.794467966157919,59,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000065361","literature","europepmc",0.921372297782836,177,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000065361","affected_pathway","crispr",0.428591212316193,1,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000065361","affected_pathway","slapenrich",0.974566139110945,33,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000065361","somatic_mutation","intogen",0.628152652885707,3,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000065361","known_drug","chembl",0.194056809871969,27,NA,NA
"Piqray","Alpelisib","ALPELISIB","CHEMBL2396661","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019,"ENSG00000121879","ENSG00000065361","somatic_mutation","cancer_gene_census",0.697803109408105,9,NA,NA
"Skytrofa","Lonapegsomatropin","Lonapegsomatropin","CHEMBL4298185","Ascendis Pharma","PEGylated human growth hormone","Other indication","Growth failure due to GHD","Growth delay","HP_0001510","Not serious","S,O",2021,"ENSG00000112964","ENSG00000259384","literature","europepmc",0.509016598389755,72,"EFO_0004339","growth delay -> height"
"Leqvio","Inclisiran","Inclisiran","CHEMBL3990033","Novartis/Alnylam","PCSK9-targeted siRNA","Other indication","HeFH or ASCVD","coronary atherosclerosis","MONDO_0021661","Serious","S",2021,"ENSG00000169174","ENSG00000169174","genetic_association","ot_genetics_portal",0.58039748904511,2,NA,NA
"Corlanor","Ivabradine","IVABRADINE","CHEMBL471737","Amgen","Hyperpolarization-activated cyclic nucleotide-gated channel blocker","Other indication","Chronic heart failure","Abnormality of the cardiovascular system","HP_0001626","Serious","P,F",2015,"ENSG00000138622","ENSG00000138622","known_drug","chembl",0.796440005771025,6,NA,NA
"Corlanor","Ivabradine","IVABRADINE","CHEMBL471737","Amgen","Hyperpolarization-activated cyclic nucleotide-gated channel blocker","Other indication","Chronic heart failure","Abnormality of the cardiovascular system","HP_0001626","Serious","P,F",2015,"ENSG00000138622","ENSG00000138622","literature","europepmc",0.146480129999001,17,NA,NA
"Corlanor","Ivabradine","IVABRADINE","CHEMBL471737","Amgen","Hyperpolarization-activated cyclic nucleotide-gated channel blocker","Other indication","Chronic heart failure","Abnormality of the cardiovascular system","HP_0001626","Serious","P,F",2015,"ENSG00000138622","ENSG00000138622","genetic_association","eva",0.802218878055303,483,NA,NA
"Skytrofa","Lonapegsomatropin","Lonapegsomatropin","CHEMBL4298185","Ascendis Pharma","PEGylated human growth hormone","Other indication","Growth failure due to GHD","Growth delay","HP_0001510","Not serious","S,O",2021,"ENSG00000112964","ENSG00000112964","known_drug","chembl",0.957517205642744,21,"EFO_0004339","growth delay -> height"
"Skytrofa","Lonapegsomatropin","Lonapegsomatropin","CHEMBL4298185","Ascendis Pharma","PEGylated human growth hormone","Other indication","Growth failure due to GHD","Growth delay","HP_0001510","Not serious","S,O",2021,"ENSG00000112964","ENSG00000112964","literature","europepmc",0.0445815918248522,3,"EFO_0004339","growth delay -> height"
"Skytrofa","Lonapegsomatropin","Lonapegsomatropin","CHEMBL4298185","Ascendis Pharma","PEGylated human growth hormone","Other indication","Growth failure due to GHD","Growth delay","HP_0001510","Not serious","S,O",2021,"ENSG00000112964","ENSG00000112964","genetic_association","genomics_england",0.607930797611621,1,"EFO_0004339","growth delay -> height"
"Skytrofa","Lonapegsomatropin","Lonapegsomatropin","CHEMBL4298185","Ascendis Pharma","PEGylated human growth hormone","Other indication","Growth failure due to GHD","Growth delay","HP_0001510","Not serious","S,O",2021,"ENSG00000112964","ENSG00000112964","genetic_association","eva",0.559296333802691,1,"EFO_0004339","growth delay -> height"
"Macrilen","Macimorelin","MACIMORELIN","CHEMBL278623","Aeterna Zentaris","Growth hormone secretagogue receptor agonist","Other indication","Diagnosis of adult growth hormone deficiency","short stature due to GHSR deficiency","MONDO_0014403","Not serious","S,O",2017,"ENSG00000121853","ENSG00000116678","animal_model","impc",0.395550173466001,2,NA,NA
"Sogroya","Somapacitan","SOMAPACITAN","CHEMBL3707290","Novo Nordisk","Growth hormone analogue","Other indication","Growth hormone deficiency","short stature due to partial GHR deficiency","MONDO_0011420","Not serious","S",2020,"ENSG00000112964","ENSG00000196396","animal_model","impc",0.303296674928438,1,NA,NA
"Odomzo","Sonidegib","SONIDEGIB","CHEMBL2105737","Novartis","Smoothened inhibitor","Oncology","Basal cell carcinoma","basal cell carcinoma","EFO_0004193","Not serious","S",2015,"ENSG00000128602","ENSG00000185920","somatic_mutation","intogen",0.790136085454591,3,NA,NA
"Odomzo","Sonidegib","SONIDEGIB","CHEMBL2105737","Novartis","Smoothened inhibitor","Oncology","Basal cell carcinoma","basal cell carcinoma","EFO_0004193","Not serious","S",2015,"ENSG00000128602","ENSG00000185920","literature","europepmc",0.94894650394861,367,NA,NA
"Odomzo","Sonidegib","SONIDEGIB","CHEMBL2105737","Novartis","Smoothened inhibitor","Oncology","Basal cell carcinoma","basal cell carcinoma","EFO_0004193","Not serious","S",2015,"ENSG00000128602","ENSG00000185920","animal_model","impc",0.508958295916155,5,NA,NA
"Odomzo","Sonidegib","SONIDEGIB","CHEMBL2105737","Novartis","Smoothened inhibitor","Oncology","Basal cell carcinoma","basal cell carcinoma","EFO_0004193","Not serious","S",2015,"ENSG00000128602","ENSG00000185920","genetic_association","uniprot_literature",0.607930797611621,1,NA,NA
"Odomzo","Sonidegib","SONIDEGIB","CHEMBL2105737","Novartis","Smoothened inhibitor","Oncology","Basal cell carcinoma","basal cell carcinoma","EFO_0004193","Not serious","S",2015,"ENSG00000128602","ENSG00000185920","affected_pathway","cancer_biomarkers",0.607930797611621,1,NA,NA
"Odomzo","Sonidegib","SONIDEGIB","CHEMBL2105737","Novartis","Smoothened inhibitor","Oncology","Basal cell carcinoma","basal cell carcinoma","EFO_0004193","Not serious","S",2015,"ENSG00000128602","ENSG00000185920","somatic_mutation","cancer_gene_census",0.759913497014526,2,NA,NA
"Odomzo","Sonidegib","SONIDEGIB","CHEMBL2105737","Novartis","Smoothened inhibitor","Oncology","Basal cell carcinoma","basal cell carcinoma","EFO_0004193","Not serious","S",2015,"ENSG00000128602","ENSG00000185920","somatic_mutation","eva_somatic",0.547137717850459,1,NA,NA
"Odomzo","Sonidegib","SONIDEGIB","CHEMBL2105737","Novartis","Smoothened inhibitor","Oncology","Basal cell carcinoma","basal cell carcinoma","EFO_0004193","Not serious","S",2015,"ENSG00000128602","ENSG00000185920","genetic_association","eva",0.772345386312182,63,NA,NA
"Odomzo","Sonidegib","SONIDEGIB","CHEMBL2105737","Novartis","Smoothened inhibitor","Oncology","Basal cell carcinoma","basal cell carcinoma","EFO_0004193","Not serious","S",2015,"ENSG00000128602","ENSG00000185920","genetic_association","genomics_england",0.759913497014526,2,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000113013","literature","europepmc",0.0664299492123499,5,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000126934","somatic_mutation","eva_somatic",0.643347591420098,7,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000108953","literature","europepmc",0.0303965398805811,1,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000126934","literature","europepmc",0.594262869903056,32,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000126934","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000126934","known_drug","chembl",0.951655201755933,138,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000126934","affected_pathway","cancer_biomarkers",0.865457038266544,4,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000108953","somatic_mutation","cancer_gene_census",0.639593859987226,4,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000126934","somatic_mutation","cancer_gene_census",0.880458054268739,9,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000078061","somatic_mutation","eva_somatic",0.579222954391072,3,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000078061","literature","europepmc",0.0863832462299419,9,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000078061","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000078061","known_drug","chembl",0.0858617816793413,5,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000078061","somatic_mutation","cancer_gene_census",0.444887135085504,5,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000095015","literature","europepmc",0.386946263983137,6,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000095015","genetic_association","ot_genetics_portal",0.3457849334203,1,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000095015","animal_model","impc",0.331565457017378,1,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000095015","somatic_mutation","cancer_gene_census",0.669694877952302,6,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000099250","literature","europepmc",0.0182379239283486,1,NA,NA
"Trogarzo","Ibalizumab","IBALIZUMAB","CHEMBL1743029","TaiMed Biologics/Theratechnologies","CD4 antibody","Other indication","HIV","hiv infection","EFO_0000764","Serious","P,O,B,F",2018,"ENSG00000010610","ENSG00000010610","literature","europepmc",0.997492193541351,11041,NA,NA
"Trogarzo","Ibalizumab","IBALIZUMAB","CHEMBL1743029","TaiMed Biologics/Theratechnologies","CD4 antibody","Other indication","HIV","hiv infection","EFO_0000764","Serious","P,O,B,F",2018,"ENSG00000010610","ENSG00000010610","known_drug","chembl",0.881555306851527,24,NA,NA
"Trogarzo","Ibalizumab","IBALIZUMAB","CHEMBL1743029","TaiMed Biologics/Theratechnologies","CD4 antibody","Other indication","HIV","hiv infection","EFO_0000764","Serious","P,O,B,F",2018,"ENSG00000010610","ENSG00000010610","affected_pathway","reactome",0.967152948166419,18,NA,NA
"Jeuveau","Prabotulinumtoxin A","PRABOTULINUMTOXINA","CHEMBL4297229","Evolus","Acetylcholine release inhibitor and a neuromuscular blocking agent","Other indication","Glabellar lines associated with corrugator and/or procerus muscle activity","Facial wrinkling","HP_0009762","Not serious","S",2019,"ENSG00000132639","ENSG00000220205","known_drug","chembl",0.607930797611621,1,NA,NA
"Daxxify","DaxibotulinumtoxinA","DaxibotulinumtoxinA","CHEMBL3707359","Revance","Botulinum toxin","Other indication","Glabellar lines","Facial wrinkling","HP_0009762","Not serious","S",2022,"ENSG00000132639","ENSG00000220205","known_drug","chembl",0.607930797611621,1,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000160691","affected_pathway","slapenrich",0.591257114400228,13,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000067225","literature","europepmc",0.110336062373189,5,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000067225","affected_pathway","crispr",0.259890415978968,1,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000157764","somatic_mutation","eva_somatic",0.886660428228313,66,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000157764","literature","europepmc",0.997750156460503,5355,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000157764","affected_pathway","slapenrich",0.951397496038773,12,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000157764","known_drug","chembl",0.970400754392014,210,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000157764","somatic_mutation","intogen",0.912933640812553,7,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000157764","genetic_association","eva",0.615695231175318,72,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000157764","affected_pathway","cancer_biomarkers",0.979400228199195,29,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000157764","somatic_mutation","cancer_gene_census",0.944821119002304,21,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000142192","literature","europepmc",0.243172319044648,1,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000044574","literature","europepmc",0.805741094463819,42,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000037280","somatic_mutation","cancer_gene_census",0.819313402031162,5,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000037280","literature","europepmc",0.2643955129186,17,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000037280","known_drug","chembl",0.499159189703293,33,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000109971","literature","europepmc",0.187394668363782,6,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000109971","affected_pathway","slapenrich",0.543165298732312,2,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000186432","literature","europepmc",0.121586159522324,1,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000133703","somatic_mutation","eva_somatic",0.531939447910168,2,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000133703","literature","europepmc",0.28868269626331,19,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000133703","affected_pathway","slapenrich",0.984325548055482,41,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000133703","somatic_mutation","intogen",0.335251427732351,1,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000133703","somatic_mutation","cancer_gene_census",0.703217493074333,10,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000150630","literature","europepmc",0.505007629769408,36,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000142798","affected_pathway","slapenrich",0.458847892503736,3,NA,NA
"Trogarzo","Ibalizumab","IBALIZUMAB","CHEMBL1743029","TaiMed Biologics/Theratechnologies","CD4 antibody","Other indication","HIV","hiv infection","EFO_0000764","Serious","P,O,B,F",2018,"ENSG00000010610","ENSG00000182866","literature","europepmc",0.179872088553564,14,NA,NA
"Trogarzo","Ibalizumab","IBALIZUMAB","CHEMBL1743029","TaiMed Biologics/Theratechnologies","CD4 antibody","Other indication","HIV","hiv infection","EFO_0000764","Serious","P,O,B,F",2018,"ENSG00000010610","ENSG00000182866","affected_pathway","reactome",0.759913497014526,2,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000100097","literature","europepmc",0.233065445601579,9,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000213281","somatic_mutation","eva_somatic",0.88272824504622,37,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000213281","literature","europepmc",0.991456204242281,995,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000213281","affected_pathway","slapenrich",0.984325548055482,41,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000213281","somatic_mutation","intogen",0.891783177139075,6,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000213281","affected_pathway","cancer_biomarkers",0.919067987742997,7,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000213281","somatic_mutation","cancer_gene_census",0.955573298828604,17,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000112715","literature","europepmc",0.749741073862625,152,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000112715","known_drug","chembl",0.488238744977415,9,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000140575","literature","europepmc",0.197577509223777,2,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000169032","somatic_mutation","eva_somatic",0.867611790651153,23,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000169032","literature","europepmc",0.942550547499249,165,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000169032","affected_pathway","slapenrich",0.827461363415818,3,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000169032","known_drug","chembl",0.951655201755933,138,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000169032","somatic_mutation","intogen",0.753829656913056,2,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000169032","affected_pathway","cancer_biomarkers",0.928566906455679,8,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000169032","somatic_mutation","cancer_gene_census",0.871955935667882,7,NA,NA
"Kimmtrak","Tebentafusp","Tebentafusp","CHEMBL4297990","Immunocore","gp100 peptide HLA _ CD3 bispecific T-cell engager","Oncology","Uveal melanoma","Uveal Melanoma","EFO_1000616","Serious","P,O,B",2022,"ENSG00000185664","ENSG00000185664","known_drug","chembl",0.136784429462615,2,NA,NA
"Kimmtrak","Tebentafusp","Tebentafusp","CHEMBL4297990","Immunocore","gp100 peptide HLA _ CD3 bispecific T-cell engager","Oncology","Uveal melanoma","Uveal Melanoma","EFO_1000616","Serious","P,O,B",2022,"ENSG00000185664","ENSG00000185664","literature","europepmc",0.0517281560901088,6,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000187555","literature","europepmc",0.856187327853795,11,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000174775","somatic_mutation","eva_somatic",0.665978247227141,12,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000174775","literature","europepmc",0.768794394602523,92,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000174775","affected_pathway","slapenrich",0.984532932603332,42,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000174775","somatic_mutation","intogen",0.228989675769526,1,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000174775","somatic_mutation","cancer_gene_census",0.694050450163589,8,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000132155","somatic_mutation","eva_somatic",0.605819926786581,4,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000132155","literature","europepmc",0.856968363380836,93,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000132155","affected_pathway","slapenrich",0.863315527562558,5,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000132155","known_drug","chembl",0.641892910628961,52,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000132155","somatic_mutation","intogen",0.174283156862006,1,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000132155","affected_pathway","cancer_biomarkers",0.607930797611621,1,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000132155","somatic_mutation","cancer_gene_census",0.833960260817156,7,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000157193","literature","europepmc",0.0729516957133945,1,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000128052","somatic_mutation","cancer_gene_census",0.639593859987226,4,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000128052","literature","europepmc",0.216027466492001,17,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000128052","known_drug","chembl",0.957627758232302,162,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000128052","affected_pathway","progeny",0.423634984708433,1,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000128052","affected_pathway","slapenrich",0.340736544061405,1,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000171132","literature","europepmc",0.680811361286111,7,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000171132","affected_pathway","slapenrich",0.607930797611621,1,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000171132","known_drug","chembl",0.0865457038266544,4,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000179776","literature","europepmc",0.0395155018447554,2,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000179776","affected_pathway","slapenrich",0.410422682537584,2,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000096384","literature","europepmc",0.136284471861654,7,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000164924","literature","europepmc",0.0182379239283486,1,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000096384","affected_pathway","slapenrich",0.332865881097454,1,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000096384","known_drug","chembl",0.183522814322701,8,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000096384","somatic_mutation","intogen",0.2071607278462,1,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000096384","somatic_mutation","cancer_gene_census",0.396843715107586,3,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000141564","literature","europepmc",0.616036541579776,3,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000105401","affected_pathway","slapenrich",0.870035707167421,5,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000197122","somatic_mutation","cancer_gene_census",0.620596022561863,3,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000197122","literature","europepmc",0.223649202115265,15,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000197122","known_drug","chembl",0.121586159522324,1,NA,NA
"Trogarzo","Ibalizumab","IBALIZUMAB","CHEMBL1743029","TaiMed Biologics/Theratechnologies","CD4 antibody","Other indication","HIV","hiv infection","EFO_0000764","Serious","P,O,B,F",2018,"ENSG00000010610","ENSG00000160791","literature","europepmc",0.963206012906976,1553,NA,NA
"Trogarzo","Ibalizumab","IBALIZUMAB","CHEMBL1743029","TaiMed Biologics/Theratechnologies","CD4 antibody","Other indication","HIV","hiv infection","EFO_0000764","Serious","P,O,B,F",2018,"ENSG00000010610","ENSG00000160791","known_drug","chembl",0.986030196289152,118,NA,NA
"Trogarzo","Ibalizumab","IBALIZUMAB","CHEMBL1743029","TaiMed Biologics/Theratechnologies","CD4 antibody","Other indication","HIV","hiv infection","EFO_0000764","Serious","P,O,B,F",2018,"ENSG00000010610","ENSG00000160791","genetic_association","ot_genetics_portal",0.0318527340767503,1,NA,NA
"Trogarzo","Ibalizumab","IBALIZUMAB","CHEMBL1743029","TaiMed Biologics/Theratechnologies","CD4 antibody","Other indication","HIV","hiv infection","EFO_0000764","Serious","P,O,B,F",2018,"ENSG00000010610","ENSG00000160791","affected_pathway","reactome",0.906661236771331,6,NA,NA
"Trogarzo","Ibalizumab","IBALIZUMAB","CHEMBL1743029","TaiMed Biologics/Theratechnologies","CD4 antibody","Other indication","HIV","hiv infection","EFO_0000764","Serious","P,O,B,F",2018,"ENSG00000010610","ENSG00000160791","genetic_association","eva",0.778911334439889,4,NA,NA
"Trogarzo","Ibalizumab","IBALIZUMAB","CHEMBL1743029","TaiMed Biologics/Theratechnologies","CD4 antibody","Other indication","HIV","hiv infection","EFO_0000764","Serious","P,O,B,F",2018,"ENSG00000010610","ENSG00000160791","rna_expression","expression_atlas",0.0448335028753409,2,NA,NA
"Cyramza","Ramucirumab","RAMUCIRUMAB","CHEMBL1743062","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014,"ENSG00000128052","ENSG00000111679","somatic_mutation","cancer_gene_census",0.379956748507263,2,NA,NA
"Jeuveau","Prabotulinumtoxin A","PRABOTULINUMTOXINA","CHEMBL4297229","Evolus","Acetylcholine release inhibitor and a neuromuscular blocking agent","Other indication","Glabellar lines associated with corrugator and/or procerus muscle activity","Facial wrinkling","HP_0009762","Not serious","S",2019,"ENSG00000132639","ENSG00000132639","known_drug","chembl",0.969123608088643,34,NA,NA
"Daxxify","DaxibotulinumtoxinA","DaxibotulinumtoxinA","CHEMBL3707359","Revance","Botulinum toxin","Other indication","Glabellar lines","Facial wrinkling","HP_0009762","Not serious","S",2022,"ENSG00000132639","ENSG00000132639","known_drug","chembl",0.969123608088643,34,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000166913","literature","europepmc",0.0364758478566973,1,NA,NA
"Braftovi","Encorafenib","ENCORAFENIB","CHEMBL3301612","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018,"ENSG00000157764","ENSG00000166913","affected_pathway","slapenrich",0.759913497014526,2,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000081237","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000081237","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000123983","somatic_mutation","cancer_gene_census",0.303965398805811,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000123983","somatic_mutation","cancer_gene_census",0.303965398805811,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000153201","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000153201","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000162434","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000162434","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000080824","somatic_mutation","cancer_gene_census",0.303965398805811,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000080824","somatic_mutation","cancer_gene_census",0.303965398805811,1,NA,NA
"Brukinsa","Zanubrutinib","ZANUBRUTINIB","CHEMBL3936761","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019,"ENSG00000010671","ENSG00000105976","known_drug","chembl",0.0607930797611621,1,NA,NA
"Imbruvica","Ibrutinib","IBRUTINIB","CHEMBL1873475","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013,"ENSG00000010671","ENSG00000105976","known_drug","chembl",0.0607930797611621,1,NA,NA
"Calquence","Acalabrutinib","ACALABRUTINIB","CHEMBL3707348","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017,"ENSG00000010671","ENSG00000105976","known_drug","chembl",0.0607930797611621,1,NA,NA
"Brukinsa","Zanubrutinib","ZANUBRUTINIB","CHEMBL3936761","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019,"ENSG00000010671","ENSG00000105976","literature","europepmc",0.340441246662508,1,NA,NA
"Imbruvica","Ibrutinib","IBRUTINIB","CHEMBL1873475","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013,"ENSG00000010671","ENSG00000105976","literature","europepmc",0.340441246662508,1,NA,NA
"Calquence","Acalabrutinib","ACALABRUTINIB","CHEMBL3707348","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017,"ENSG00000010671","ENSG00000105976","literature","europepmc",0.340441246662508,1,NA,NA
"Brukinsa","Zanubrutinib","ZANUBRUTINIB","CHEMBL3936761","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019,"ENSG00000010671","ENSG00000005700","literature","europepmc",0.109341973366206,9,NA,NA
"Imbruvica","Ibrutinib","IBRUTINIB","CHEMBL1873475","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013,"ENSG00000010671","ENSG00000005700","literature","europepmc",0.109341973366206,9,NA,NA
"Calquence","Acalabrutinib","ACALABRUTINIB","CHEMBL3707348","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017,"ENSG00000010671","ENSG00000005700","literature","europepmc",0.109341973366206,9,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000179295","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000179295","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000178568","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000178568","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Brukinsa","Zanubrutinib","ZANUBRUTINIB","CHEMBL3936761","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019,"ENSG00000010671","ENSG00000117560","animal_model","impc",0.32851060475938,2,NA,NA
"Imbruvica","Ibrutinib","IBRUTINIB","CHEMBL1873475","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013,"ENSG00000010671","ENSG00000117560","animal_model","impc",0.32851060475938,2,NA,NA
"Calquence","Acalabrutinib","ACALABRUTINIB","CHEMBL3707348","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017,"ENSG00000010671","ENSG00000117560","animal_model","impc",0.32851060475938,2,NA,NA
"Brukinsa","Zanubrutinib","ZANUBRUTINIB","CHEMBL3936761","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019,"ENSG00000010671","ENSG00000117560","literature","europepmc",0.0182379239283486,1,NA,NA
"Imbruvica","Ibrutinib","IBRUTINIB","CHEMBL1873475","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013,"ENSG00000010671","ENSG00000117560","literature","europepmc",0.0182379239283486,1,NA,NA
"Calquence","Acalabrutinib","ACALABRUTINIB","CHEMBL3707348","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017,"ENSG00000010671","ENSG00000117560","literature","europepmc",0.0182379239283486,1,NA,NA
"Brukinsa","Zanubrutinib","ZANUBRUTINIB","CHEMBL3936761","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019,"ENSG00000010671","ENSG00000169083","known_drug","chembl",0.121586159522324,1,NA,NA
"Imbruvica","Ibrutinib","IBRUTINIB","CHEMBL1873475","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013,"ENSG00000010671","ENSG00000169083","known_drug","chembl",0.121586159522324,1,NA,NA
"Calquence","Acalabrutinib","ACALABRUTINIB","CHEMBL3707348","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017,"ENSG00000010671","ENSG00000169083","known_drug","chembl",0.121586159522324,1,NA,NA
"Brukinsa","Zanubrutinib","ZANUBRUTINIB","CHEMBL3936761","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019,"ENSG00000010671","ENSG00000169083","literature","europepmc",0.0121586159522324,1,NA,NA
"Imbruvica","Ibrutinib","IBRUTINIB","CHEMBL1873475","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013,"ENSG00000010671","ENSG00000169083","literature","europepmc",0.0121586159522324,1,NA,NA
"Calquence","Acalabrutinib","ACALABRUTINIB","CHEMBL3707348","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017,"ENSG00000010671","ENSG00000169083","literature","europepmc",0.0121586159522324,1,NA,NA
"Brukinsa","Zanubrutinib","ZANUBRUTINIB","CHEMBL3936761","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019,"ENSG00000010671","ENSG00000117461","known_drug","chembl",0.143539216102744,3,NA,NA
"Imbruvica","Ibrutinib","IBRUTINIB","CHEMBL1873475","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013,"ENSG00000010671","ENSG00000117461","known_drug","chembl",0.143539216102744,3,NA,NA
"Calquence","Acalabrutinib","ACALABRUTINIB","CHEMBL3707348","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017,"ENSG00000010671","ENSG00000117461","known_drug","chembl",0.143539216102744,3,NA,NA
"Brukinsa","Zanubrutinib","ZANUBRUTINIB","CHEMBL3936761","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019,"ENSG00000010671","ENSG00000117461","literature","europepmc",0.0303965398805811,1,NA,NA
"Imbruvica","Ibrutinib","IBRUTINIB","CHEMBL1873475","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013,"ENSG00000010671","ENSG00000117461","literature","europepmc",0.0303965398805811,1,NA,NA
"Calquence","Acalabrutinib","ACALABRUTINIB","CHEMBL3707348","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017,"ENSG00000010671","ENSG00000117461","literature","europepmc",0.0303965398805811,1,NA,NA
"Onpattro","Patisiran","PATISIRAN","CHEMBL3989987","Alnylam Pharmaceuticals","TTR-directed small interfering RNA","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,B,F",2018,"ENSG00000118271","ENSG00000142192","literature","europepmc",0.0121586159522324,1,NA,NA
"Tegsedi","Inotersen","INOTERSEN","CHEMBL4297770","Ionis Pharmaceuticals","TTR-directed antisense oligonucleotide","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,F",2018,"ENSG00000118271","ENSG00000142192","literature","europepmc",0.0121586159522324,1,NA,NA
"Brukinsa","Zanubrutinib","ZANUBRUTINIB","CHEMBL3936761","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019,"ENSG00000010671","ENSG00000010671","affected_pathway","cancer_biomarkers",0.607930797611621,1,NA,NA
"Imbruvica","Ibrutinib","IBRUTINIB","CHEMBL1873475","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013,"ENSG00000010671","ENSG00000010671","affected_pathway","cancer_biomarkers",0.607930797611621,1,NA,NA
"Calquence","Acalabrutinib","ACALABRUTINIB","CHEMBL3707348","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017,"ENSG00000010671","ENSG00000010671","affected_pathway","cancer_biomarkers",0.607930797611621,1,NA,NA
"Brukinsa","Zanubrutinib","ZANUBRUTINIB","CHEMBL3936761","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019,"ENSG00000010671","ENSG00000010671","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Imbruvica","Ibrutinib","IBRUTINIB","CHEMBL1873475","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013,"ENSG00000010671","ENSG00000010671","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Calquence","Acalabrutinib","ACALABRUTINIB","CHEMBL3707348","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017,"ENSG00000010671","ENSG00000010671","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Brukinsa","Zanubrutinib","ZANUBRUTINIB","CHEMBL3936761","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019,"ENSG00000010671","ENSG00000010671","known_drug","chembl",0.959796877116394,77,NA,NA
"Imbruvica","Ibrutinib","IBRUTINIB","CHEMBL1873475","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013,"ENSG00000010671","ENSG00000010671","known_drug","chembl",0.959796877116394,77,NA,NA
"Calquence","Acalabrutinib","ACALABRUTINIB","CHEMBL3707348","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017,"ENSG00000010671","ENSG00000010671","known_drug","chembl",0.959796877116394,77,NA,NA
"Brukinsa","Zanubrutinib","ZANUBRUTINIB","CHEMBL3936761","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019,"ENSG00000010671","ENSG00000010671","literature","europepmc",0.743900725860221,211,NA,NA
"Imbruvica","Ibrutinib","IBRUTINIB","CHEMBL1873475","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013,"ENSG00000010671","ENSG00000010671","literature","europepmc",0.743900725860221,211,NA,NA
"Calquence","Acalabrutinib","ACALABRUTINIB","CHEMBL3707348","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017,"ENSG00000010671","ENSG00000010671","literature","europepmc",0.743900725860221,211,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000082898","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000082898","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Brukinsa","Zanubrutinib","ZANUBRUTINIB","CHEMBL3936761","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019,"ENSG00000010671","ENSG00000116017","literature","europepmc",0.0303965398805811,1,NA,NA
"Imbruvica","Ibrutinib","IBRUTINIB","CHEMBL1873475","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013,"ENSG00000010671","ENSG00000116017","literature","europepmc",0.0303965398805811,1,NA,NA
"Calquence","Acalabrutinib","ACALABRUTINIB","CHEMBL3707348","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017,"ENSG00000010671","ENSG00000116017","literature","europepmc",0.0303965398805811,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000168610","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000168610","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Brukinsa","Zanubrutinib","ZANUBRUTINIB","CHEMBL3936761","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019,"ENSG00000010671","ENSG00000096384","known_drug","chembl",0.143539216102744,3,NA,NA
"Imbruvica","Ibrutinib","IBRUTINIB","CHEMBL1873475","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013,"ENSG00000010671","ENSG00000096384","known_drug","chembl",0.143539216102744,3,NA,NA
"Calquence","Acalabrutinib","ACALABRUTINIB","CHEMBL3707348","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017,"ENSG00000010671","ENSG00000096384","known_drug","chembl",0.143539216102744,3,NA,NA
"Brukinsa","Zanubrutinib","ZANUBRUTINIB","CHEMBL3936761","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019,"ENSG00000010671","ENSG00000096384","literature","europepmc",0.607930797611621,1,NA,NA
"Imbruvica","Ibrutinib","IBRUTINIB","CHEMBL1873475","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013,"ENSG00000010671","ENSG00000096384","literature","europepmc",0.607930797611621,1,NA,NA
"Calquence","Acalabrutinib","ACALABRUTINIB","CHEMBL3707348","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017,"ENSG00000010671","ENSG00000096384","literature","europepmc",0.607930797611621,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000085832","somatic_mutation","cancer_gene_census",0.607930797611621,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000085832","somatic_mutation","cancer_gene_census",0.607930797611621,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000197122","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000197122","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000127329","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000127329","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000145675","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000145675","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000165025","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000165025","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000146648","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000146648","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000072274","somatic_mutation","cancer_gene_census",0.151982699402905,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000072274","somatic_mutation","cancer_gene_census",0.151982699402905,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000096384","somatic_mutation","cancer_gene_census",0.303965398805811,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000096384","somatic_mutation","cancer_gene_census",0.303965398805811,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000163399","somatic_mutation","cancer_gene_census",0.303965398805811,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000163399","somatic_mutation","cancer_gene_census",0.303965398805811,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000143322","somatic_mutation","cancer_gene_census",0.607930797611621,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000143322","somatic_mutation","cancer_gene_census",0.607930797611621,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000157168","somatic_mutation","cancer_gene_census",0.607930797611621,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000157168","somatic_mutation","cancer_gene_census",0.607930797611621,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000065361","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000065361","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000101213","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000101213","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000135605","somatic_mutation","cancer_gene_census",0.303965398805811,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000135605","somatic_mutation","cancer_gene_census",0.303965398805811,1,NA,NA
"Onpattro","Patisiran","PATISIRAN","CHEMBL3989987","Alnylam Pharmaceuticals","TTR-directed small interfering RNA","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,B,F",2018,"ENSG00000118271","ENSG00000204305","literature","europepmc",0.0121586159522324,1,NA,NA
"Tegsedi","Inotersen","INOTERSEN","CHEMBL4297770","Ionis Pharmaceuticals","TTR-directed antisense oligonucleotide","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,F",2018,"ENSG00000118271","ENSG00000204305","literature","europepmc",0.0121586159522324,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000152894","somatic_mutation","cancer_gene_census",0.607930797611621,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000152894","somatic_mutation","cancer_gene_census",0.607930797611621,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000141736","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000141736","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000141736","known_drug","chembl",0.607930797611621,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000141736","known_drug","chembl",0.607930797611621,1,NA,NA
"Onpattro","Patisiran","PATISIRAN","CHEMBL3989987","Alnylam Pharmaceuticals","TTR-directed small interfering RNA","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,B,F",2018,"ENSG00000118271","ENSG00000118271","literature","europepmc",0.51687006012817,310,NA,NA
"Tegsedi","Inotersen","INOTERSEN","CHEMBL4297770","Ionis Pharmaceuticals","TTR-directed antisense oligonucleotide","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,F",2018,"ENSG00000118271","ENSG00000118271","literature","europepmc",0.51687006012817,310,NA,NA
"Onpattro","Patisiran","PATISIRAN","CHEMBL3989987","Alnylam Pharmaceuticals","TTR-directed small interfering RNA","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,B,F",2018,"ENSG00000118271","ENSG00000118271","genetic_association","genomics_england",0.939111878932769,10,NA,NA
"Tegsedi","Inotersen","INOTERSEN","CHEMBL4297770","Ionis Pharmaceuticals","TTR-directed antisense oligonucleotide","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,F",2018,"ENSG00000118271","ENSG00000118271","genetic_association","genomics_england",0.939111878932769,10,NA,NA
"Onpattro","Patisiran","PATISIRAN","CHEMBL3989987","Alnylam Pharmaceuticals","TTR-directed small interfering RNA","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,B,F",2018,"ENSG00000118271","ENSG00000118271","somatic_mutation","eva_somatic",0.699120417253364,2,NA,NA
"Tegsedi","Inotersen","INOTERSEN","CHEMBL4297770","Ionis Pharmaceuticals","TTR-directed antisense oligonucleotide","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,F",2018,"ENSG00000118271","ENSG00000118271","somatic_mutation","eva_somatic",0.699120417253364,2,NA,NA
"Onpattro","Patisiran","PATISIRAN","CHEMBL3989987","Alnylam Pharmaceuticals","TTR-directed small interfering RNA","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,B,F",2018,"ENSG00000118271","ENSG00000118271","genetic_association","clingen",0.607930797611621,1,NA,NA
"Tegsedi","Inotersen","INOTERSEN","CHEMBL4297770","Ionis Pharmaceuticals","TTR-directed antisense oligonucleotide","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,F",2018,"ENSG00000118271","ENSG00000118271","genetic_association","clingen",0.607930797611621,1,NA,NA
"Onpattro","Patisiran","PATISIRAN","CHEMBL3989987","Alnylam Pharmaceuticals","TTR-directed small interfering RNA","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,B,F",2018,"ENSG00000118271","ENSG00000118271","genetic_association","orphanet",0.759913497014526,2,NA,NA
"Tegsedi","Inotersen","INOTERSEN","CHEMBL4297770","Ionis Pharmaceuticals","TTR-directed antisense oligonucleotide","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,F",2018,"ENSG00000118271","ENSG00000118271","genetic_association","orphanet",0.759913497014526,2,NA,NA
"Onpattro","Patisiran","PATISIRAN","CHEMBL3989987","Alnylam Pharmaceuticals","TTR-directed small interfering RNA","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,B,F",2018,"ENSG00000118271","ENSG00000118271","known_drug","chembl",0.88840729896298,16,NA,NA
"Tegsedi","Inotersen","INOTERSEN","CHEMBL4297770","Ionis Pharmaceuticals","TTR-directed antisense oligonucleotide","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,F",2018,"ENSG00000118271","ENSG00000118271","known_drug","chembl",0.88840729896298,16,NA,NA
"Onpattro","Patisiran","PATISIRAN","CHEMBL3989987","Alnylam Pharmaceuticals","TTR-directed small interfering RNA","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,B,F",2018,"ENSG00000118271","ENSG00000118271","genetic_association","uniprot_literature",0.607930797611621,1,NA,NA
"Tegsedi","Inotersen","INOTERSEN","CHEMBL4297770","Ionis Pharmaceuticals","TTR-directed antisense oligonucleotide","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,F",2018,"ENSG00000118271","ENSG00000118271","genetic_association","uniprot_literature",0.607930797611621,1,NA,NA
"Onpattro","Patisiran","PATISIRAN","CHEMBL3989987","Alnylam Pharmaceuticals","TTR-directed small interfering RNA","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,B,F",2018,"ENSG00000118271","ENSG00000118271","genetic_association","uniprot_variants",0.985702485030815,42,NA,NA
"Tegsedi","Inotersen","INOTERSEN","CHEMBL4297770","Ionis Pharmaceuticals","TTR-directed antisense oligonucleotide","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,F",2018,"ENSG00000118271","ENSG00000118271","genetic_association","uniprot_variants",0.985702485030815,42,NA,NA
"Onpattro","Patisiran","PATISIRAN","CHEMBL3989987","Alnylam Pharmaceuticals","TTR-directed small interfering RNA","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,B,F",2018,"ENSG00000118271","ENSG00000118271","genetic_association","eva",0.947080007473646,548,NA,NA
"Tegsedi","Inotersen","INOTERSEN","CHEMBL4297770","Ionis Pharmaceuticals","TTR-directed antisense oligonucleotide","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,F",2018,"ENSG00000118271","ENSG00000118271","genetic_association","eva",0.947080007473646,548,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000111252","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000111252","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000113263","somatic_mutation","cancer_gene_census",0.303965398805811,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000113263","somatic_mutation","cancer_gene_census",0.303965398805811,1,NA,NA
"Crysvita","Burosumab","BUROSUMAB","CHEMBL3707326","Ultragenyx Pharmaceutical/Kyowa Hakko Kirin","FGF23 antibody","Other indication","X-linked hypophosphataemia","Hypophosphatemia","HP_0002148","Not serious","P,O,B,F",2018,"ENSG00000118972","ENSG00000077782","literature","europepmc",0.0522871146845795,5,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000124181","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000124181","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Bavencio","Avelumab","AVELUMAB","CHEMBL3833373","Merck KGaA/Pfizer","PDL1-blocking antibody","Oncology","Merkel cell carcinoma","Merkel cell skin cancer","EFO_1001471","Serious","P,O,B,A,F",2017,"ENSG00000120217","ENSG00000197646","somatic_mutation","cancer_gene_census",0.303965398805811,1,NA,NA
"Bavencio","Avelumab","AVELUMAB","CHEMBL3833373","Merck KGaA/Pfizer","PDL1-blocking antibody","Oncology","Merkel cell carcinoma","Merkel cell skin cancer","EFO_1001471","Serious","P,O,B,A,F",2017,"ENSG00000120217","ENSG00000188389","known_drug","chembl",0.568281546440603,11,NA,NA
"Bavencio","Avelumab","AVELUMAB","CHEMBL3833373","Merck KGaA/Pfizer","PDL1-blocking antibody","Oncology","Merkel cell carcinoma","Merkel cell skin cancer","EFO_1001471","Serious","P,O,B,A,F",2017,"ENSG00000120217","ENSG00000188389","literature","europepmc",0.339342600452839,21,NA,NA
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000097007","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000097007","somatic_mutation","cancer_gene_census",0.455948098208716,1,NA,NA
"Sotyktu","Deucravacitinib","Deucravacitinib","CHEMBL4435170","Bristol Myers Squibb","TYK2 inhibitor","Other indication","Plaque psoriasis","psoriasis vulgaris","EFO_1001494","Not serious","S",2022,"ENSG00000105397","ENSG00000170581","genetic_association","ot_genetics_portal",0.0869438282895088,1,"EFO_0000676","psoriasis vulgaris -> psoriasis (parent)"
"Sotyktu","Deucravacitinib","Deucravacitinib","CHEMBL4435170","Bristol Myers Squibb","TYK2 inhibitor","Other indication","Plaque psoriasis","psoriasis vulgaris","EFO_1001494","Not serious","S",2022,"ENSG00000105397","ENSG00000170581","literature","europepmc",0.085110311665627,1,"EFO_0000676","psoriasis vulgaris -> psoriasis (parent)"
"Tukysa","Tucatinib","TUCATINIB","CHEMBL3989868","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020,"ENSG00000141736","ENSG00000141968","somatic_mutation","cancer_gene_census",0.303965398805811,1,NA,NA
"Margenza","Margetuximab","MARGETUXIMAB","CHEMBL2364649","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020,"ENSG00000141736","ENSG00000141968","somatic_mutation","cancer_gene_census",0.303965398805811,1,NA,NA
